

# Emergency Medicine Reports

The Practice of Emergency Physicians

2003 Subject Index enclosed  
with this issue.

Volume 25, Number 2

January 12, 2004

*Human organ transplantation has made phenomenal strides since the first successful recorded transplant of a cornea in Austria in 1905.<sup>1</sup> Organ transplantation not only improves the quality of life in many patients but also proves to be life-saving as well. Transplant recipients have their own set of special problems that often require emergency department (ED) visits, extensive diagnostic evaluations, and frequent hospital admissions. The interplay of the patient's immunosuppressive medications, pre-existing co-morbid illnesses, potential problems with the allograft, and the occurrence of routine illness also seen in the general population make evaluation of the organ transplant recipient (OTR) a challenge even for the most skilled physicians. Typically, OTRs are followed closely by their transplant surgeons, primary care providers, and transplant coordinators, all of whom are valuable resources for the emergency physician caring for these complex patients. Emergency physicians should attempt to*

*involve the patient's transplant team early in the decision-making process to help coordinate the timing and location of much of the diagnostic evaluation, as well as to discuss major treatment decisions.<sup>2</sup>*

—The Editor

## Evaluation and Management of Solid Organ Transplant Patients in the Emergency Department

*Authors:* **Lisa Freeman, MD, FACEP**, Assistant Professor, University of Texas

Medical School at Houston, Department of Emergency Medicine; and **Sally Henin Awad, MD, FACEP**, Assistant Professor, University of Texas Medical School at Houston, Department of Emergency Medicine.

*Peer Reviewers:* **Kenneth H. Butler, DO**, Associate Residency Director, University of Maryland Emergency Medicine Residency Program, University of Maryland School of Medicine, Baltimore; and **Ralph J. Riviello, MD, FACEP**, Assistant Professor and Clinical Research Director, Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA.

## Organ Procurement

There are three types of donor organs based on donor source: cadaveric, living-related, and living-unrelated donors. The potential cadaveric donor pool is estimated to be about 60-80% greater than what currently is being captured. In 2001, there were 107,450 people waiting for an organ transplant; 6% of these patients died while waiting.<sup>3-5</sup> Several myths circulate in the general population that may dissuade many potential donors

from discussing the option of organ donation with their families. (See Table 1.) Potential organ donors have causes of death that include intracranial bleeding, motor vehicle accidents, gunshot wounds, closed head injuries, and anoxia. Emergency physicians can play a key role in the organ donation process by identifying

**EDITOR IN CHIEF**

**Gideon Bosker, MD**  
Special Clinical Projects and Medical Education Resources  
Assistant Clinical Professor  
Section of Emergency Services  
Yale University School of Medicine  
Associate Clinical Professor  
Oregon Health Sciences University

**EDITORIAL BOARD**

**Paul S. Auerbach, MD, MS, FACEP**  
Clinical Professor of Surgery  
Division of Emergency Medicine  
Department of Surgery  
Stanford University School of Medicine  
Stanford, California

**Brooks F. Bock, MD, FACEP**

Dayanandan Professor and Chairman  
Department of Emergency Medicine  
Detroit Receiving Hospital  
Wayne State University  
Detroit, Michigan

**William J. Brady, MD, FACEP, FAAEM**

Vice Chairman of Emergency Medicine and Associate Professor,  
Department of Emergency Medicine,  
Associate Professor of Internal Medicine and Program Director of Emergency Medicine Residency,  
Department of Internal Medicine  
University of Virginia School of Medicine  
Charlottesville, Virginia

**Kenneth H. Butler, DO**

Associate Residency Director  
University of Maryland Emergency Medicine Residency Program  
University of Maryland School of Medicine  
Baltimore, Maryland

**Michael L. Coates, MD, MS**

Professor and Chair  
Department of Family and Community Medicine  
Wake Forest University School of Medicine  
Winston-Salem, North Carolina

**Alasdair K.T. Conn, MD**

Chief of Emergency Services  
Massachusetts General Hospital  
Boston, Massachusetts

**Charles L. Emerman, MD**

Chairman  
Department of Emergency Medicine  
MetroHealth Medical Center  
Cleveland Clinic Foundation  
Cleveland, Ohio

**Kurt Kleinschmidt, MD, FACEP**

Assistant Professor  
University of Texas Southwestern Medical Center, Dallas  
Associate Director  
Department of Emergency Medicine  
Parkland Memorial Hospital  
Dallas, Texas

**David A. Kramer, MD, FACEP, FAAEM**

Program Director,  
York Hospital Emergency Medicine Residency  
Clinical Associate Professor  
Department of Emergency Medicine  
Penn State University  
York, Pennsylvania

**Larry B. Mellick, MD, MS, FAAP, FACEP**

Vice Chairman for Academic Development and Research  
Department of Emergency Medicine  
Medical College of Georgia  
Augusta, Georgia

**Paul E. Pepe, MD, MPH, FACEP, FCCM**

Professor and Chairman  
Division of Emergency Medicine  
University of Texas Southwestern Medical Center  
Dallas, Texas

**Charles V. Pollack, MA, MD, FACEP**

Chairman, Department of Emergency Medicine, Pennsylvania Hospital  
Associate Professor of Emergency Medicine  
University of Pennsylvania School of Medicine  
Philadelphia, Pennsylvania

**Robert Powers, MD, MPH, FACP**

Chief and Professor, Emergency Medicine  
University of Connecticut  
School of Medicine  
Farmington, Connecticut

**David J. Robinson, MD, MS, FACEP**

Assistant Professor, Vice-Chairman, Research Director  
Department of Emergency Medicine  
The University of Texas - Health Science Center at Houston  
Director, Diagnostic Observation Center  
Memorial Hermann Hospital  
Houston, Texas

**Steven G. Rothrock, MD, FACEP, FAAP**

Associate Professor of Emergency Medicine  
University of Florida College of Medicine,  
Department of Emergency Medicine  
Orlando Regional Medical Center  
Orlando, Florida

**Barry H. Rumack, MD**

Director, Emeritus  
Rocky Mountain Poison and Drug Center  
Clinical Professor of Pediatrics  
University of Colorado Health Sciences Center  
Denver, Colorado

**Richard Salluzzo, MD, FACEP**

Chief Executive Officer and Chief Medical Officer  
Conemaugh Health System  
Johnstown, Pennsylvania

**Sandra M. Schneider, MD**

Professor and Chair  
Department of Emergency Medicine  
University of Rochester School of Medicine  
Rochester, New York

**John A. Schriver, MD**

Chief, Section of Emergency Medicine  
Yale University School of Medicine  
New Haven, Connecticut

**David Sklar, MD, FACEP**

Professor and Chair  
Department of Emergency Medicine  
University of New Mexico School of Medicine  
Albuquerque, New Mexico

**Corey M. Slovis, MD, FACP, FACEP**

Professor and Chairman  
Department of Emergency Medicine  
Vanderbilt University School of Medicine,  
Medical Director  
Metro Nashville EMS  
Nashville, Tennessee

**J. Stephan Stapezyski, MD**

Professor and Chairman  
Department of Emergency Medicine  
University of Kentucky Medical Center  
Lexington, Kentucky

**Charles E. Stewart, MD, FACEP**

Emergency Physician  
Colorado Springs, Colorado

**Gregory A. Valturo, MD, FACEP**

Vice Chairman and Associate Professor  
Department of Emergency Medicine  
University of Massachusetts Medical School  
Worcester, Massachusetts

**Albert C. Wehl, MD**

Assistant Professor of Medicine and Surgery  
Department of Surgery  
Section of Emergency Medicine  
Yale University School of Medicine  
New Haven, Connecticut

**Steven M. Winograd, MD, FACEP**

Attending Physician  
Department of Emergency Medicine  
St. Joseph Hospital  
Reading, Pennsylvania

**Allan B. Wolfson, MD, FACEP, FACP**

Program Director,  
Affiliated Residency in Emergency Medicine  
Professor of Emergency Medicine  
University of Pittsburgh  
Pittsburgh, Pennsylvania

© 2004 Thomson American Health Consultants. All rights reserved.

potential donors. The family of any potential organ donor ideally should be approached by a trained organ procurement coordinator. (See Table 2.)

## Problems Common to All Transplant Patients

Transplant patients are susceptible to all of the acute illnesses that affect the general population, as well as to problems related to immune suppression, such as opportunistic infections, adverse effects of the medications themselves, or increased risk of neoplasm. Various neurologic problems are seen as well. Each of the four major transplanted organs—kidney, heart, liver, and pancreas—will be discussed individually. Of note, patients with gastroenteritis require special attention, as the inability to ingest or absorb their medications may precipitate an episode of acute rejection.<sup>6</sup>

**Emergency Medicine Reports™** (ISSN 0746-2506) is published biweekly by Thomson American Health Consultants, 3525 Piedmont Road, N.E., Six Piedmont Center, Suite 400, Atlanta, GA 30305. Telephone: (800) 688-2421 or (404) 262-7436.

**Vice President/Group Publisher:** Brenda Mooney

**Editorial Group Head:** Valerie Loner

**Specialty Editor:** Shelly Morrow Mark

**Marketing Manager:** Schandale Kornegay

**GST Registration No.:** R129870672

Periodicals postage paid at Atlanta, GA. **POSTMASTER:** Send address changes to **Emergency Medicine Reports**, P.O. Box 740059, Atlanta, GA 30374.

Copyright © 2004 by Thomson American Health Consultants, Atlanta, GA. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

**Back issues:** \$31. Missing issues will be fulfilled by customer service free of charge when contacted within one month of the missing issue's date.

**Multiple copy prices:** One to nine additional copies, \$359 each; 10 to 20 additional copies, \$319 each.

## Accreditation

**Emergency Medicine Reports™** continuing education materials are sponsored and supervised by Thomson American Health Consultants. Thomson American Health Consultants designates this continuing education activity for up to 60 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This CME activity was planned and produced in accordance with the ACCME Essentials.

**Emergency Medicine Reports™** also is approved by the American College of Emergency Physicians for 60 hours of ACEP Category 1 credit and has been approved for 52 Category 2B credit hours by the American Osteopathic Association. Emergency Medicine



## Statement of Financial Disclosure

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Drs. Freeman, Awad (authors), Butler, and Riviello (peer reviewers) report no relationships with companies related to the field of study covered by this CME program. Dr. Bosker (editor) is on the speaker's bureau for Pfizer, Rhone-Poulenc Rorer, and Parke-Davis. Dr. Bosker also acknowledges that he receives royalties, commissions, and other compensation relating to the sale of textbooks, reprints of articles, and other written materials to the following pharmaceutical companies: Pfizer, Genentech, Aventis, Pharmacia, and Bayer.

**Infection.** The majority of infections that occur in organ transplant recipients are opportunistic and are a major cause of death in the immunocompromised patient. There are three general time frames during which infection can occur in the post-transplant period: first month, second through sixth month, and after the sixth month.

Infections in the first month usually are related to surgical and technical complications and are bacterial in origin. The most common viral infection seen in the first few weeks post-transplantation is reactivation of human herpes simplex virus. After the first six months, patients usually have community-acquired infections. Patients who have chronic graft rejection and thus require higher doses of immunosuppressive medications, and patients with reactivation of chronic illnesses such as hepatitis tend to get the opportunistic infections in the late transplant period (after six months). (See Table 3.)

The highest incidence of fungal infections occurs during the first two months post-transplantation. Early fungal infections usually are secondary to *Candida* or *Aspergillus* species. *Aspergillus* infections are more aggressive and can present as pneumonia or central nervous system (CNS) infection with intracranial mass lesions. Infections can be superficial or invasive, and it's important to differentiate between them. Transplant recipients with invasive fungal infections have a very high mortality rate. Amphotericin B remains the drug of choice to treat aggressive fungal infection. Other opportunistic infections are rare during this period. Another common viral infection during the first month is reactivated varicella zoster infection.<sup>7</sup> Viruses (especially cytomegalovirus [CMV]) and opportunistic agents become more common in months 1-6.

**Individual Organisms.** *Cytomegalovirus (CMV)*. CMV is the most common pathogen in transplant patients. There are three patterns of infection—primary, reactivation, and superinfection. Primary infection occurs when infected cells are transmitted from donor to recipient via transplant or transfusion. More than 50% of patients will develop disease as a result of this transmission, including pneumonia, enterocolitis, or encephalitis.<sup>8</sup> Reactivation occurs when latently infected patients have symptomatic disease after transplant. Superinfection occurs when both the donor and recipient are infected with different strains of CMV. CMV has four major effects in transplant patients: infectious disease syndromes, leukopenia and decreased cell mediated immunity, acute and chronic rejection, and decreased long-term patient survival. CMV can affect a wide range of organ systems. The typical presentation of illness caused by CMV involves a mononucleosis-like syndrome of fever, malaise, arthralgias, myalgias, leukopenia, mild atypical lymphocytosis, and mild elevation of the transaminases. Any portion of the GI tract can be affected. Retinitis is another important manifestation of CMV infection, one that is the most difficult to treat.

The diagnosis of CMV infection most accurately is made via demonstration of viremia via polymerase chain reaction or tissue invasion via biopsy. Antibody titers typically are drawn, but these have little diagnostic value as the presence of antibodies does not necessarily indicate active disease. Treatment involves intravenous ganciclovir for 2-4 weeks.<sup>7,8</sup>

## Subscriber Information

**Customer Service: 1-800-688-2421**

**Customer Service E-Mail:** customerservice@ahcpub.com

**Editorial E-Mail:** shelly.mark@thomson.com

**World Wide Web page:** http://www.ahcpub.com

## Subscription Prices

1 year with 60 ACEP/60 AMA/60 AAFP

Category 1/Prescribed credits

(52 AOA Category 2B credits): \$544

1 year without credit: \$399

Resident's rate \$199

All prices U.S. only.

U.S. possessions and Canada, add \$30 plus applicable GST. Other international orders, add \$30.

Reports has been reviewed by the American Academy of Family Physicians as having educational content acceptable for Prescribed credit hours. This volume has been approved for up to 60 Prescribed credit hours. Term of approval covers issues published within one year from the beginning distribution date of 1/04. Credit may be claimed for one year from the date of this issue. Thomson American Health Consultants (AHC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This is an educational publication designed to present scientific information and opinion to health professionals, to stimulate thought, and further investigation. It does not provide advice regarding medical diagnosis or treatment for any individual case. It is not intended for use by the layman. Opinions expressed are not necessarily those of this publication. Mention of products or services does not constitute endorsement. Clinical, legal, tax, and other comments are offered for general guidance only; professional counsel should be sought for specific situations.

## For Customer Service and CME questions,

Please call our customer service department at (800) 688-2421. For editorial questions or comments, please contact **Shelly Morrow Mark**, Specialty Editor, at shelly.mark@thomson.com or (404) 262-5514.

**Table 1. Organ Donation and Transplantation Myths<sup>9</sup>**

- If the emergency physician knows you are an organ donor, the physician will not work as hard to save you.
- Having "organ donor" noted on your driver's license or carrying a donor card is all you have to do to become a donor.
- Only hearts, livers, and kidneys can be transplanted.
- A history of medical illness means organs or tissues are unfit for donation.
- Being too old prohibits organ donation.
- If you agree to donate your organs, your family will be charged for the cost.
- Organ donation disfigures the body and changes the way it looks in a casket.
- Religion prohibits organ donation.

*Epstein-Barr Virus (EBV).* Epstein-Barr Virus is a herpes virus that can cause a mononucleosis syndrome, hepatitis, and post-transplant lymphoproliferative disorder. EBV causes a similar clinical syndrome to CMV. Illness from EBV usually is not seen until after six months post-transplant. Post-transplant lymphoproliferative disorder is the most severe form of EBV infection. Diagnosis of this virus may be difficult because it usually is not associated with a positive heterophile test (Monospot), splenomegaly, or pharyngitis in the transplant patient.<sup>8</sup>

*Varicella-Zoster Virus and Herpes Simplex Virus.* Primary varicella infection is a serious problem. It rapidly can disseminate and lead to pneumonia, encephalitis, pancreatitis, hepatitis, and disseminated intravascular coagulation. If an OTR who is varicella-zoster virus (VZV) seronegative is exposed to a person with chicken pox or shingles, strong consideration should be given to admission for IV varicella zoster immune globulin. Reactivation of a latent VZV infection usually only causes a cutaneous eruption, typically confined to one dermatome. Herpes simplex reactivation is common and causes oral or genital ulcers that may be treated with oral acyclovir.<sup>6</sup>

**Immunosuppressive Drugs.** There is no consensus for optimal induction immunosuppressive protocols. Several combinations of therapy are possible and vary from center to center. Most patients begin with a three-drug protocol that includes:

- A calcineurin inhibitor (cyclosporin or tacrolimus);
- A purine synthesis inhibitor (azathioprine or mycophenolate mofetil); and
- A corticosteroid (prednisone or methylprednisolone).

The risk of acute rejection and graft loss is highest in the first three months after transplantation. Therefore, the number and doses of immunosuppressive drugs should be highest at this time. The most serious side effects of immunosuppressive therapy are infection and malignancy, as well as direct organ toxicity. These side effects correlate with the total amount of immune suppression. The medications typically are tapered to maintenance levels by 6-12 months post-transplantation.

*Cyclosporine.* Since its introduction in the early 1980s, cyclosporine has been the mainstay of transplant immunosup-

**Table 2. Contraindications for Organ Donation<sup>8</sup>**

- Significant disease in the organ to be transplanted
- Significant mental dysfunction in donor and/or recipient
- Significant transmissible disease (HIV, sepsis)
- ABO blood type incompatibility
- Immunologic incompatibility
- High risk of perioperative morbidity and mortality
- Malignancy other than isolated CNS
- Extreme old or young age

pression. It is classified as a calcineurin inhibitor<sup>10</sup> and blocks the proliferation of helper and cytotoxic T cells and inhibits lymphokine release.<sup>11</sup> The most significant side effect of cyclosporine is acute and chronic nephrotoxicity. Nephrotoxicity occurs in about one-third of patients. It is dose-dependent and generally is reversible after dose reduction or short-term discontinuation. Other side effects include hypertension, hirsutism, gout, hepatotoxicity, and gingival hyperplasia. Neurotoxicity manifested by headache, hand tremors, and memory loss may be seen. The starting dose is 8-10 mg/kg/day that is tapered over six months to 3-5 mg/kg/day. Monitoring of serum levels is of limited clinical utility, but levels typically are maintained between 50 and 150 ng/mL.<sup>8</sup> Cyclosporine has many significant drug interactions, as noted in Table 4.

*Tacrolimus (FK 506).* Tacrolimus is a macrolide antibiotic derivative that also is a calcineurin inhibitor and inhibits lymphocyte activation. It initially was approved for liver transplant patients, but studies have demonstrated efficacy in renal transplant as primary or rescue therapy.<sup>12,13</sup> This drug has shown significant improvement in graft survival.<sup>14</sup> As with cyclosporine, the major adverse effect is nephrotoxicity.<sup>12,15,16</sup> Other adverse effects include hyperkalemia, hemolytic uremic syndrome, confusion, seizures, encephalopathy, headache, sleep disturbances, paresthesias, aphasia, and hyperglycemia. Do not give a concurrent macrolide antibiotic as this may induce acute toxicity.<sup>17</sup> Sirolimus is a new drug that structurally is related to tacrolimus but works at a different site of the cell signaling pathway. Unlike tacrolimus, sirolimus has no associated nephrotoxicity or hypertension. It presently is being studied for use in maintenance immunosuppression and rescue therapy for refractory acute rejection.<sup>18</sup> The most common side effects are thrombocytopenia and increases in serum LDH, cholesterol, and triglyceride levels.

*Mycophenolate Mofetil (MMF).* MMF is a newly approved synthetic derivative of a fungal antibiotic. It blocks a step in the pathway of purine synthesis. Lymphocytes are relatively dependent on the de novo pathway of purine synthesis, unlike other cells that predominately use the salvage pathway.<sup>8</sup> By blocking this pathway, MMF inhibits cytotoxic T cell generation. It also inhibits antibody formation. MMF has replaced azathioprine in many centers for maintenance immunosuppression, although no long-term benefit in graft survival has been shown.<sup>19</sup> It is effective for refractory acute rejection and may

**Table 3. Infections in Transplant Patients<sup>11</sup>**

TIME POST-TRANSPLANT	LIKELY SOURCE OF INFECTION
0-1 month	Post-surgical infection; UTIs ( <i>Escherichia coli</i> ), IV lines ( <i>S. aureus</i> , <i>S. viridans</i> ), wound infection ( <i>S. viridans</i> ), pneumonia ( <i>S. pneumoniae</i> )
1-6 months	CMV, EBV, PCP, meningitis (Listeria), fungal sepsis
> 6 months	<b>Good graft function:</b> same as general population <b>Chronic infection with immune modulating viruses (i.e., hepatitis B/C):</b> ongoing end-organ damage <b>Chronic rejection:</b> acute and chronic opportunistic infections

**Key:**  
UTI = urinary tract infection; CMV = cytomegalovirus; EBV = Epstein-Barr Virus; PCP = *Pneumocystis carinii* pneumonia

prevent chronic rejection. The dose is 2 g/day. MMF is not nephrotoxic and appears to have less bone marrow suppressive effects than azathioprine. The major side effects typically are mild and include gastritis, esophagitis, nausea, and diarrhea. Use caution when using magnesium or aluminum antacids to treat the gastrointestinal (GI) symptoms, as they interfere with the absorption of MMF.<sup>6</sup>

**Corticosteroids.** Corticosteroids alter T cell proliferation, inhibit cytokine production, suppress macrophage function, and induce lymphocyte apoptosis. Intravenous pulse methylprednisolone is the first-line therapy for acute uncomplicated allograft rejection. The dose is 500-1000 mg/day for 3-5 days as pulse therapy. Oral therapy then is restarted with a rapid taper back to maintenance levels, which usually are 10 mg/day. The major, long-term side effects of steroids include avascular bone necrosis, hypertension, adrenal suppression, cataracts, GI bleeding, glucose intolerance, delayed wound healing, and psychiatric disturbances.

**Azathioprine.** Azathioprine is a purine analog anti-metabolite derivative that is a bone marrow toxin. It blocks activation of T-lymphocytes and inhibits lymphocyte replication and function by inhibiting DNA synthesis. The typical dose is 2 mg/kg/day. The major side effects are leukopenia, thrombocytopenia, hepatotoxicity, and increased risk of neoplasm. Other adverse effects include alopecia, pancreatitis, rash, and GI upset.

**Antilymphocyte Monoclonal Antibody Preparations.** Antilymphocyte serum (ALS) is made from immunizing rabbits or horses with human lymphoid cells derived from the thymus or cultured B cell lines. It is used as primary treatment for and prophylaxis against acute rejection. The dose is 10-15 mg/kg/day for 7-10 days. The side effects include fever, chills, and, rarely, anaphylaxis.

**Table 4. Cyclosporine Drug Interactions<sup>8</sup>**

INCREASES LEVEL	DECREASES LEVEL
Diltiazem	IV Trimethoprim sulfamethoxazole
Verapamil	Isoniazid
Nicardipine	Rifampin
Erythromycin	Phenytoin
Ticarcillin	Phenobarbital
Doxycycline	Carbamazepine
Fluconazole	Omeprazole
Ketoconazole	
Nafcillin	
Metoclopramide	
Alcohol	
FK506	

OKT3 is the only mouse antibody that is licensed for anti-rejection therapy. It inhibits T-cell mediated immunity. It is used for primary therapy for acute rejection and as rescue therapy for resistant rejection. The typical dose is 5 mg IV per day for 10-14 days. The adverse effects include increased risk of infection, especially CMV and EBV. The first dose is associated with fever, chills, vomiting, diarrhea, hypotension, chest pain, and wheezing. Serious complications include fatal pulmonary edema, graft thrombosis, and graft loss.

**Cancer.** Malignancy is common in long-term OTRs. The chronic use of immunosuppressive drugs increases this risk. The types of cancers encountered in OTRs are different from those in the general population. There is a much higher incidence of squamous cell skin cancer; non-Hodgkin's lymphoma; Kaposi's sarcoma; cancer of the cervix, vulva, and perineum; hepatobiliary cancer; and various sarcomas.<sup>20</sup> The malignancies that are most common in the general population—lung, breast, prostate, and uterine—are not seen in increased frequency in OTRs.<sup>21</sup> Overall, the most common post-transplant cancers are those of the skin and lips, which are seen in one-third of patients.<sup>20,21</sup> Lymphoproliferative disorders, ranging in severity from lymphoid hyperplasia to non-Hodgkin's lymphoma, comprise about 20% of all post-transplant malignancies.<sup>22</sup>

**Neurologic Complications.** Neurologic complications occur in 30-60% of patients receiving solid organ transplants.<sup>23</sup> These include CNS infection, encephalopathy, seizure, stroke, and peripheral neuropathy.<sup>24</sup> CNS infection most often presents as meningitis, encephalitis, and brain abscess. The most common causative organisms are *Listeria monocytogenes*, *Aspergillus fumigatus*, and *Cryptococcus neoformans*. Drugs such as tacrolimus and cyclosporine can cause encephalopathy that mimics CNS infection.<sup>23</sup> Immunosuppressive therapy reduces the inflammatory response to infection, thus the response to infection often is blunted in transplant patients. They typically have headache, altered mental status, or fever without focal deficits. However, focal deficits may occur in association with aspergillosis, toxoplasmosis, or fungal abscess.<sup>23</sup> Lumbar puncture strongly should be considered for patients with new

**Table 5. Most Common Diagnoses in Patients Requiring a Renal Transplant<sup>5</sup>**

Glomerular diseases	24%
Diabetes	20%
Hypertensive nephrosclerosis	14%
Polycystic kidney disease	9%
Tubular and interstitial diseases	5%

headache, fever, or altered mental status. Computed tomography (CT) of the brain is indicated before lumbar puncture in patients who are obtunded or have focal deficits. Spinal fluid should be tested for the usual studies, as well as fungal cultures, cryptococcal antigen, and polymerase chain reaction (PCR) viral assays.

### Renal Transplant

**Overview.** Renal transplants are the most common solid organ transplants in the United States. In 2001, there were 23,848 solid organ transplants, of which 59% were kidneys.<sup>5</sup> However, more than 64,000 patients were on the waiting list for a kidney in 2001, and almost 5% of the patients died while awaiting a kidney. The most common diagnoses in patients who required a renal transplant are listed in Table 5. The waiting time for a cadaveric renal transplant varies from 422 days to 1453 days, depending on the recipient's blood type.<sup>25</sup> Graft prognosis is directly related to the source of the donor kidney. Presently, one-year cadaveric graft survival rates are greater than 90%.<sup>25</sup> However, recipients from living related donors have lower mortality rates than recipients from cadaveric donors. This is multifactorial, however, depending on the donor and the recipient. Patient survival after a cadaveric renal transplant is 80% at five years, but rises to 90% at five years with a living donor.<sup>5</sup>

**Transplant Procedure.** The allograft usually is placed extraperitoneally in the recipient's iliac fossa. The left iliac fossa often is avoided in recipients older than age 40 because of the prevalence of diverticulosis in this age group and problems with confusing diverticulitis with acute inflammation of the transplanted kidney.<sup>8</sup> The nonfunctional kidney usually is not removed.

**Complications.** The most common causes of death in renal transplant recipients (RTRs) are cardiovascular disease, infection, and cancer.<sup>1</sup> Patient death is the second most common cause of graft failure, often as a result of morbidity acquired before transplantation. The major causes of morbidity after transplantation, aside from rejection, are: hypertension (46%), cataracts (24%), avascular necrosis (18%), malignancy (14%), urinary tract infection (17%), pneumonia (9%), steroid-induced diabetes (6%), chronic hepatitis (6%), peptic ulcer disease (4%), diverticulitis (3%), myocardial infarction (4%), and stroke (2%).<sup>26</sup> (Patients may have more than one cause of morbidity.)

**Table 6. Causes of Late Post-Transplant Graft Dysfunction<sup>29</sup>**

- Obstruction
- Cyclosporine nephrotoxicity
- Other drug-related nephrotoxicity: ACE inhibitors, trimethoprim
- CMV infection
- Renal artery stenosis: uncommon, usually causes severe hypertension
- Recurrent primary disease, especially glomerulonephritis and metabolic disorders
- Hypertension
- Pyelonephritis
- Rejection

**Post-Surgical Complications. Urine.** Most surgical complications present in the early post-transplant period. A common early complication is ureteral obstruction, resulting in painless, decreased urine flow. Causes of this include blood clots, stones, ureteral necrosis, or intraoperative technical problems. The diagnosis is made via demonstrating dilatation of the urinary collecting system via ultrasound. Urine leakage usually presents in the first few post-operative weeks and is a serious complication that can lead to infection and death. It usually is due to necrosis of the distal ureter. The most common reason for this is interruption or thrombosis of the ureteral artery due to damage incurred during the donor nephrectomy. Other causes include infection or clot retention, leading to acute bladder distention. Clinically, the patient presents with symptoms that may mimic acute rejection, including allograft tenderness, fever, and abdominal swelling. Urine flow will remain unchanged initially. The diagnosis is made via ultrasound demonstrating a perinephric fluid collection. Treatment involves placement of a percutaneous nephrostomy tube followed by ureteral repair.

**Bleeding and Lymphatic.** Hematuria is common in the first post-operative week and usually resolves without intervention. Later on, it may be associated with rejection. Painful hematuria may be due to leakage of small vessels in the renal hilum or perinephric fat. Urgent surgical exploration is indicated in that case.

Lymphocele is a fairly common complication that occurs when lymph collects in the retroperitoneal space if the lymphatic vessels are not ligated carefully at the time of surgery. Diagnosis is made via ultrasound and often is managed by laparoscopic drainage.

**Vascular.** Renal artery thrombosis is reasonably uncommon but can cause decreased renal function, usually between three months and two years post-operatively. The etiology usually is technical, but it may develop as a result of immunologic complications. The diagnosis is confirmed by angiography.<sup>27</sup>

**Rejection.** Approximately 15-20% of renal transplant patients have recurrent episodes of acute rejection.<sup>8</sup> Rejection is divided into three categories: hyperacute, acute, and chronic, although there are overlapping features and transitions among these categories.

Hyperacute rejection occurs in the operating room within minutes of revascularization. The kidney becomes cyanotic and

**Table 7. Most Common Infectious Causes of Death in Renal Transplant Recipients<sup>8</sup>**

- Pneumonia
- Sepsis
- Peritonitis
- Meningitis

aggressive graft destruction ensues. This form of rejection consists of an immunologic cascade that involves platelet aggregation, degranulation, and microvascular obstruction.<sup>8,28</sup> This form of rejection usually is correlated with the presence of preformed circulating antibodies against donor antigens. Hyperacute rejection is rare today, as the antibodies readily can be identified in a pretransplant crossmatch.

Most patients have at least one episode of acute rejection in the days and weeks post-transplantation.<sup>8</sup> The classic presentation of acute rejection includes fever, malaise, oliguria, hypertension, and tenderness over the allograft. Laboratory abnormalities include proteinuria, hematuria, red blood cell casts, leukocytosis, and increased creatinine.<sup>28</sup> However, many of these symptoms rarely are seen in patients on the newer immunosuppressive agents. Impaired renal function often is the only finding. The pathophysiology is cellular infiltration with lymphocytes and macrophages followed by vascular involvement. The usual method of evaluating a patient with possible acute rejection is radioisotope perfusion scan to exclude other conditions. A biopsy may be needed for definitive diagnosis. When acute rejection is diagnosed, anti-rejection therapy, including steroids, ALS, and OKT3, is initiated.

Chronic rejection, also known as chronic allograft nephropathy (CAN), is defined as a progressive decline of graft function that is not caused by the interruption of immunosuppressive medications, recurrence of renal disease, or surgical complications.<sup>30</sup> CAN is the most frequent cause of graft failure today. Chronic rejection typically presents as hypertension, a progressive increase in creatinine, and proteinuria. Many factors play a role in CAN, including under-immunosuppression, poor compliance, drug toxicity, ischemia-reperfusion injury, and HLA incompatibility.<sup>30</sup> Table 6 contains common causes of late post-transplant graft dysfunction.

**Cardiovascular Disease.** Cardiovascular disease accounts for 36% of total mortality in renal transplant recipients.<sup>31</sup> Cardiovascular disease develops about 20 years earlier in transplant recipients than in the general population.<sup>32</sup> Hypertension is extremely common in renal patients, with a 60-100% prevalence.<sup>33</sup> Pre-transplant hypertension is a strong predictor of post-transplant hypertension. The most common cause of post-transplant hypertension is impaired renal function associated with chronic allograft dysfunction.<sup>34</sup> Post-transplant hypertension can be treated with calcium channel blockers, beta-blockers, diuretics (except potassium-sparing), or angiotensin-converting enzyme inhibitors. Hyperlipidemia is a well-known feature of renal transplant recipients and contributes to the development of cardiovascular dis-

**Table 8. Causes of Early (1-12 Week) Graft Dysfunction<sup>8</sup>**

- Acute rejection
- Cyclosporine nephrotoxicity
- Urinary tract obstruction
- Recurrence of primary renal disease
- Infection

ease. Renal disease is associated with significant abnormalities in lipid metabolism. Factors that influence post-transplant hyperlipidemia include age, body weight, pre-transplant lipid levels, proteinuria, and allograft dysfunction.<sup>35</sup>

**Infection.** The most important risk factor for post-transplant infections is the intensity of immunosuppression. Infection accounts for the most common causes of death in renal transplant patients, as noted in Table 7. Age, malnourishment, long duration of dialysis, presence of infectious foci, and hepatitis B virus or hepatitis C virus positivity are predisposing factors for post-transplant infection.<sup>36</sup> Factors that influence risk of infection include exposures and state of immunosuppression, as well as indwelling catheters, malnutrition, uremia, hyperglycemia, and infection with immunomodulating viruses such as EBV, herpes simplex virus (HSV), hepatitis C virus, or human immunodeficiency virus (HIV).<sup>37</sup>

**Bacterial Infections.** Urinary tract infections (UTIs) are common post-transplant, especially in the first year. UTIs presenting in the first three months post-transplant frequently are associated with overt pyelonephritis and bacteremia. There is a lower rate of pyelonephritis later in the transplant course unless anatomic or functional abnormalities of the urinary tract are present. Patients presenting with urosepsis in the late post-transplant period have a high likelihood of stone disease.<sup>7</sup> The pathogens are similar to what is seen in the general population, including *Escherichia coli*, enterococci, and *Pseudomonas aeruginosa*. Transplant recipients are susceptible to developing pyelonephritis and/or sepsis. Patients usually are on trimethoprim-sulfamethoxazole for the first year. Infections can be treated with quinolones, and admission strongly should be considered. Many patients are maintained on antibiotic prophylaxis, so many of the infecting organisms have multiple drug resistances, and urine cultures are indicated prior to treatment. Salmonella commonly is seen in RTRs. The annual incidence of nontyphoid salmonella in RTRs is 20 times that in the general adult population. The most common presentation is febrile illness with bacteremia.<sup>7,38</sup> It also may cause a variety of localized infections, such as UTIs, gastroenteritis, soft-tissue abscesses, and pneumonia.<sup>7</sup>

**Emergency Department Evaluation.** In addition to the history taken for all OTRs, the patient should be questioned about baseline body weight, creatinine and cyclosporine level, as well as urine output. Physical exam should focus on volume status and overall patient stability. The allograft should be palpated for swelling, and tenderness. The abdomen and incision should be examined for erythema and drainage.

**Table 9. Ultrasound Findings in Acute Rejection<sup>8,47</sup>**

- Increase in volume of the graft outside the normal range
- Enlarged and abnormally echo-poor pyramids that result in a more distinct cortico-medullary boundary
- Alternating echo-poor and echo-bright regions within the cortex due to hemorrhage or infarction
- Perirenal fluid collections

Causes of early graft dysfunction are difficult to differentiate clinically, but there are some common treatable causes of early graft dysfunction, as noted in Table 8.

In addition to routine laboratory testing, the most useful specialized diagnostic study that readily can be obtained from the ED is a renal ultrasound. Ultrasound is a useful modality, however, because of its availability and lack of nonionizing radiation or contrast injection. Duplex doppler ultrasound, although non-invasive, is neither sufficiently sensitive nor specific to make the definitive diagnosis of acute rejection.<sup>39</sup> Ultrasonographic findings of acute rejection are debated, but the ones that generally are accepted are noted in Table 9.

Perirenal fluid collections may consist of urine, lymph, blood, or pus. They may be associated with rejection, post-surgical complications, or a UTI. Physical exam in a patient with a perirenal fluid collection may reveal suprapubic swelling, drainage from the wound, edema over the graft, and ipsilateral leg edema.

**Treatment.** The most life-threatening complications that an RTR may present with in the ED are overwhelming infection and acute graft failure. Serious infection may lead to acute decompensation in a seemingly stable patient. Broad-spectrum antibiotic coverage should be initiated (after appropriate cultures are taken) whenever a significant infection is suspected. Acute graft failure may lead to life-threatening hyperkalemia or volume overload with resultant pulmonary edema and respiratory decompensation. Both of these conditions may require emergent dialysis.

## Heart Transplant

**Overview.** The first human heart transplant was performed by Christian Barnard in Capetown, South Africa, in 1967.<sup>40</sup> There are approximately 2000 heart transplants performed each year. One-year survival is 85%, up from 15% when the procedure first was developed. Five-year survival is 70%.<sup>5,40</sup> There were 7318 patients waiting for heart transplants in 2001; 8.5% of these patients died while waiting.<sup>5</sup> The most frequent indications for cardiac transplant are ischemic coronary artery disease and cardiomyopathy.<sup>41</sup> (See Tables 10 and 11.)

**Transplant Procedure.** The current technique for orthotopic heart transplantation involves a median sternotomy incision, and the patient is placed on cardiopulmonary bypass. A large portion of the posterior wall of the right and left atrium is left in the recipient, and the donor heart is implanted via the atria and end-to-end anastomosis of the aorta and pulmonary artery. There often is venous anastomosis at the level of the superior and inferi-

**Table 10. Etiology of Heart Failure in Transplant Patients<sup>11</sup>**

Coronary artery disease	45%
Dilated cardiomyopathy	46%
Valvular	3.5%
Retransplantation	2%
Congenital	2%
Miscellaneous	2%

or vena cavae and pulmonary veins. The procedure typically takes 45-80 minutes. Temporary pacer wires and chest tubes usually are placed.<sup>42</sup>

**Physiology.** The transplanted heart typically is completely denervated, but it is thought that partial reinnervation occurs by one year.<sup>42</sup> The heart has a baseline rate of 100-110 bpm, without vagal parasympathetic tone. The heart rate increases in response to exercise or stress, but this is due to circulating catecholamines. Acceleration and deceleration of the heart rate occurs more slowly than in the native heart. Respiratory arrhythmia and sinus-mediated reflex bradycardia do not occur. Unless rejection is present, arrhythmias are uncommon.

**Complications.** Infection and rejection are common causes of mortality in the first year. The most common ED complaints of heart transplant recipients (HTR) are fever (37%), shortness of breath (13%), GI (i.e., nausea, vomiting, and diarrhea) (10%), and chest pain (19%). The most common ED diagnoses to rule out are sepsis (18%), rejection (11%), and pneumonia (8%).<sup>43</sup>

**Infection.** In most centers, infectious complications are the most common cause of death after transplantation.<sup>41</sup> Infections in the first month commonly are bacterial and usually pulmonary. Nosocomial organisms such as *Legionella*, *Pseudomonas*, and *Proteus* often are culprits. Other typical causes of post-operative infection, such as UTIs and bacteremias, are seen as well. Late post-transplant infections often are due to opportunists such as CMV, herpes, *Pneumocystis carinii*, and fungi.

**Rejection.** Almost every patient experiences some acute rejection episode during the first transplant year. The signs and symptoms may be subtle and easily overlooked. Generalized fatigue and arrhythmias may be the only findings. Sinus tachycardia may reflect hypovolemia, hypoglycemia, rejection, silent myocardial infarction (MI), pulmonary adrenal insufficiency, cardiac tamponade, or an abdominal process that is being masked by corticosteroids.<sup>41</sup> Atrial arrhythmias, especially atrial flutter, may signal rejection. Ventricular arrhythmias may be seen in severe rejection or ischemic disease. Most episodes of rejection are not clinically detectable, so surveillance endomyocardial biopsies routinely are done.

**Coronary Artery Disease.** The major long-term problem after transplantation is the development of coronary artery disease in the transplanted heart. Chest pain in HTRs rarely is related to cardiac ischemia because the denervated heart is incapable of producing angina.<sup>6,44</sup> Ischemia often presents as congestive heart failure, ventricular arrhythmias, hypotension, syncope, or sudden death.<sup>45,46</sup> The cause of graft coronary artery disease

**Table 11. Contraindications to Heart Transplant<sup>41</sup>**

- Advanced age (> 70 yr)
- Irreversible hepatic, renal, or pulmonary dysfunction
- Severe peripheral vascular disease or cerebrovascular disease
- Insulin-requiring diabetes mellitus with end-organ damage
- Active infection
- Recent cancer with uncertain status
- Psychiatric illness with poor medical compliance
- Systemic disease that significantly would limit survival or rehabilitation
- Pulmonary hypertension with increased pulmonary vascular resistance

(CAD) is controversial and is probably multifactorial, with immunologic factors being important. Development of CAD may reflect chronic rejection.<sup>41</sup>

**Emergency Department Evaluation. Cardiac Evaluation.**

The auscultatory exam of an HTR often is unrevealing. An S3 or S4 may reflect cardiac failure. Irregular rhythms will present with arrhythmias. There may be crackles or rales present in congestive failure with varying degrees of respiratory distress. Peripheral edema may be present as well. The electrocardiogram (ECG) should demonstrate sinus rhythm. The ECG will reflect electrical activity from the recipient as well as from the donor's heart. Both sinus nodes will produce distinct P waves. Sinus dysfunction may appear in the early post-operative period and usually is self-limited. Some patients, however, may require treatment with theophylline or a permanent pacer. Chest radiographs should be normal. Apparent cardiomegaly may be due to transplantation of a donor heart that was larger than the recipient's heart. Cardiac enzymes may be elevated during rejection or ischemia.<sup>6,11</sup>

**Treatment.** The main cause of death after the first transplant year is chronic rejection from accelerated allograft arteriosclerosis.<sup>48</sup> Due to lack of native innervation, transplanted hearts will not respond to atropine or carotid sinus massage or other vagal maneuvers. Atrial dysrhythmias can be treated with digoxin or calcium channel blockers. Ventricular rhythms may be refractory, but lidocaine or similar agents may be tried. If the rhythm is unstable, cardioversion should be considered as well as 1 g of methylprednisolone IV for adrenal insufficiency.

A high level of suspicion for infectious complications should be maintained. The first three months post-transplant is the most vulnerable period for serious infections. Life-threatening infection is rare after one year due to the typically lower level of immune suppression used. All patients with fever should have an aggressive evaluation, including complete blood count, electrolytes, chest radiograph, urinalysis, blood and urine cultures, and CT of the brain, and lumbar puncture in selected patients. Broad-spectrum antibiotics should be given after cultures are drawn. Endocarditis prophylaxis is indicated before procedures such as abscess drainage or urethral catheterization. (See Table 12.)

**Table 12. Indications for Admission of a Heart Transplant Patient<sup>5,6,41</sup>**

- Congestive heart failure
- Fever
- Shortness of breath
- Hypoxia
- Poorly controlled hypertension
- New arrhythmia

### Liver Transplant

**Overview.** Orthotopic liver transplantation has been established as effective therapy for both acute and end stage liver disease. In 2001, there were 18 transplants per million population,<sup>49</sup> making it the second most common solid organ transplant procedure. The five-year survival for recipients from cadaveric donors is 72%, while it is 86% for recipients from living donors. The median time to transplant was 770 days, and 7% of patients died while waiting for a liver.<sup>5</sup> (See Tables 13 and 14.)

**Transplant Procedure.** The harvested liver functions best if ischemia is limited to 8 hours, but it can tolerate up to 24 hours cold ischemia. A cholecystectomy is performed on the donor liver prior to transplantation. The recipient's diseased liver is removed. The donor liver is anastomosed to the suprahepatic inferior vena cava, the infrahepatic vena cava, hepatic artery, and portal vein to secure it an orthotopic position. After reperfusion of the liver, the final anastomosis is performed, which is the bile duct. Biliary reconstruction is done via choledochocholedochostomy with T tube placement. The T tube typically is left in place for three months. Alternatively, a Roux-en-Y loop with a choledochochojejunostomy may be performed, especially if the patient has intrinsic biliary disease. Early bile production is most indicative of graft function.<sup>2</sup>

The first successful living-donor liver transplant was performed in 1989 using the left hepatic lobe. Since 1994, right hepatic lobe transplantation has become more prevalent because it is smaller. Advantages of a living donor transplant include performing the transplant before the clinical condition deteriorates and markedly decreased cold ischemia time. The main disadvantage is the risk to the donor.<sup>50</sup> One-year patient survival rates are close to 90%.

**Infectious Complications.** Mortality related to infections in liver transplant patients decreased from more than 50% in the 1980s to less than 10% in the 1990s.<sup>51</sup> Most infections occur during times of peak immunosuppression, and the majority are seen during the first two months post-transplant.<sup>52</sup> The most common infections after orthotopic liver transplant are bacterial infections of the liver, biliary tract, peritoneal cavity, blood, and laparotomy wound.<sup>53</sup>

The risk of infection is highest soon after surgery. Early post-operative infections usually are related to surgical complications, initial graft dysfunction, or preexisting morbid conditions.

Biliary tract infections include cholangitis, abscesses, peritonitis, or wound infections.

**Table 13. Most Common Diagnoses in Patients Requiring Liver Transplant<sup>28</sup>**

- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Fulminant and subfulminant hepatitis
- Cirrhosis due to hepatitis B or C virus (most common)
- Alcoholic liver disease
- Biliary atresia and metabolic diseases
- Hepatocellular carcinoma

Patients are the most immunosuppressed at the first month post-transplant. Infection is primarily bacterial, specifically gram-negative enteric organisms, but infections often are polymicrobial. In the first month, patients also may present with nosocomial pneumonia or with urinary tract infections secondary to intubation or indwelling bladder catheterization. Meningitis due to organisms including *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Listeria monocytogenes*, and gram-negative rods also is seen. Fungal infections occur most often in the early post-operative period and may present as disseminated multi-organ infection, peritonitis or asymptomatic colonization, or fungemia.<sup>2</sup> *Candida albicans* is the most common fungal pathogen seen.<sup>54</sup>

Active CMV infection is seen in 35% of liver transplant recipients (LTRs), usually in the first 1-2 months post-transplant. Infection of the blood or graft is the most common presentation.<sup>2</sup> Recurrence of hepatitis B or C is common. Eighty-six percent of allografts are reinfected with HBV, and half of those patients lose their graft as result.<sup>49</sup>

**Postoperative Complications.** In addition to problems due to systemic infection, rejection, and immunosuppressive drug effect, postoperative complications that could be seen in the ED are most commonly a result of bleeding, biliary, vascular, and wound complications.

**Bleeding.** Intra-abdominal hemorrhage occurs postoperatively in 7-15% of patients and requires exploration in approximately 50% of cases.<sup>55</sup> Post-operative bleeding usually is the result of failure of a vascular anastomosis. These patients usually present while still in the hospital. Emergency physicians are most likely to encounter patients with GI bleeding, most commonly three months post-transplant, and caused by ulcers, viral enteritis, portal hypertensive lesions, or Roux-en-Y bleeds.<sup>56</sup> Endoscopy remains the best diagnostic tool for establishing the source of upper GI bleeding and management is in the standard fashion.<sup>2</sup> GI bleeding also may signal graft dysfunction, and the patient may have profound hypoglycemia and progressive coagulopathy.<sup>2,11</sup> Lower GI bleeding after transplantation often is secondary to colitis. CMV, *Clostridium difficile*, and fungi usually are responsible for the colitis.

**Vascular Complications.** In the immediate postoperative period, thrombosis of the hepatic artery or the portal vein is of concern. It occurs in 2-12% of liver transplants.<sup>57</sup> Hepatic artery thrombosis (HAT) can occur, leading to biliary obstruction, liver infarction, or both. Patients may present asymptotically because of collateral

**Table 14. Contraindications for Liver Transplantation<sup>28</sup>**

- Extrahepatic malignancy
- Liver metastases
- Extrahepatic organ failure
- Noncompliance
- Active substance abuse
- AIDS
- Uncontrolled systemic infection

vessels or with biliary tract complications, recurrent bacteremias, abscess, or fulminant hepatic necrosis.<sup>57</sup> Doppler ultrasound is the initial investigation of choice, although spiral CT may be used as well. Angiography is the gold standard in diagnosis. Urgent exploration with thrombectomy and revision of the anastomosis are indicated if HAT is detected. Retransplantation usually is required if HAT occurs early postoperatively because it usually results in necrosis of the liver and/or biliary tree.

Portal vein thrombosis is far less frequent than HAT. Portal vein thrombosis may present as liver dysfunction, tense ascites, and variceal bleeding. Doppler ultrasound of the portal vein should be helpful in establishing the diagnosis.

**Biliary Complications.** Biliary complications occur in 8-15% of liver transplant patients with mortality rate of 10%.<sup>58,59</sup> Patients with biliary complications such as leaks, strictures, and obstruction may have elevated bilirubin, gammaglutamyltransferase (GGT), and alkaline phosphatase levels. These laboratory findings also may be found in sepsis, graft injury secondary to ischemia, and rejection. Patients with leaks may present with peritonitis, fever, abdominal pain, constipation, jaundice, and abdominal distention. Elevations of the transaminases and bilirubin are expected. After the first month, leaks occur with either elective or inadvertent removal of an indwelling biliary catheter.<sup>4,11</sup> During the first month, leaks are more severe and are more difficult to treat. If there is an associated abscess, that must be drained and the patient should be started on IV antibiotics that cover the usual biliary organisms. Ultrasound is helpful in detecting biliary dilatation, fluid collections, and thrombosis of the hepatic artery or portal vein. Cholangiography is used to evaluate for leaks or strictures. Cholescintigraphy using 99mTc-labeled hepatoiminodiacetic acid is used to look for bile leaks from the cut surfaces of the liver or from the anastomosis.<sup>61</sup> Obstruction to the flow of bile may occur secondary to stent obstruction, sludging, or stone formation or strictures (late). Spiral CT is useful in the evaluation of a patient with suspected biliary obstruction, but the diagnosis is made definitively with an invasive tool, such as endoscopic retrograde cholangiopancreatography (ERCP) or surgical exploration.<sup>2</sup>

**Rejection.** The liver is relatively resistant to the hyperacute rejection that sometimes destroys kidney and heart transplants.<sup>61</sup> Acute allograft rejection occurs 7-14 days post-transplant. The incidence of acute rejection currently is about 20-30%. Usually patients with acute rejection have no symptoms and present with only elevated transaminases and bilirubin.

**Table 15. Indications for Admission in Liver Transplant Patients**

- New onset graft failure
- Fever without obvious source less than one year post-transplant
- Fever in chronic rejection patient
- Persistent hypoglycemia

Symptomatic patients may experience malaise, weakness, fever, right upper quadrant pain, or change in bile color. Rejection is definitively diagnosed by percutaneous liver biopsy. Acute rejection is treated with high dose corticosteroids and sometimes antilymphocyte therapy.

Chronic rejection usually presents six months after transplantation. The incidence of chronic rejection is 5-9%,<sup>62,63</sup> and it is a significant cause of graft failure. Patients with chronic rejection have elevated alkaline phosphatase levels and cholestasis and may present with pruritis. Patients with chronic rejection often require retransplantation.

**Emergency Department Evaluation.** The emergency physician typically does not see the immediate postoperative complications since patients typically remain hospitalized for two weeks. Attention should be paid to airway, breathing, and circulation (ABCs), as patients may present in shock with sequelae of sepsis and coagulopathy or altered mental status due to hepatic encephalopathy or hypoglycemia. Skin should be examined for turgor, reflecting hydration status, jaundice, and ecchymoses. Sources of infection should be sought, even in afebrile patients. An elevated temperature may be due to rejection or drug reaction as well. The wound should be inspected for drainage, swelling, or erythema. LTRs who present to the ED with any suspected complications of the transplant should receive complete blood count, electrolytes, blood urea nitrogen (BUN), creatinine, liver function tests, amylase, lipase, blood and urine cultures, cultures of ascites if present, chest x-ray, and abdominal ultrasound with Doppler flow studies. Cultures of indwelling lines and biliary fluid (if a T tube still is present) also should be taken.

Abdominal CT to look for fluid collections should be considered. Broad-spectrum antibiotics should be started after cultures have been taken if a patient has a persistent high fever or appears toxic. (See Table 15.)

### **Pancreas Transplant**

**Epidemiology.** In 1966, the first human pancreas transplant was performed, and the first simultaneous kidney/pancreas transplant was performed in 1967. As of October 2000, more than 16,000 pancreas transplants have been reported to the International Pancreas Transplant Registry. Of these, 11,000 were performed in the United States. Pancreas transplants can be subdivided into simultaneous pancreas and kidney (SPK), pancreas after kidney (PAK), and pancreas transplant alone (PTA). In the United States, the majority of pancreas transplant cases were SPK. PAK transplant comprises about 10% of pancreas cases, and PTA comprises about 5% of all pancreas transplant cases.

**Table 16. Contraindications to Pancreas Transplant**

- Uncorrectable cardiovascular disease
- Active infection
- AIDS
- Malignancy within the past 3 years
- Active substance abuse
- Recent history of noncompliance
- Psychiatric illness
- Active untreated peptic ulcer disease
- Hepatitis B surface antigen positive
- Irreversible hepatic or pulmonary dysfunction

The median waiting time for a pancreas is one year. Five-year patient survival is 78% post-transplant.<sup>5</sup> The most common reason for pancreas transplantation is diabetes mellitus type I. (See Table 16.)

**Transplant Procedure.** The pancreas can be preserved safely for about 12-15 hours. The recipient's failed pancreas is not removed. If a combined pancreas-kidney transplant is to be done, the pancreas usually is placed on the right side and the kidney on the left. The pancreas usually is implanted first and then the kidney. The pancreatic exocrine secretions are drained into either the small intestine or the bladder.

**Clinical Islet Transplantation.** Surgeons can restore the function of the pancreas with a far less invasive procedure than a pancreas transplant. This procedure involves transplantation of the islets of Langerhans that contain insulin-producing beta cells. It requires only a local anesthetic and takes about one hour. The islets are injected into the liver where they secrete insulin directly into the circulatory system to control blood sugars. A single islet transplant can achieve insulin independence.<sup>64</sup>

**Complications. Rejection.** Acute rejection usually occurs from approximately one week to three months post-transplantation and can be treated but eventually will lead to graft loss if left untreated. Chronic rejection occurs after three months post-transplantation and leads to progressive loss of graft function. The early diagnosis of pancreatic allograft rejection is important. Hyperglycemia, which is indicative of islet damage, is a late indicator of rejection. There are some nonspecific indicators for early rejection and these include increases in serum amylase, lipase, and anodal trypsinogen. Patients who receive a concomitant kidney transplant need to have close monitoring of kidney function because increased serum creatinine usually occurs before pancreatic damage. Patients with pancreas-alone transplants can have decreases in urinary amylase in rejection in the case of bladder-drained allografts. In patients with enteric drainage and without concomitant kidney transplant, the diagnosis of rejection must rely on serum amylase, biopsy, and hyperglycemia. Early rejection episodes usually can be reversed, but if extensive islet damage has occurred there is significantly less chance of saving the transplant. Pancreas biopsy is the most sensitive and specific method for diagnosing acute rejection of the pancreas allograft.<sup>65</sup> High

**Table 17. Targeted Physical Exam of the Organ Transplant Recipient<sup>11</sup>**

**General:** Vital signs (include orthostatic), volume status  
**Face:** Periorbital edema (glomerulonephritis), sinus tenderness (sinusitis)  
**Ears:** Otitis media or externa  
**Mouth:** Thrush  
**Neck:** Nuchal rigidity (meningitis, retropharyngeal abscess)  
**Lymphadenopathy:** CMV, EBV, hepatitis  
**Skin:** Rash (viral syndrome), jaundice, cellulitis  
**Lung:** Pneumonia, pulmonary edema  
**Heart:** Pericardial friction rub—virus, uremia  
**Abdomen:** Peritonitis (often nonspecific), wound infection, localized tenderness  
**Rectal:** Perirectal abscess  
**Extremities:** Hemodialysis sites, central lines (bacteremia, cellulitis); peripheral edema (volume overload, venous thrombosis secondary to renal vein thrombosis)  
**Neurologic:** Mental status, focal deficits

dose steroids and anti-T-cell antibodies are used in the treatment of rejection. However, steroids, cyclosporine, tacrolimus, and OKT3 all can damage islet cells.<sup>28</sup>

*Vascular Thrombosis.* Vascular thrombosis, which appears to be secondary to sluggish blood flow, is the most common nonimmunologic cause of pancreas allograft failure.<sup>66</sup> This usually occurs within the first seven days and almost always results in loss of the graft. Thrombosis occurs in 10-20% of pancreas transplant recipients. Risk of thrombosis is highest in pancreas after kidney transplants. Graft thrombosis can be venous or arterial. Venous thrombosis presents with significant swelling of the graft, acute onset of pain, sharp rise in serum glucose, and increased serum amylase level. It rarely is reversible.<sup>67</sup> Arterial thrombosis may involve the splenic artery, superior mesenteric artery, or both. The serum glucose acutely rises and serum amylase level decreases. The patient with superior mesenteric artery thrombosis presents with gray urine and develops a urine leak from the duodenal segment. There is no abdominal pain or discomfort.

*Metabolic Acidosis.* In the immediate postoperative period, metabolic acidosis occurs as a result of release of vasoactive pancreatic peptides secondary to cold ischemia in the graft and dehydration. This usually resolves within days with IV bicarbonate administration except for patients with bladder-drained pancreas graft. In those patients, metabolic acidosis persists because of large amounts of bicarbonate loss through the urine. Blood glucose levels approach normal values within 12-24 hours and normalize within several days after transplantation.

*Pancreatitis.* In the early post-transplant period, allograft pancreatitis occurs in about 10-20% of patients.<sup>28</sup> There are many predisposing factors and these include donor abnormalities such as hemodynamic instability and vasopressor administration, procurement injury, perfusion injury, ischemic damage, and reperfusion injury. When pancreatitis occurs several weeks postoperatively, it most likely is due to reflux of urine into the

pancreatic duct of a bladder-drained pancreas. Typically patients present with tenderness over the graft site, low grade fever, and increased amylase level. Serum amylase and lipase levels may not accurately reflect the degree of pancreatitis. Pancreatitis also may result from constipation, abdominal distention, and ileus called reflux pancreatitis. Reflux pancreatitis is treated with continuous bladder drainage, intravenous fluid (IVF), antibiotics, and decreased oral intake.

Allograft pancreatitis can be difficult to differentiate from other complications, such as extravasation of pancreatic juice, extravasation of urine or enteric contents, or even rejection.

*Fistula and Abscess.* Patients who are bladder-drained and develop leaks may have abdominal pain and tenderness along with ileus, leukocytosis, elevated amylase and lipase, and abnormalities on CT scan. In patients who have leaks, Foley-catheter decompression can be used. Patients may require enteric conversion, however, if the leaks are large or persistent.

A small bowel leak is much worse than leakage of urine because of microbial contamination and activation of pancreatic proenzymes. Small bowel leaks may occur early or late after surgery. Early leaks usually occur from technical problems or ischemia, while late leaks usually are secondary to rejection or infection. Late leaks sometimes may develop from ischemia at the duodenal staple line.<sup>68</sup>

Anastomotic leaks can lead to formation of an external pancreatic fistula with discharge of clear fluid and peripancreatic abscess. Patients may present with fever, tenderness of graft, and leukocytosis. If an exterior fistula develops, a high amylase content in the drainage and erythema of the skin due to contact with digestive enzymes usually is present. An ultrasound or CT scan may be used to confirm the diagnosis. Intrapancreatic abscess can develop several weeks post transplantation and may be due to chronic rejection or viral infection. Patients may present with persistent fever, pain over the graft site, and the gradual development of hyperglycemia. Serum amylase levels should not rise. Pancreatectomy is necessary for intrapancreatic abscess.

*Urologic Complications.* Urethritis, urethral disruption, hematuria, and recurrent urinary tract infections are very common in bladder-drained recipients. Pancreatic exocrine secretions irritate and inflame the bladder mucosa, resulting in hematuria and discomfort that may become chronic. Chronic acidosis from bicarbonate losses also is a major disadvantage of bladder-drained recipients. Urethritis usually resolves with Foley catheter drainage. Some patients eventually may need to be converted to enteric drainage to avoid scarring or disruption of the urethra. Hematuria sometimes may respond to bladder irrigation.

**Emergency Department Evaluation.** Pancreas transplant patients who present with a suspected complication of the transplant should have a complete blood count, electrolytes, BUN, creatinine, amylase, lipase, blood and urine cultures, chest radiograph, and urinalysis. A urinary amylase level also should be obtained in patients with a bladder-drained allograft. Abdominal ultrasound or CT should be obtained if intrapancre-

atic abscess is suspected. An arterial blood gas is indicated if acidosis secondary to bicarbonate losses is suspected in bladder-drained patients.

## General Evaluation of the Transplant Patient

**History.** The presence of a recent fever is one of the most important portions of the history that should be obtained. Fever is the most common reason for an OTR to present to the ED.<sup>69</sup> However, fever can be masked by steroids, hyperglycemia, or uremia, so the absence of fever does not equal the absence of infection in these patients.<sup>11</sup> The date of the transplant surgery should be noted, as this helps create a time frame to determine the most likely sources of infection. Graft source is important as well, since cadaveric donor recipients have more complications than do living-related recipients. History of previous episodes of rejection should be noted, as this gives an indication as to the overall health of the graft, and the patient may say that the present symptoms are “just like my last episode of rejection.” Obtain the patient’s list of medications and note any changes in drugs or doses. Determine if the patient has taken his medications for that day. Note any new medications, either prescription or over-the-counter. The presence of chronic infections, especially CMV or hepatitis B/C, should be noted as well as any recent exposures to sick contacts. Lastly, attempt to determine the patient’s baseline blood pressure and determinants of organ function, such as creatinine, bilirubin, or ejection fraction.

**Physical Examination.** If infection is suspected, the patient should be examined from head to toe, with a focus on identifying not only routine sources of infection, but uncommon sources, such as the head, neck, perineum, and rectum. Evidence of allograft failure should be sought as well as possible drug adverse effects or malignancy. See Table 17 for examination.

**Diagnostic Evaluation.** Any OTR with fever should receive a complete blood count, electrolytes, glucose, BUN, and creatinine, urinalysis, chest radiograph, and cultures of the blood and urine. A low index of suspicion should be maintained for meningitis; lumbar puncture with spinal fluid analysis and cultures should be obtained in high-risk patients. Organ-specific testing is indicated for suspicion of an allograft-related complication.

**Disposition.** Organ transplant recipients are complex patients in whom seemingly simple problems may pose serious risk to survival of the allograft or even the patient. Consultation with the patient’s transplant physician and transplant coordinator or local transplant specialist strongly is recommended before any disposition decisions are made. OTRs have a much higher rate of hospitalization than the average ED patient<sup>2</sup> and consideration should be given to transfer the patient to a transplant center if inpatient care is necessary.

Assessing the severity and possible causes of an acute illness in an OTR as well as stabilizing the patient’s condition and transferring the care of these patients to their primary transplant team should be the goal of ED management.<sup>2</sup>

## References

1. Gift of Life Donor Program web site. Accessed at [www.donors1.org](http://www.donors1.org) 12-17-2003.
2. Savitsky EA, Uner AB, Votey SR. Evaluation of orthotopic liver transplant recipient presenting to the emergency department. *Ann Emerg Med* 1998;31:507-517.
3. Evans RW, Oviens CE, Ascher M. The potential supply of organ donors. *JAMA* 1992;267:239-244.
4. Spital A. Mandated choice for organ donation. *Ann Intern Med* 1996;125:66-69.
5. Scientific Registry of Transplant Recipients web site. Accessed at [www.ustransplant.org](http://www.ustransplant.org) 12-17-2003.
6. Marx JA, Hockberger RS, Walls RM, et al, eds. *Rosen’s Emergency Medicine: Concepts and Clinical Practice*, 5th ed. St. Louis: Mosby; 2002:2504-2510.
7. Patel R. Infections in patients with kidney transplants. *Infect Dis Clin North Am* 2001;15:901-952.
8. Brenner BM, ed. *Brenner and Rector’s The Kidney* 6th ed. Philadelphia: WB Saunders; 2000:2542-2590.
9. The Organ Procurement and Transplantation Network web site. Accessed at [www.optn.org](http://www.optn.org) 12-17-2003.
10. Lo A, Alloway RR. Strategies to reduce toxicities and improve outcomes in renal transplant recipients. *Pharmacotherapy* 2002;22:316-328.
11. Tintinalli JE, Kelen GD, Stapczynski JS, eds. *Emergency Medicine: A Comprehensive Study Guide*. 5th ed. McGraw Hill; 2000:422-427, 644-660.
12. Pirsch J, Miller RJ, Deierhoi M, et al. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK 506 Kidney Transplant Study Group. *Transplantation* 1997;63:977-983.
13. Mayer A, Dmitrewski J, Squifflet J, et al. Multicenter randomized trial comparing tacrolimus (FK 506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. *Transplantation* 1997;64:436-443.
14. Gjertson D, Cecka J, Terasaki P. The relative effects of FK 506 and cyclosporine on short- and long-term kidney survival. *Transplantation* 1995;60:1384-1388.
15. Vanrenterghen Y. Tacrolimus (FK 506) in kidney transplantation. *Transplant Proc* 1998;30:2171-2173.
16. Porayko M, Textor S, Krom R, et al. Nephrotoxic effects of primary immunosuppression with FK 506 and cyclosporine regimens after liver transplantation. *Mayo Clin Proc* 1994;69:105-111.
17. Klintman GB. Tacrolimus. In: Ginns LC, Cosimi AB, Morris PJ, eds. *Transplantation*. Malden, Mass.: Blackwell Science; 1999.
18. Gerber D, Bonham C, Thomson A. immunosuppressive agents: Recent developments in molecular action and clinical application. *Transplant Proc* 1998;30:1573-1579.
19. Mathew TH. A blinded, long-term randomized study of mycophenolate mofetil in cadaveric renal transplantation: Results at 3 years. *Transplantation* 1998;65:1450-1454.
20. Penn I. The changing pattern of posttransplant malignancies. *Transplant Proc* 1991;23:1101-1103.
21. Penn I. Cancers complicating organ transplantation. *N Engl J Med*


- 1990;323:1767-1769.
22. Penn I. Malignant neoplasms in the immunosuppressed patient. In: Cooper DKC, Novitzky D, eds. *The Transplantation and Replacement of Thoracic Organs. The Present Status of Biological and Mechanical Replacement of the Heart and Lungs*. Dordrecht: Kluwer Academic; 1990.
  23. Zunt JR. Central nervous system infection during immunosuppression. *Neurologic Clinics* 2002;20:1-22.
  24. Patchell RA. Neurological complications of organ transplantation. *Ann Neurol* 1994;36:688-703.
  25. Ramos E, Aoun S, Harmon WE. Expanding the donor pool: Effect on graft outcome. *J Am Soc Nephrol* 2002;13:2590-2599.
  26. Braun WE. Long-term complications of renal transplantation (clinical conference). *Kidney Int* 1990;37:1363-1368.
  27. Walsh PC, ed. *Campbell's Urology*, 8th ed. Elsevier; 2002.
  28. Townsend CM, ed. *Sabiston Textbook of Surgery*, 16th ed. Philadelphia: W.B. Saunders; 2001:429-466.
  29. McGeown MG, ed. *Clinical Management of Renal Transplantation*. Dordrecht: Kluwer; 1992.
  30. Ponticelli C. Renal transplantation strengths and shortcomings. *J Nephrol* 2001;14(suppl 14):S1-6.
  31. Raine AEG, Margreiter R, Brenner EP. Report on management of renal failure in Europe, XXII, 1992. *Nephrol Dial Transplant* 1992; 7:7-35.
  32. Aakhus S, Dahl K, Widerne TE. Cardiovascular mortality and risk factors in renal transplant patients. *Nephrol Dial Transplant* 1999; 54:648-654.
  33. Dimeny EM. Cardiovascular disease after renal transplantation. *Kidney International* 2002;61:suppl 80:S78-S84.
  34. Curtis JJ. Cyclosporine and post-transplantation hypertension. *J Am Soc Nephrol* 2 1992; S243-245.
  35. Massey ZA, Kasiske BL. Post-transplant hyperlipidemia: Mechanisms and management. *J AM Soc Nephrol* 1996;7:971-977.
  36. Fishman JA, Rubin RH. Infection in organ transplant recipients. *N Engl J Med* 1998;338:1741-1751.
  37. Rubin RH. Infectious disease complications of renal transplantation. *Kidney Int* 1993;44:221-236.
  38. Dhar JM, Al-Khader AA, Al-Sulaiman M, et al. Non-typhoid Salmonella in renal transplant recipients: A report of 20 cases and review of the literature. *Quarterly Jnl of Med* 1991;78:235-250.
  39. Meyer M, Paushter D, Steinmuller DR. The use of duplex Doppler ultrasonography to evaluate renal allograft dysfunction. *Transplantation* 1990;50:974-978.
  40. Barnard CN. The operation. A human cardiac transplant: An interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. *S Afr Med J* 1967;41:1271-1274.
  41. Miniati DN, Robbins RC, Reitz BA. Heart and lung transplantation. In: Braunwald E. *Heart Disease: A Textbook of Cardiovascular Medicine*, 6th ed. Philadelphia: WB Saunders; 2001:615-630.
  42. Traversi E, Pozzoli M, Grande E, et al. The bicaval anastomosis technique for orthotopic heart transplantation yields better atrial function than the standard technique: An echocardiographic autonomic boundary detection study. *J Heart Lung Transplant* 1998; 17:1065-1074.
  43. Sternbach GL, Varon J, Hunt SA, et al. Emergency department pres-

entation and care of heart and heart/lung transplant recipients. *Ann Emerg Med* 1992;21:1140-1144.

44. Gao S, Schroeder JS, Hunt A, et al. Acute myocardial infarction in cardiac transplant recipients. *Am J Cardiol* 1989;64:1093-1097.
45. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. *Am Heart J* 1999;138: S469-S472.
46. Weis M, von Scheidt W. Cardiac allograft vasculopathy: A review. *Circulation* 1997;96:2069-2077.
47. Meyer M, Paushter D, Steinmuller DR. The use of duplex ultrasonography to evaluate renal allograft dysfunction. *Transplantation* 1990;50:974-978.
48. Cainelli F, Vento S. Infections and solid organ transplantation rejection: a cause and effect relationship? *The Lancet Inf Dis* 2002;2: 543-549.
49. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. *J Hepatol* 1992;14:

**Your FREE 30-day preview copy of *The 2003 Hospital Infection Control Yearbook* has been reserved.**

As one of our valued subscribers, we have reserved a copy of *The 2003 Hospital Infection Control Yearbook* for you, which compiles the best articles of 2003 from *Hospital Infection Control* newsletter. This reference is conveniently organized to provide you with easy access to the information you need on:



- SARS
- Superbugs
- Bioterrorism
- Outbreaks and problem pathogens
- Hand hygiene
- Infection control beyond the hospital
- The Joint Commission
- Infection control salary survey
- Occupational health
- and more!
- Patient safety

Take advantage of this opportunity to receive the comprehensive and practical information of *Hospital Infection Control* at the incredibly low price of \$199. When you do, you will have the opportunity to earn approximately 15 nursing contact hours or 15 AMA Category 1 CME credits.

**Order your risk-free copy today — call 1-800-688-2421!**

Order your copy of *The 2003 Hospital Infection Control Yearbook* today, and if you are not completely satisfied, simply return it to us within 30 days in resalable condition, and we'll provide you with a 100% refund. No questions asked.

**THOMSON**  
  
**AMERICAN HEALTH CONSULTANTS**

**Call 1-800-688-2421 to order!**

104-111.

50. Trotter JF, Wachs M, Everson GT. Medical Progress: Adult-to-adult transplantation of the right hepatic lobe from a living donor. *N Engl J Med* 2002;346:1074-1082.
51. Winston DJ, Emmanouilides C, Busuttill RW. Infections in liver transplant recipients. *Clin Infect Dis* 1995;21:1077-1091.
52. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation: An analysis of 101 consecutive cases. *Medicine* 1988; 67:132-143.
53. Dummer S, Kusne S. Liver transplantation and related infections. *Semin Respir Infect* 1993;8:191-198.
54. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. *Arch Surg* 1991;126: 149-156.
55. Ozaki CF, Katz SM, Monsour HP, et al. Surgical complications of liver transplantation. *Surg Clin North Am* 1994;74:1155-1167.
56. Tabasco-Minguillan J, Jain A, Naik M, et al. Gastrointestinal bleeding after liver transplantation. *Transplantation* 1997;63:60-67.
57. Tzakis AG, Gordon RD, Byers W, et al. Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. *Transplantation* 1985;40:667-671.
58. Lemmer ER, Spearman CW, Krige JE, et al. The management of biliary complications following orthotopic liver transplantation. *S Afr J Surg* 1997;35:77-81.
59. O'Connor TP, Lewis WD, Jenkins RL. Biliary tract complications after liver transplantation. *Arch Surg* 1995;130:312-317.
60. Kurzawinski TR, Selves L, Farouk M, et al. Prospective study of hepatobiliary scintigraphy and endoscopic cholangiography for the detection of early biliary complications after orthotopic liver transplantation. *Br J Surg* 1997;84:620-623.
61. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. *Surgery* 1986;100:707-715.
62. Klintmalm GBG, Nery GR, Husberg BS, et al. Rejection in liver transplantation. *Hepatology* 1989;10:978-985.
63. Freese DK, Shorer DC, Sharp HL, et al. Liver allograft rejection: An analysis of the use of biopsies in determining the outcome of rejection. *Hepatology* 1989;10:978-985.

## Emergency Medicine Reports CME Objectives

To help physicians:

- quickly recognize or increase index of suspicion for specific conditions;
- understand the epidemiology, etiology, pathophysiology, and clinical features of the entity discussed;
- apply state-of-the-art diagnostic and therapeutic techniques (including the implications of pharmaceutical therapy discussed) to patients with the particular medical problems discussed;
- understand the differential diagnosis of the entity discussed;
- understand both likely and rare complications that may occur.

## Bestseller! EM Reports' Study Guide for the Emergency Physician Self-Assessment Exam

### EM Reports' Study Guide for the Emergency Physician Self-Assessment Exam

Volume I

The 20 Journal Articles For The 2004 Exam

Earn up to 20  
hours of CME



- HELPFUL STUDY POINTS THROUGHOUT THE TEXT OF EACH ARTICLE TO HELP YOU PREPARE FOR THE EXAM.
- IMPORTANT PASSAGES HIGHLIGHTED IN THE TEXT TO EMPHASIZE KEY CONCEPTS.
- CME QUESTIONS TO TEST YOUR KNOWLEDGE AND HELP YOU STUDY.

#### FOCUS TOPICS COVERED INCLUDE:

Immune System Disorders,  
Musculoskeletal Disorders  
(Nontraumatic), Thoracic-  
Respiratory Disorders

This convenient, all-in-one resource includes the full text of all 20 articles designated for the 2004 Life-long Learning and Self-Assessment (LLSA) exam. This useful book saves you from searching multiple web sites and journals. You save time because we've gathered all of the information for you.

We've also added several features to help streamline your study time. You'll benefit from:

- **Key study points**—conveniently located in the margins throughout each article, these points emphasize important concepts and help you to easily remember key information.
- **Important passages highlighted**—you'll be able to quickly hone in on essential concepts from each article with this useful feature.
- **Easy to handle study guide format**—designed with spiral binding so you can easily lay it flat for studying. All of the articles, study points, highlighted passages, and CME questions are included in this one convenient book that's portable.
- **Earn up to 20 CME credit hours**—earn valuable AMA and ACEP Category 1 CME credits while you read.

Please order your copy now for only \$199— a better value than other study guides when you consider the one-stop convenience this book provides!

Call now, **1-800-688-2421** or **404-262-5476** (please refer to code 82971). You also may order online at [www.ahcpub.com](http://www.ahcpub.com).

8-1/2x11, 300 pages, spiral bound, #S03170, \$199

**THOMSON**  
AMERICAN HEALTH  
CONSULTANTS

64. Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet transplantation and single infusions. *Ann Surg* 2003;237:741-750.
65. Klassen DK, Hoen-Saric EW, Weir MR, et al. Isolated pancreas rejection in combined kidney pancreas transplantation. *Transplantation* 1996;61:974-977.
66. Troppmann C, Gruessner AC, et al. Vascular graft thrombosis after pancreatic transplantation: Univariate and multivariate operative and nonoperative risk factor analysis. *J Am Coll Surg* 1996;182:285-315.
67. Allen RM. Pancreas transplantation. In: Forsythe JLR, ed. *Transplantation Surgery*. London: WB Saunders; 1997.
68. Auchincloss H, Shaffer D. Pancreas Transplantation. In: Ginnis LC, Cosmi AB, et al eds. *Transplantation*. Malden, Mass: Blackwell Science; 1999.
69. Bromberg JS, Grossman RA. Care of the organ transplant recipient. *J Am Board Fam Prac* 1993;6:563-576.

# SARSE

## Protecting Health Care Workers from an Emerging Infection

Order today, and take advantage of our 30-day risk-free guarantee!

The CDC predicts that SARS is, and will continue to be, a factor that health care facilities will have to contend with. **SARS: Protecting Health Care Workers from an Emerging Infection** offers in-depth coverage of important infection control practices that should be in place at your facility, and provides practical and useful guidance on:

- Infection control triage protocols, diagnosis, epidemiology, the relationship between SARS and the flu season, and hand hygiene
- Occupational health issues including staffing, quarantine and home care information, how to prevent transmission in health care facilities, N95s and respirator guidelines, and lessons from the Toronto outbreak
- SARS across the health care continuum: what risk managers need to know, SARS and the proper legal response, balancing public policy and individual freedom, and SARS and EMTALA
- Also included are CDC resources and a PowerPoint presentation from the audio conference *SARS: What U.S. Hospitals Must Learn from the Canadian Outbreak*

Plus, earn approximately 12 **FREE** nursing contact hours or up to 12 **FREE** AMA Category 1 CME credits. All you must do to receive your credit is read **SARS: Protecting Health Care Workers from an Emerging Infection** and complete a short self-graded post-test.

Order today for the incredible price of just \$99!

Call 1-800-688-2421 and receive your no-risk copy now.



Review your copy for 30 days and if you aren't completely satisfied, simply return this critical reference in resalable condition for a 100% refund. Promotion Code: 51262

## Physician CME Questions

11. Which of the following statements about hepatic artery thrombosis is *not* true?
  - A. It can lead to biliary obstruction and/or liver infarction.
  - B. Patients may present asymptotically because of collateral vessels.
  - C. Angiography is the initial investigation of choice.
  - D. Urgent exploration with thrombectomy and revision of the anastomosis are indicated if HAT is detected.
  - E. Retransplantation usually is required if hepatic artery thrombosis occurs early postoperatively.
12. Which of the following statements is true regarding pancreas transplants?
  - A. Hyperglycemia, which is indicative of islet damage, is an early indicator of rejection.
  - B. Patients who receive a concomitant kidney transplant need to have close monitoring of kidney function because increased serum creatinine usually occurs before pancreatic damage.
  - C. Ultrasound is the most sensitive and specific method for diagnosing acute rejection of the pancreas allograft.
  - D. Steroids, cyclosporine, tacrolimus, and OKT3 have not been shown to damage islet cells.
  - E. Patients with pancreas-alone transplants can have increases in urinary amylase in rejection in the case of bladder-drained allografts.
13. Metabolic acidosis may persist in patients with pancreas transplant because of large amounts of bicarbonate loss through the urine.
  - A. True
  - B. False
14. Post-transplant pancreatitis may result from:
  - A. constipation.
  - B. abdominal distention.
  - C. ileus.
  - D. all of the above.
15. Which of the following regarding pancreas transplant is *not* true?
  - A. Bladder-drained recipients may require enteric conversion if the leaks are large or persistent.
  - B. Urethritis, urethral disruption, hematuria, and recurrent urinary tract infections are very common in bladder-drained recipients.
  - C. Urethritis usually resolves with Foley catheter drainage.
  - D. Intrapancreatic abscess can develop several weeks post-transplantation and may be due to chronic rejection or viral infection.
  - E. Pancreatectomy rarely is indicated for intrapancreatic abscess.
16. Which of the following is the most common solid organ transplanted in the United States?
  - A. Kidney
  - B. Liver
  - C. Heart
  - D. Intestine

17. Regarding infection in organ transplant recipients, which of the following statements is true?
- Infections during the first month post-transplant usually are due to opportunistic organisms.
  - The most common viral agent affecting OTRs is CMV.
  - Salmonella is an uncommon infection in renal transplant recipients.
  - Broad spectrum antibiotics should be withheld in the febrile transplant patient until a source of infection is identified.
18. Of the following immunosuppressive medications, which usually has mild side effects?
- Cyclosporine
  - Steroids
  - Tacrolimus
  - Azathioprine
  - MMF
19. Which of the following malignancies is more common in organ transplant recipients than in the general population?
- Uterine
  - Colon
  - Non-Hodgkin's lymphoma
  - Lung
  - Breast

20. Which statement about cardiac transplant recipients is true?
- The most common reason for needing a heart transplant is valvular disease.
  - The transplanted heart will respond to atropine.
  - Coronary artery disease manifests as anginal chest pain.
  - The main cause of death after the first post-transplant year is chronic rejection from accelerated allograft arteriosclerosis.
  - The electrocardiogram will not demonstrate a sinus rhythm.

## Sourcebook Guides You Through Final EMTALA Rule

You and your facility waited more than a year for the final revisions to the Emergency Medical Treatment and Labor Act (EMTALA), but are they really good news?

*EMTALA: The Essential Guide to Compliance* from Thomson American Health Consultants, publisher of *Emergency Medicine Reports*, *ED Management*, *ED Legal Letter*, and *Hospital Risk Management*, explains how the changes to EMTALA will affect emergency departments and off-campus clinics. In-depth articles, at-a-glance tables, and Q-and-As on real-life situations are presented, and key differences between the "old" EMTALA and the new changes are succinctly explained.

Here are some of the vital questions you must be able to answer to avoid violations and hefty fines:

- Do the revisions mean hospitals are less likely to be sued under EMTALA?
- How does EMTALA apply during a disaster?
- What are the new requirements for maintaining on-call lists?
- How does EMTALA apply to inpatients admitted through the ED?
- What are the rules concerning off-campus clinics?

Edited by **James R. Hubler, MD, JD, FACEP, FAAEM, FCLM**, attending physician and clinical assistant professor of surgery, Department of Emergency Medicine, OSF Saint Francis Hospital and University of Illinois College of Medicine, Peoria, and reviewed by **Kay Ball, RN, MSA, CNOR, FAAN**, Perioperative Consultant/Educator, K&D Medical, Lewis Center, OH, *EMTALA: The Essential Guide to Compliance* draws on the knowledge and experience of physicians, nurses, ED managers, medicolegal experts, and risk managers to cover the EMTALA topics and questions that are most important to you, your staff, and your facility.

*EMTALA: The Essential Guide to Compliance* also provides 18 AMA Category I CME credits and 18 nursing contact hours.

Order your copy today for the special price of \$249! Call 1-800-688-2421 to receive this valuable guide to the new EMTALA.

### In Future Issues:

### Management of Esophageal Foreign Bodies in the Pediatric Population

### CME Answer Key

- |       |       |
|-------|-------|
| 11. C | 16. A |
| 12. B | 17. B |
| 13. A | 18. E |
| 14. D | 19. C |
| 15. E | 20. D |

### CME Instructions

Physicians participate in this continuing medical education program by reading the article, using the provided references for further research, and studying the questions at the end of the article. Participants should select what they believe to be the correct answers, then refer to the list of correct answers to evaluate their knowledge. To clarify confusion surrounding any questions answered incorrectly, please consult the source material. *After completing this activity, you must complete the evaluation form that will be provided at the end of the semester and return it in the reply envelope provided to receive a certificate of completion.* When your evaluation is received, a certificate will be mailed to you.

**Organ Donation and Transplantation Myths**

- If the emergency physician knows you are an organ donor, the physician will not work as hard to save you.
- Having "organ donor" noted on your driver's license or carrying a donor card is all you have to do to become a donor.
- Only hearts, livers, and kidneys can be transplanted.
- A history of medical illness means organs or tissues are unfit for donation.
- Being too old prohibits organ donation.
- If you agree to donate your organs, your family will be charged for the cost.
- Organ donation disfigures the body and changes the way it looks in a casket.
- Religion prohibits organ donation.

**Contraindications for Organ Donation**

- Significant disease in the organ to be transplanted
- Significant mental dysfunction in donor and/or recipient
- Significant transmissible disease (HIV, sepsis)
- ABO blood type incompatibility
- Immunologic incompatibility
- High risk of perioperative morbidity and mortality
- Malignancy other than isolated CNS
- Extreme old or young age

**Infections in Transplant Patients**

TIME POST-TRANSPLANT	LIKELY SOURCE OF INFECTION
0-1 month	Post-surgical infection; UTIs ( <i>Escherichia coli</i> ), IV lines ( <i>S. aureus</i> , <i>S. viridans</i> ), wound infection ( <i>S. viridans</i> ), pneumonia ( <i>S. pneumoniae</i> )
1-6 months	CMV, EBV, PCP, meningitis (Listeria), fungal sepsis
> 6 months	<b>Good graft function:</b> same as general population <b>Chronic infection with immune modulating viruses (i.e., hepatitis B/C):</b> ongoing end-organ damage <b>Chronic rejection:</b> acute and chronic opportunistic infections

**Key:**  
 UTI = urinary tract infection; CMV = cytomegalovirus; EBV = Epstein-Barr Virus; PCP = *Pneumocystis carinii* pneumonia

**Cyclosporine Drug Interactions**

INCREASES LEVEL	DECREASES LEVEL
Diltiazem	IV Trimethoprim sulfamethoxazole
Verapamil	Isoniazid
Nicardipine	Rifampin
Erythromycin	Phenytoin
Ticarcillin	Phenobarbital
Doxycycline	Carbamazepine
Fluconazole	Omeprazole
Ketoconazole	
Nafcillin	
Metoclopramide	
Alcohol	
FK506	

**Most Common Diagnoses in Patients Requiring a Renal Transplant**

Glomerular diseases	24%
Diabetes	20%
Hypertensive nephrosclerosis	14%
Polycystic kidney disease	9%
Tubular and interstitial diseases	5%

**Causes of Late Post-Transplant Graft Dysfunction**

- Obstruction
- Cyclosporine nephrotoxicity
- Other drug-related nephrotoxicity: ACE inhibitors, trimethoprim
- CMV infection
- Renal artery stenosis: uncommon, usually causes severe hypertension
- Recurrent primary disease, especially glomerulonephritis and metabolic disorders
- Hypertension
- Pyelonephritis
- Rejection

**Most Common Infectious Causes of Death in Renal Transplant Recipients**

- Pneumonia
- Sepsis
- Peritonitis
- Meningitis

**Causes of Early (1-12 Week) Graft Dysfunction**

- Acute rejection
- Cyclosporine nephrotoxicity
- Urinary tract obstruction
- Recurrence of primary renal disease
- Infection

**Ultrasound Findings in Acute Rejection**

- Increase in volume of the graft outside the normal range
- Enlarged and abnormally echo-poor pyramids that result in a more distinct cortico-medullary boundary
- Alternating echo-poor and echo-bright regions within the cortex due to hemorrhage or infarction
- Perirenal fluid collections

**Etiology of Heart Failure in Transplant Patients**

Coronary artery disease	45%
Dilated cardiomyopathy	46%
Valvular	3.5%
Retransplantation	2%
Congenital	2%
Miscellaneous	2%

**Contraindications to Heart Transplant**

- Advanced age (> 70 yr)
- Irreversible hepatic, renal, or pulmonary dysfunction
- Severe peripheral vascular disease or cerebrovascular disease
- Insulin-requiring diabetes mellitus with end-organ damage
- Active infection
- Recent cancer with uncertain status
- Psychiatric illness with poor medical compliance
- Systemic disease that significantly would limit survival or rehabilitation
- Pulmonary hypertension with increased pulmonary vascular resistance

**Indications for Admission of a Heart Transplant Patient**

- Congestive heart failure
- Fever
- Shortness of breath
- Hypoxia
- Poorly controlled hypertension
- New arrhythmia

**Most Common Diagnoses in Patients Requiring Liver Transplant**

- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Fulminant and subfulminant hepatitis
- Cirrhosis due to hepatitis B or C virus (most common)
- Alcoholic liver disease
- Biliary atresia and metabolic diseases
- Hepatocellular carcinoma

**Contraindications for Liver Transplantation**

- Extrahepatic malignancy
- Liver metastases
- Extrahepatic organ failure
- Noncompliance
- Active substance abuse
- AIDS
- Uncontrolled systemic infection

## Targeted Physical Exam of the Organ Transplant Recipient

**General:** Vital signs (include orthostatic), volume status

**Face:** Periorbital edema (glomerulonephritis), sinus tenderness (sinusitis)

**Ears:** Otitis media or externa

**Mouth:** Thrush

**Neck:** Nuchal rigidity (meningitis, retropharyngeal abscess)

**Lymphadenopathy:** CMV, EBV, hepatitis

**Skin:** Rash (viral syndrome), jaundice, cellulitis

**Lung:** Pneumonia, pulmonary edema

**Heart:** Pericardial friction rub—virus, uremia

**Abdomen:** Peritonitis (often nonspecific), wound infection, localized tenderness

**Rectal:** Perirectal abscess

**Extremities:** Hemodialysis sites, central lines (bacteremia, cellulitis); peripheral edema (volume overload, venous thrombosis secondary to renal vein thrombosis)

**Neurologic:** Mental status, focal deficits

## Contraindications to Pancreas Transplant

- Uncorrectable cardiovascular disease
- Active infection
- AIDS
- Malignancy within the past 3 years
- Active substance abuse
- Recent history of noncompliance
- Psychiatric illness
- Active untreated peptic ulcer disease
- Hepatitis B surface antigen positive
- Irreversible hepatic or pulmonary dysfunction

## Indications for Admission in Liver Transplant Patients

- New onset graft failure
- Fever without obvious source less than one year post-transplant
- Fever in chronic rejection patient
- Persistent hypoglycemia

---

Supplement to *Emergency Medicine Reports*, January 12, 2004: "Evaluation and Management of Solid Organ Transplant Patients in the Emergency Department." *Authors:* **Lisa Freeman, MD, FACEP**, Assistant Professor, University of Texas Medical School at Houston, Department of Emergency Medicine; and **Sally Awad, MD, FACEP**, Assistant Professor, University of Texas Medical School at Houston, Department of Emergency Medicine.

*Emergency Medicine Reports' "Rapid Access Guidelines."* Copyright © 2004 Thomson American Health Consultants, Atlanta, GA. **Editor-in-Chief:** Gideon Bosker, MD. **Vice President and Group Publisher:** Brenda Mooney. **Editorial Group Head:** Valerie Loner. **Specialty Editor:** Shelly Morrow Mark. For customer service, call: **1-800-688-2421**. This is an educational publication designed to present scientific information and opinion to health care professionals. It does not provide advice regarding medical diagnosis or treatment for any individual case. Not intended for use by the layman.

# Emergency Medicine Reports

For a complete title index,  
please see page 16.

Volume 24

SUPPLEMENT

## 2003 Subject Index: Volume 24, Numbers 1-26

Entries are organized alphabetically by subject matter and key words, with entries followed by the issue number and page number (e.g., issue number 2, page 20 would be listed as 2:20). Tables are indicated by a lowercase *t*, figures by a lowercase *f*. Supplements are indicated by an uppercase *S* or their report number. Trauma Reports is indicated by *Trauma* and then the issue number and page number.

### A

A-230, 9:123

A-232, 9:123

Abbreviated Cognitive Test for Delirium, 13:179t

Abbreviated Mental Test, 13:179t

#### Abdomen

pain, in immigrants, 5:54t

problems elicited by physical examination, 4:33-34, 34t

trauma to, Trauma 5:6-7, 8f

ABECB. *See* Acute bacterial exacerbations of chronic bronchitisABE/COPD. *See* Acute bacterial exacerbations of chronic obstructive pulmonary diseaseABIM. *See* American Board of Internal Medicine

Abscesses, IDU-related, 15:203-204

bacteria associated with, 15:203, 204t

spinal epidural, 15:206-207

treatment of, 15:203-204, 205t

#### Abuse

head trauma, 539Z (June):5-7

physical, Trauma 5:4-10

Abusive physicians, S03180:5-6

AC (hydrogen cyanide HCN), 9:127

ACE-inhibitors, 19:245t

Acetaminophen, 10:139

Achalasia, 17:223, 224t

Achilles tendon rupture, 20:269-271

location and incidence, 20:269-270, 269f

loss of Kager's triangle with, 20:270-271, 271f

mechanism of, 20:270, 270t

Acid suppression test, 17:223

ACP. *See* Antivenin (Crotalidae) polyvalentACS. *See* American College of Surgeons

Activated charcoal, 14:188-189

#### Activated protein C

mechanism of, 25:332, 335f

for sepsis, 25:334-335

Acute bacterial cystitis, 10:138-139

Acute bacterial exacerbations of chronic bronchitis (ABECB), 22:293-295, 295-296

antibiotic agents for, 23:306-307

antibiotic outcome-effectiveness and total cost of therapy for, 23:307-308

antibiotic selection strategies for, 22:296-298, 23:301-304, 303t, 309

antibiotic therapy for, 23:301-311

antimicrobial selection strategies for, 22:298-299

epidemiology of, 23:306

etiology, 22:295-296

infectious precipitants in, 23:306-308

risk-directed therapy for, 23:309

risk stratification, 22:295-296

SERF pathway for outcome-effective drug selection for, 23:301-304, 303t

short-course therapeutic regimens for, 23:305-306 stages, 23:304

Acute bacterial exacerbations of chronic obstructive pulmonary disease (ABE/COPD), 22:295, 23:302-304

antibiotic outcome-effectiveness and total cost of therapy for, 23:307, 308

antibiotic selection strategies for, 22:296-298, 23:303t, 304, 305t

antimicrobial selection strategies for, 22:298-299 comparative trials of antibiotic efficacy in, 23:304-306

factors influencing patient disposition in, 22:295t, 296

intensification of treatment trigger (IOTT) criteria for risk-stratification in, 23:304, 305t

SERF risk-stratification pathway for antibiotic selection in, 23:304, 304t, 305t

treatment guidelines, 22:296, 297t, 23:302, 303t

Acute confusional state, 13:176

Acute respiratory distress syndrome (ARDS), 25:332

Acute trauma, 3:21-29

Adenopathy, 4:33-34, 34t

Adrenergics, 12:164-165, 165t

Advanced generation fluoroquinolones (AFQs)

for ABECB, 22:298, 23:305, 309

for UTIs, 10:137

Aedes aegypti, 5:58

AFQs. *See* Advanced generation fluoroquinolones

#### Africa

commonly encountered diseases, 5:61-64

common refugee conditions, 5:53t

Africanized ("killer") honeybees, Trauma 3:8

Agent HT, 8:112

Agent T, 8:112

#### Agitation

drug-induced, 12:164-165, 165t, 167-169

treatment of, 12:167-169

AIDS therapy, 19:245t

Air embolism, massive, Trauma 6:4

#### Airway

CX effects, 8:113

difficult, Trauma 2:1-2

direct trauma to, Trauma 2:4-5

failed, Trauma 2:2-3

laryngeal mask, Trauma 2:7-8

Mallampati classification, Trauma 2:2

mechanical distortion of, Trauma 1:2

preexisting difficult, Trauma 1:1-2

surgical, Trauma 2:8-9

trauma, Trauma 1:1-2

Airway adjuncts, Trauma 1:4t, Trauma 2:6-8

Airway cart, Trauma 1:4t

#### Airway management

complicating factors, Trauma 1:2t

in hypotensive patient, Trauma 1:9

indications for invasive intervention, Trauma 1:2-3

LEMON law, Trauma 2:2, 3t

pediatric, Trauma 1:9

<p>strategies for, Trauma 1:1-11, Trauma 2:1-11 in trauma patient, Trauma 2:3-6</p> <p><b>Albendazole</b> for hookworm, 4:41 for liver flukes, 5:61 for neurocysticercosis, 5:54 for pinworm, 4:40 for roundworm, 4:40 for whipworm, 4:40</p> <p><b>Albuterol</b>, 24:320</p> <p><b>Alcohols</b>, 12:164-165, 165t</p> <p><b>Alprazolam</b>, 18:236</p> <p><b>Altered mental status</b> algorithm for diagnosis and management, 12:168f DONT treatment, 12:167 drug-induced, 12:164</p> <p><b>Amantadine</b>, 14:192t</p> <p><b>American Board of Internal Medicine (ABIM)</b>, S03180:1-2</p> <p><b>American College of Surgeons Committee on Trauma (ACS-COT) Subcommittee on Outcomes</b>, Trauma 6:8, 9t</p> <p><b>Amidate (etomidate)</b>, Trauma 1:6-7, 6t</p> <p><b>Amoebiasis</b>, 5:55-56, 57t</p> <p><b>Amoxicillin</b> for ABECB, 23:307, 309 for ABE/COPD, 23:307 for acute bacterial cystitis, 10:138 for acute UTI, 7:92t for UTIs, 10:139t</p> <p><b>Amoxicillin-clavulanate</b> for ABECB, 23:309 for acute exacerbations of COPD, 22:297t, 23:303t, 304, 307, 308 for acute UTI, 7:92t for pyelonephritis, 7:93t, 10:141t for UTIs, 10:139t</p> <p><b>Ampicillin resistance</b>, 7:88</p> <p><b>Ampicillin/sulbactam</b>, 7:93t, 10:141t</p> <p><b>Amylase</b>, 19:246, 246t</p> <p><b>Analgesia</b>, 18:237</p> <p><b>Anaphylactic shock</b> management of, 26:355 medications for, 26:355, 355t</p> <p><b>Anatomy</b> of cervical spine, Trauma 4:1, 2f, 3t of congenital heart disease, 6:73-77 of foot, 21:277-279 pediatric airway, Trauma 1:9 vascular, lower extremity, 2:12, 13f</p> <p><b>Ancylostoma duodenale</b>, 4:40-41</p> <p><b>Anectine (succinylcholine)</b>, Trauma 1:7t, 8</p> <p><b>Anemia</b>, 5:54t, 59</p> <p><b>Anesthesia</b> local, 15:203-204, 205t topical, Trauma 2:6t</p> <p><b>Aneurysm dissection</b>, 17:224</p> <p><b>Aneurysms, popliteal artery</b>, 2:17f, 18, 18f</p> <p><b>Ankle</b>, 20:257-275 evaluation of, 20:258-259</p>	<p>imaging of, 20:259-260</p> <p>Ottawa ankle rules, 20:259, 259t, 21:280, 281t</p> <p>tendon injuries, 20:269-273</p> <p><b>Ankle dislocation</b>, 20:269</p> <p><b>Ankle fractures</b>, 20:264-268 classification of, 20:265 complications, 20:267-268 Danis-Weber classification of, 20:265, 265f Lauge-Hansen classification of, 20:265 open, 20:265-266 orthopedic consultation, 20:264-265, 264t pediatric, 20:268-269</p> <p><b>Ankle sprains</b>, 20:260-264 assessment of, 20:261 classification of, 20:260-261, 260t differential diagnosis of, 20:261, 261t lateral, 20:262 medial, 20:262-263 misdiagnosis, 20:261-262 outcome, 20:263-264 prevention of, 20:264 syndesmotic, 20:262-263 treatment of, 20:262</p> <p><b>Anomalous left coronary artery</b>, 6:76</p> <p><b>Anterior drawer test</b>, 20:259</p> <p><b>Anterior vertebral wedging, apparent</b>, Trauma 4:8, 8f</p> <p><b>Antiarrhythmics</b> potassium efflux blockers, 14:195t sodium channel blockers, 14:192t</p> <p><b>Antibiotic therapy</b> for ABECB, 22:293-295, 296-298, 23:301-311 for acute bacterial cystitis, 10:138-139 appropriate use of, 22:296-298 for asymptomatic bacteriuria, 10:138 for bronchiolitis, 24:320-321 for chlorine exposure, 8:103 for IDU abscesses, 15:203-204, 205t options, 23:302 outcome-optimizing and compliance-enhancing, 10:137-138 for PFIB inhalation, 8:106 for phosgene inhalation, 8:105 for pyelonephritis, 7:93t, 10:141t risk-directed, 23:309 for sepsis, 25:339 for septic shock, 25:339t, 26:352, 352t SERF pathway for outcome-effective drug selec- tion, 23:301-304 for UTI, 7:89, 92t, 10:135-145, 139t for UTI in pregnancy, 10:142t</p> <p><b>Anticholinergics</b>, 12:164-165, 165t, 166t</p> <p><b>Anticoagulants</b>, 25:335f</p> <p><b>Antidepressants</b>, 12:164-165, 165t</p> <p><b>Antidotes</b> cyanide antidote kit, 9:128-129 for drug toxicity, 12:169, 170t Lilly cyanide kit, 9:128 MARK I kits, 9:126, 127 Pasadena kit, 9:128</p>	<p>pediatric doses for chemical warfare agents, 9:124t, 126-127</p> <p><b>Antiemetics</b>, 12:164-165, 165t</p> <p><b>Antihistamines</b> potassium efflux blockers, 14:195t toxidromes, 12:164-165, 165t</p> <p><b>Anti-inflammatory drugs</b>, 19:245t</p> <p><b>Antimalarial drugs</b>, 4:38-39, 39t</p> <p><b>Antimicrobial therapy</b>. <i>See also</i> Antibiotic therapy drugs strongly associated with acute pancreatitis, 19:245t selection strategies for ABECB, 22:298-299</p> <p><b>Antipsychotics</b> potassium efflux blockers, 14:195t toxidromes, 12:164-165, 165t</p> <p><b>Antithrombin III</b>, 25:332, 335f</p> <p><b>Antivenin therapy</b> antivenin (Crotalidae) polyvalent (ACP), Trauma 3:3-4 for snakebite, Trauma 3:3-4</p> <p><b>Antiviral therapy</b>, 24:321</p> <p><b>Aorta, cross-clamp of</b>, Trauma 6:8f</p> <p><b>Aortic dissection</b>, 17:224-226 DeBakey classification, 17:224, 225 diagnostic testing for, 17:225-226, 226t differential diagnosis of, 17:225, 225t Stanford classification, 17:224, 225</p> <p><b>APACHE II criteria</b>, 19:250</p> <p><b>Apache II scale</b>, 11:148</p> <p><b>Apert's syndrome</b>, Trauma 4:4t</p> <p><b>Apnea test</b>, 11:159</p> <p><b>Arachnida</b>, Trauma 3:5</p> <p><b>ARDS</b>. <i>See</i> Acute respiratory distress syndrome</p> <p><b>Arrhythmia</b>, 14:193, 193f</p> <p><b>Arrington v. Wong</b>, 539Z (March):3</p> <p><b>Arsine</b>, 9:129</p> <p><b>Arteries</b> of foot, 21:279 switch repair, 6:78-79</p> <p><b>Arthritis, septic</b>, 15:205-206</p> <p><b>Ascaris (roundworm)</b>, 4:39, 40, 41f complications of, 4:40t time between infection and symptom onset, 4:33t</p> <p><b>Ascaris lumbricoides</b>, 4:39</p> <p><b>Asia</b> commonly encountered diseases, 5:59-61 common refugee conditions, 5:53t</p> <p><b>Aspiration protection</b>, Trauma 1:3</p> <p><b>Asymptomatic bacteriuria</b> antimicrobial management of, 10:138 management of, 7:89-90</p> <p><b>Ativan (lorazepam)</b> for acute panic, 18:236 for delirium, 13:183</p> <p><b>Atlantoaxial injuries</b>, Trauma 4:7</p> <p><b>Atlantoaxial rotary subluxation</b>, Trauma 4:7-8</p> <p><b>Atlas fractures</b>, Trauma 4:7</p> <p><b>Atrial baffle procedures</b>, 6:79</p> <p><b>Atrial septal defects</b>, 6:76</p> <p><b>Atrioventricular block</b>, 14:194-195, 196f</p>
---	---	--

**Atrioventricular septal defects**, 6:76-77  
**Atropine**, 9:124-125  
for beta-blocker toxicity, 14:191  
for calcium channel blocker toxicity, 14:190  
pediatric doses, 9:124t  
in pregnancy, 9:127  
**Authorization, prior**, 539Z (March):6  
**Autonomic response**, 26:347  
**AVPU scale**, 11:148  
**Awake intubation**, Trauma 2:6, 6t  
**Axid (nizatidine)**, 26:355t  
**Azithromycin**  
for ABECB, 23:305-306, 308-309, 309  
for ABE/COPD, 22:295, 297t, 23:303t, 304, 305, 307

## B

**Baber v. Hospital Corporation of America**, 539Z (March):2  
**Bacterial infections**  
acute bacterial cystitis, 10:138-139  
acute bacterial exacerbations of COPD (ABE/COPD), 22:295, 295t, 296-298, 297t, 298-299, 23:302-304, 303t, 304-306, 305t, 307, 308  
acute exacerbations of chronic bronchitis (ABECB), 22:293-299, 23:301-311  
associated with IDU abscesses, 15:203, 204t  
associated with injection drug use, 15:200  
in lower respiratory tract, 22:296, 297t, 23:302, 303t  
**Bacteriuria, asymptomatic**, 7:89-90, 10:138  
**Bacteroides**, 15:203, 204t  
**Bag-valve mask (BVM)**, Trauma 2:1  
**Baker's cysts**, 2:17f, 18  
**Barbiturates**, 12:164-165, 165t  
**Bark scorpion (*Centruroides exilicauda*)**, Trauma 3:7  
**Battered babies**, 539Z (June):6  
**Bees, wasps, and ants**, Trauma 3:8  
**Belladonna alkaloids**, 12:164-165, 165t  
**Benadryl**. *See* Diphenhydramine  
**Benznidazole**, 5:57  
**Benzodiazepines**  
for acute panic, 18:236  
for delirium, 13:182-183  
for drug-induced seizures, 12:170  
for nerve agents, 9:126  
toxidromes, 12:164-165, 165t  
**Beta-blockers**, 14:191, 191t  
**Beta-blocker toxicity**, 14:191-192  
**Bicarbonate therapy**, 25:338  
**Bilharzia**, 5:61  
**Bimalleolar fractures**, 20:266  
**BIMC test**. *See* Blessed Information-Memory-Concentration test  
**Binary agents**, 9:124  
**Biomedical industry**, S03180:6  
**Biot's respiration**, 11:150  
**Bispyridinium oximes (H oximes)**, 9:125-126

**Bites and envenomations**, Trauma 3:1-11  
hymenoptera, Trauma 3:8  
scorpions, Trauma 3:7  
snakes, Trauma 3:1-5  
spiders, Trauma 3:5-7  
**Black widow spiders (*Latrodectus*)**, Trauma 3:6-7  
**Blalock-Taussig shunt**, 6:77, 78f  
**Blessed Information-Memory-Concentration (BIMC) test**, 13:179, 179t  
**Blessed Orientation-Memory-Concentration (BOMC) test**, 13:179, 179t  
**Blister (vesicant) agents**, 8:102t, 107-112  
CDC threat list, 9:131t  
improvisational, 9:130t  
threat analysis, 8:113-114  
**Blood agents**, 8:102t, 9:127-129  
CDC threat list, 9:131t  
improvisational, 9:130t  
**Blood transfusions**, 25:339  
**Boerhaave's syndrome**, 17:224, 224t  
**Bohler's angle**, 21:280, 280f  
**BOMC test**. *See* Blessed Orientation-Memory-Concentration test  
**Bone scan, radionuclide**, Trauma 5:4  
**Bones**, of foot, 21:277, 279f  
**Bowel**, 3:27, 28f  
**Brain death**, 11:158-159  
**Brain injury**  
secondary, 11:154  
traumatic, 11:156, 156t  
**Brain natriuretic peptide (BNP)**, 16:212-213  
in CHF and symptomatic LV dysfunction, 16:213-214, 216f  
comparison with other diagnostic variables of CHF, 16:213, 215t  
diagnostic implications, 16:213-214, 215t  
effects of, 16:212, 213t  
prevention of VTE in HF with, 16:216-217  
prognostic implications, 16:214-216  
therapeutic implications, 16:216  
use in ED, 16:217  
**Brain stem coma**, 11:148-149, 151t  
**Brief Mental Status Examination**, 13:179t  
**Bronchiolitis**, 24:313-327  
chest x-ray findings in, 24:318, 318f  
Cincinnati Guidelines, 24:321-322, 321t  
clinical evaluation of, 24:316-318  
clinical presentation of, 24:316  
definition of, 24:314  
ED and outpatient issues, 24:319-320, 320-321  
evidence-based therapy for, 24:323t  
hospital guidelines for, 24:321-322, 321t  
recommendations for palivizumab (Synagis) prophylaxis candidates, 24:322t, 324  
summary recommendations, 24:323t, 324  
treatment and controversy, 24:318-319  
**Bronchitis, chronic**, 22:293-299, 23:301-311  
**Bronchodilators**, 24:319  
**Brooker v. Desert Hospital**, 539Z (March):4-5  
**Brown recluse spider (*Loxosceles*)**, Trauma 3:5-6

**Brown recluse spider bite**  
management, Trauma 3:6  
systemic effects, Trauma 3:6, 6t  
unproven treatments, Trauma 3:6, 6t  
**Bruises**  
in babies, Trauma 5:6t  
in child abuse, 539Z (June):2-3, 3f, Trauma 5:8-9  
conditions that may be confused with, 539Z (June):3  
linear and looped, 539Z (June):2-3, 3f  
**Bryant v. Redbud Community Hospital**, 539Z (March):5  
**B-type natriuretic peptide**, 16:211-219  
**Bucket handle fractures**, 539Z (June):5  
**Bullard laryngoscope**, Trauma 2:7  
**Bullous impetigo**, 539Z (June):4  
**Burditt v. United States Department of Health and Human Services**, 539Z (March):5-6  
**Burns**  
abusive, 539Z (June):3-4, Trauma 5:9-10  
airway management in, Trauma 2:5-6  
full-thickness, 539Z (June):4, 5f  
medical conditions that may be confused with, 539Z (June):4  
**BVM (bag-valve mask)**, Trauma 2:1

## C

**Calcaneal fractures**, 21:281-283  
**Calcification, delayed**, Trauma 4:9  
**Calcium**  
for beta-blocker toxicity, 14:191  
for calcium channel blocker toxicity, 14:190  
**Calcium channel blockers**, 14:189, 189t  
for esophageal motility disorders, 17:224t  
toxicity, 14:189-191  
**Calcium gluconate**, Trauma 3:6-7  
**CAM**. *See* Confusion Assessment Method  
**CAM-ICU**. *See* Confusion Assessment Method-ICU  
**Cao Gaio**, 539Z (June):3  
**CAP**. *See* Community-acquired pneumonia  
**Carbamate insecticides**, 12:164-165, 165t  
**Carbamazepine**, 14:192t  
**Carbon dioxide**  
end-tidal (etCO<sub>2</sub>), 26:350  
partial pressure of (pCO<sub>2</sub>), 26:350  
**Carbonyl chloride (COCl<sub>2</sub>)**, 8:103  
**Cardiac chest pain**, 18:236t  
**Cardiac massage, open**, Trauma 6:4-5, 7f  
**Cardiac physiology**, 14:188, 189f  
after diphenhydramine overdose, 14:193, 193f  
after hydroxychloroquine overdose, 14:192-193, 193-194, 193f, 194f  
after propoxyphene overdose, 14:192-193, 192f  
after verapamil overdose, 14:189, 190f  
**Cardiogenic shock**, 26:353  
**Cardiotoxins**, 14:187-198  
**Cardiovascular dysfunction**, 25:332t  
**Cardiovascular support**, Trauma 1:3  
**Cardioversion**, 14:194

**Cartridge respirators**, 9:132

**Catecholamines**  
for beta-blocker toxicity, 14:191  
for calcium channel blocker toxicity, 14:190

**Catheterized patients**  
pulmonary artery (PA) catheters, 25:336-337, 26:350  
UTI management in, 10:140-141

**Cavitary tuberculosis**, 4:36, 36f

**Cefactor**, 23:307

**Cefazolin**, 21:281

**Cefprozil**, 23:307

**Ceftriaxone**, 7:93t, 10:141t

**Cefuroxime**, 23:307

**Cefuroxime-axetil**, 23:307

**Cellular hypoxia**, 26:347

**Centers for Disease Control and Prevention threat list**, 9:130-131, 131t

**Centers for Medicare and Medicaid Services (CMS)**, 539Z (March):1

**Central nervous system depression, drug-induced**, 12:169-170

**Central nervous system toxicity**, 12:163-173  
differential diagnosis, 12:167, 169t  
general treatments, 12:167  
history and physical examination, 12:166-167  
manifestations, 12:164-166

**Central neurogenic or primary hyperventilation (CNH)**, 11:150

**Central venous oxygen saturation (ScvO<sub>2</sub>)**, 26:350

**Central venous pressure (CVP)**, 26:350

***Centruroides exilicauda* (bark scorpion)**, Trauma 3:7

**Cephalexin**, 10:138

**Cephalosporin resistance**, 7:88

**Cephadrine**, 23:307

**Cervical spine**  
anatomy of, Trauma 4:1, 2f  
developmental biology of, Trauma 4:1-3  
malformations and anomalies, Trauma 4:2-3, 4t  
pseudosubluxation of, Trauma 4:8  
tethering ligaments, Trauma 4:1, 3t  
trauma considerations, Trauma 1:2

**Cervical spine injury**  
airway management in, Trauma 2:5  
atlantoaxial, Trauma 4:7  
diagnosis of, Trauma 4:7, 7f  
distribution of, Trauma 4:3  
etiology, Trauma 4:3-4  
fracture with subluxation, Trauma 4:6, 6f  
ligamentous, Trauma 4:6, 6f  
pediatric, Trauma 4:1-11  
radiographic evaluation of, Trauma 4:5-7, 5t, 6f  
radiographic variants simulating, Trauma 4:8-9  
severe, Trauma 4:3, 5f

**Cervical vertebra**, Trauma 4:1, 2f

**Chagas disease**, 4:33t, 5:56-57

**Charcoal, activated**, 14:188-189

**Chemical protective attire**, 9:131-132

**Chemical warfare agents**, 8:99-116, 102t, 9:119-133

blood agents, 8:102t, 9:127-129

CDC threat list, 9:130-131, 131t

choking (pulmonary), 8:101-107, 102t

improvisational, 8:102t, 9:130, 130t

incapacitating agents, 8:102t

lethal, 8:101, 102t

nerve agents, 8:102t

nonlethal, 8:102t

pediatric antidote doses for, 9:124t, 126-127

vesicant (blister) agents, 8:102t, 107-112, 113-114

vomit agents, 8:102t

**Chest pain**  
cardiac causes, 18:236t  
causes of, 18:236t, 237  
gastrointestinal causes, 17:222-224, 224t, 18:236t  
musculoskeletal causes, 18:235t, 236-237  
neurologic causes, 18:236t  
noncardiac, 17:221-228, 18:229-240  
psychiatric causes, 18:235-236, 236t  
pulmonary causes, 18:229-235, 236t  
vascular causes, 18:236t

**Chest physiotherapy**, 24:321

**Chest problems**, 4:33-34, 34t

**Chest wall pain**  
causes of, 18:236t  
musculoskeletal causes of, 18:235t, 236

**Chest wound**  
penetrating, Trauma 6:4, 5f  
stab wound, Trauma 6:4, 6f

**Chest X-ray**  
in bronchiolitis, 24:318, 318t  
in cavitary tuberculosis, 4:36f

**Cheyne-Stokes respiration (CSR)**, 11:150

**Child abuse**, 539Z (June):1-8, Trauma 5:1-11  
abusive head trauma, 539Z (June):5-7  
cutaneous manifestations, 539Z (June):2-4, 3f, 5f  
definition, 539Z (June):1  
epidemiology, 539Z (June):1-2  
fractures, 539Z (June):4-5, 6f  
history and physical examination, Trauma 5:2-3  
indicators of, Trauma 5:2  
laboratory and radiographic data, Trauma 5:3-4  
manifestations of, Trauma 5:4-10

**Child Abuse Prevention and Treatment Act (P.L. 93-247)**, 539Z (June):1

**Child Protective Services (CPS)**, Trauma 5:1

**Children**. *See also* Pediatric patients  
cervical spine injury distribution (age/location), Trauma 4:3  
head trauma in, Trauma 5:4-6  
intracranial injury in, Trauma 5:5, 5f  
physical abuse of, 539Z (June):1-8  
rib fractures in, Trauma 5:3-4, 4f  
steroids in, Trauma 4:9  
Tucson Children's Respiratory Study, 24:315, 316t

**Children's Hospital Medical Center (Cincinnati, OH)**, 24:321-322

***Chlamydia trachomatis***, 7:87, 88

**Chlorine (Cl) gas**, 8:101-103, 103t

**Chloropicrin (PS)**, 8:101

**Chloroquine**, 14:192t, 195t  
for amoebiasis, 5:56  
for malaria, 4:38, 39t

**Choking (pulmonary) agents**, 8:101-107, 102t  
CDC threat list, 9:131t  
improvisational, 9:130t

**Cholinergics**, 12:164-165, 165t, 166t

**Cholinesterase**  
"aging" associated with GD (soman), 9:122, 123f, 125  
regeneration by 2PAM, 9:125, 125f

**Chronic bronchitis, acute bacterial exacerbations of (ABECB)**, 22:293-299, 23:301-311

**Chronic digoxin toxicity**, 14:194-195, 196f

**Chronic obstructive pulmonary disease, acute bacterial exacerbations of (ABE/COPD)**, 22:295, 295t, 296-298, 297t, 298-299, 23:302-304, 303t, 304-306, 305t, 307, 308

**Cincinnati experience**, 24:321-322

**Cincinnati Guidelines**  
for bronchiolitis, 24:321-322, 321t  
multisite extension of, 24:322

**Ciprofloxacin (Cipro<sup>®</sup>)**  
for acute exacerbations of COPD, 22:297t, 23:303t, 307, 308, 309  
for acute pyelonephritis, 10:140  
adverse events, 10:138, 138t  
for pyelonephritis, 7:93t, 10:139-140, 141t  
resistance to, 7:88  
side effect, safety, and tolerability profile, 7:91t, 10:138t  
for UTIs, 7:91t, 10:136, 137-138, 138t

**Ciprofloxacin extended release (Cipro XR<sup>®</sup>)**  
adverse events, 10:138, 138t  
side effect, safety, and tolerability profile, 7:91t, 10:138t  
for UTIs, 7:91t, 10:137, 138t, 139t

**Circumcision**  
female, 5:62-64  
pharaonic, 5:63  
sunna, 5:63

**Cisapride**, 14:195t

**Citrobacter**, 7:87, 88t

**Civilian threats**, 8:100

**CK (cyanogen chloride CNCl)**, 9:127

**Clarithromycin**  
for ABECB, 23:305-306, 307, 308-309, 309  
for acute exacerbations of COPD, 22:297t, 23:303t

**Cleveland Clinic (Cleveland, OH)**, 24:322-323

**Clitoridectomy**, 5:63, 64f

**Clonorchis sinensis**, 4:33t, 5:60

**Closed head trauma**  
airway management in, Trauma 2:3  
that may be confused with abusive head trauma, 539Z (June):7

**Clouding of consciousness**, 11:147

**CMS**. *See* Centers for Medicare and Medicaid Services

**CNH**. *See* Central neurogenic or primary

<p>hyperventilation</p> <p><b>Coagulation cascade</b>, 25:332, 334f</p> <p><b>Coarctation of the aorta</b>, 6:75-76, 78</p> <p><b>Cocaine</b>, 14:192t, 15:199-200</p> <p><b>Cognitive impairment screening tests</b>, 13:179, 179t</p> <p><b>Cognitive Test for Delirium</b>, 13:179t</p> <p><b>Cohen, William</b>, 8:99</p> <p><b>Coin-rubbing</b>, 539Z (June):3</p> <p><b>Cold calorics</b>, 11:152</p> <p><b>Color flow Doppler</b>, 2:15, 16f</p> <p><b>Coma</b>, 11:147-161</p> <ul style="list-style-type: none"> <li>ancillary diagnostic testing, 11:155-156</li> <li>brain stem vs hemispheric, 11:148-149, 151t</li> <li>causes, 11:156</li> <li>conditions that mimic, 11:157-158</li> <li>definition, 11:148</li> <li>emergency management, 11:153-154</li> <li>Glasgow Outcome Scale, 11:158, 158t</li> <li>initial assessment, 11:149-153</li> <li>myxedema, 11:156-157</li> <li>neurologic examination, 11:150-153</li> <li>pathophysiology, 11:148-149</li> <li>physical examination, 11:149-153, 153t</li> <li>physical signs, 11:153, 154t</li> <li>scenarios that require specific consideration, 11:156-157</li> <li>shortened protocol for, 11:157f</li> </ul> <p><b>Coma cocktail</b>, 11:154-155</p> <p><b>Coma scales</b>, 11:148</p> <p><b>Common femoral vein</b>, 2:15, 17f</p> <p><b>Community-acquired pneumonia (CAP)</b>, 10:137</p> <p><b>Computed tomography</b>. <i>See</i> CT scans</p> <p><b>Concentration camp syndrome</b>, 4:43</p> <p><b>Concentration time product (Cot or Ct)</b>, 8:101</p> <p><b>Confusional state, acute</b>, 13:176</p> <p><b>Confusion Assessment Method (CAM)</b>, 13:179, 179t, 181t</p> <p><b>Confusion Assessment Method-ICU (CAM-ICU)</b>, 13:179, 179t</p> <p><b>Confusion Rating Scale</b>, 13:179t</p> <p><b>Congenital heart disease</b>, 6:71-83</p> <ul style="list-style-type: none"> <li>anatomy of, 6:73-77</li> <li>critical, 6:72-73</li> <li>glossary, 6:73t</li> <li>initial presentation of, 6:72-73</li> <li>in newborn, 6:73</li> <li>in shock, 6:73</li> <li>shunt procedures for, 6:77</li> <li>surgical procedures for, 6:76-80</li> <li>treatment of, 6:73</li> </ul> <p><b>Congestive heart failure</b>. <i>See</i> Heart failure</p> <p><b>Consciousness, clouding of</b>, 11:147</p> <p><b>Consolidated Omnibus Budget Reconciliation Act (COBRA) of 1986</b>, 539Z (March):2</p> <p><b>Contusion, chest wall pain secondary to</b>, 18:235t, 236</p> <p><b>Cooley's disease</b>, 5:60</p> <p><b>Copperhead snakebite</b>, Trauma 3:2, 4f</p> <p><b>Coral snakes (Elapidae)</b>, Trauma 3:1</p> <p><b>Core rewarming</b>, Trauma 1:3</p>	<p><b>Corrosive industrial acids and bases</b>, 9:131t</p> <p><b>Corticosteroids</b></p> <ul style="list-style-type: none"> <li>for bronchiolitis, 24:320</li> <li>long-term considerations of use, 24:320</li> </ul> <p><b>Corticotropin IV</b>, 25:336</p> <p><b>Cost containment</b></p> <ul style="list-style-type: none"> <li>antibiotic outcome-effectiveness and total cost of therapy, 23:307-308</li> <li>with emergency ultrasound, 1:2</li> </ul> <p><b>Costochondritis, chest wall pain secondary to</b>, 18:235t, 237</p> <p><b>Co-trimoxazole</b>, 23:307</p> <p><b>CPS</b>. <i>See</i> Child Protective Services</p> <p><b>Cranial CT imaging</b>, 11:156, 156t</p> <p><b>Cricothyrotomy</b></p> <ul style="list-style-type: none"> <li>difficult, predictors of, Trauma 2:8, 8t</li> <li>technique, Trauma 2:8-9, 9f</li> </ul> <p><b>Cross-clamp, aorta</b>, Trauma 6:8f</p> <p><b>Crotalidae</b>, Trauma 3:1</p> <p><b>Crotalidae Polyvalent Immune Fab antivenin (FabAV)</b>, Trauma 3:3-4</p> <p><b>Crotalid envenomation</b></p> <ul style="list-style-type: none"> <li>antivenin (Crotalidae) polyvalent (ACP), Trauma 3:3-4</li> <li>recommended laboratory studies, Trauma 3:3, 6t</li> </ul> <p><b>Crouzon syndrome</b>, Trauma 4:4t</p> <p><b>CSR</b>. <i>See</i> Cheyne-Stokes respiration</p> <p><b>Cot or Ct (concentration time product)</b>, 8:101</p> <p><b>CT scans</b></p> <ul style="list-style-type: none"> <li>in children with non-accidental injuries, Trauma 5:4</li> <li>in children with subdural hemorrhage and ischemic changes, Trauma 5:5, 5f</li> <li>in traumatic brain injury, 11:156, 156t</li> </ul> <p><b>CT severity index</b>, 19:247, 247t, 250</p> <p><b>Cuboid fractures</b>, 21:286</p> <p><b>Culture, urine</b>, 7:92</p> <p><b>Cuneiform fractures</b>, 21:286</p> <p><b>CVP</b>. <i>See</i> Central venous pressure</p> <p><b>Cyanide</b>, 9:127-129</p> <p><b>Cyanide antidote kit</b>, 9:128-129</p> <p><b>Cyanogen chloride CNCl (CK)</b>, 9:127</p> <p><b>Cyanosis</b>, 6:71-72</p> <p><b>Cysticercosis</b>, 4:33t</p> <p><b>Cystitis</b></p> <ul style="list-style-type: none"> <li>antimicrobial management of, 10:138-139</li> <li>incidence of, 7:88, 89t</li> </ul> <p><b>Cytokines</b>, 25:332, 334f</p> <p><b>D</b></p> <p><b>Danis-Weber ankle fracture classification of</b>, 20:265, 265f</p> <p><b>Dating skeletal trauma</b>, 539Z (June):5</p> <p><b>Death, brain</b>, 11:158-159</p> <p><b>DeBakey classification</b>, 17:224, 225</p> <p><b>Decongestants</b>, 12:164-165, 165t</p> <p><b>Decontamination</b></p> <ul style="list-style-type: none"> <li>chlorine, 8:102</li> <li>CX, 8:113</li> </ul>	<p>mustard, 8:110</p> <p>PFIB, 8:106</p> <p>phosgene, 8:105</p> <p><b>Decreased mental status, drug-induced</b>, 12:165</p> <p><b>Dedicated EDs</b>, 539Z (March):3</p> <p><b>Deep venous thrombosis</b></p> <ul style="list-style-type: none"> <li>anatomy, 2:12</li> <li>diagnosis, 2:11-12</li> <li>incidence, 2:11</li> <li>ultrasound evaluation, 2:11-19, 13f</li> </ul> <p><b>Delirium</b>, 13:175-186</p> <ul style="list-style-type: none"> <li>assessment methods, 13:179, 179t</li> <li>causes, 13:180-181, 183t</li> <li>definition of, 11:147-148</li> <li>diagnosis, 13:177-180, 177t</li> <li>diagnostic classification systems, 13:179, 179t</li> <li>diagnostic instruments and rating scales, 13:179, 179t</li> <li>historical background, 13:175-176</li> <li>incidence, 13:176-177</li> <li>"I Watch Death" mnemonic, 13:180-181</li> <li>management, 13:181-183</li> <li>medications that may cause, 13:177, 177t</li> <li>pathophysiology, 13:177</li> <li>patient evaluation, 13:180-181</li> </ul> <p><b>Delirium Assessment Scale</b>, 13:179t</p> <p><b>Delirium Rating Scale (DRS)</b>, 13:179, 179t</p> <p><b>Delirium Symptom Interview</b>, 13:179t</p> <p><b>Delirium Writing Test</b>, 13:179t</p> <p><b>Dengue fever</b>, 5:58-59</p> <p><b>Dengue hemorrhagic fever (DHF)</b>, 5:58</p> <p><b>Dengue shock syndrome (DSS)</b>, 5:58, 59t</p> <p><b>DES</b>. <i>See</i> Diffuse esophageal spasm</p> <p><b>Desert Hospital, Brooker v.</b>, 539Z (March):4-5</p> <p><b>Developmental biology</b>, Trauma 4:1-3</p> <p><b>Dexamethasone</b></p> <ul style="list-style-type: none"> <li>for anaphylactic shock, 26:355t</li> <li>for bronchiolitis, 24:320</li> <li>for neurocysticercosis, 5:55</li> <li>for sepsis, 25:336</li> </ul> <p><b>Dextrose solution</b>, 13:181</p> <p><b>Diabetes</b>, 10:142</p> <p><b>Diarylaminopropylamine ether</b>, 14:189, 189t</p> <p><b>Diazepam</b>, 9:126</p> <ul style="list-style-type: none"> <li>for acute panic, 18:236</li> <li>doses, 9:126t</li> <li>for drug-induced seizures, 12:170</li> </ul> <p><b>DIC</b>. <i>See</i> Disseminated intravascular coagulation</p> <p><b>Dichloroform oxime</b>, 8:112</p> <p><b>Dicobalt-EDTA (Kelocyanor)</b>, 9:129</p> <p><b>Difficult airway</b></p> <ul style="list-style-type: none"> <li>approach to, Trauma 2:2</li> <li>LEMON law, Trauma 2:2, 3t</li> <li>Mallampati classification, Trauma 2:2</li> <li>predicting, Trauma 2:1-2</li> </ul> <p><b>Diffuse esophageal spasm (DES)</b>, 17:223, 224t</p> <p><b>Digoxin</b></p> <ul style="list-style-type: none"> <li>chronic toxicity, 14:194-195, 196f</li> <li>serum levels, 14:195</li> </ul> <p><b>Digoxin-specific Fab (Digibind or DigiTab)</b>,</p>
---	--	--

14:195-196  
**Dihydropyridines**, 14:189, 189t  
**Dilated and hypodynamic heart**, 3:23f  
**Diltiazem**, 14:192t, 17:224t  
**Diphenhydramine (Benadryl)**, 14:192t  
 for anaphylactic shock, 26:355t  
 for hymenoptera stings, Trauma 3:8  
 overdose, 14:193, 193f  
**Diphosgene (DP)**, 8:101  
**Diprivan (propofol)**, Trauma 1:6t, 7  
**Dislocations**  
 occipitotantal, Trauma 4:7  
 phalangeal, 21:288  
 talar, 21:285  
**Disseminated intravascular coagulation (DIC)**,  
 25:332  
**Diuretics**  
 for chlorine exposure, 8:103  
 for PFIB inhalation, 8:106-107  
 for phosgene inhalation, 8:105  
**Doll's eye reflex test**, 11:152  
**Dopamine**, 25:338  
**Double outlet right ventricle**, 6:76  
**Doxycycline**, 4:39t  
 for ABECB, 23:309  
 for acute exacerbations of COPD, 22:297t, 23:303t  
**Droperidol (Inapsine)**, 13:182, 14:195t  
**Drowsiness**, 11:148  
**Drugs**  
 for anaphylactic shock, 26:355, 355t  
 antimalarial, 4:38-39, 39t  
 injection drug use (IDU), 15:199-209  
 strongly associated with acute pancreatitis, 19:244,  
 245t  
**Drug toxicity**  
 antidotes, 12:169, 170t  
 cardiotoxicity, 14:187-198  
 CNS toxicity, 12:163-173, 169t  
**Duke diagnostic criteria for endocarditis**, 15:202,  
 202t  
**Dyspnea**, 5:54t  
**Dysrhythmia**, 14:193, 193f

## E

**Ectopic pregnancy**, 1:6, 7f, 8f  
**ED50 (effective dose)**, 8:101  
**Effective dose (ED50)**, 8:101  
**Ehlers-Danlos syndrome**, Trauma 4:4t  
**Eikenella**, 15:203, 204t  
**Elapidae (coral snakes)**, Trauma 3:1  
**Electrocardiography (ECG)**, 26:348  
**Embolism**  
 air, massive, Trauma 6:4  
 pulmonary (PE), 18:231-235  
 thromboembolic disease, 18:231-232, 232t  
**Embryology**, 1:4-5, 4f  
**Emergency departments (EDs)**  
 avoiding liability, 539Z (March):7  
 dedicated, 539Z (March):3

**EMTALA requirements**, 539Z (March):2-4  
 screening examinations, 539Z (March):4  
**Emergency department thoracotomy (EDT)**. *See*  
 Thoracotomy  
**Emergency Medical Treatment and Active Labor  
 Act (EMTALA)**, 539Z (March):1  
 history of, 539Z (March):1-2  
 hospital obligations under, 539Z (March):2  
 liability, avoiding, 539Z (March):7  
 on-call requirements, 539Z (March):6  
 proposed changes, 539Z (March):1  
 requirements for emergency departments, 539Z  
 (March):2-4  
 requirements for enforcement, 539Z (March):6-7  
 requirements for notification, 539Z (March):6  
 requirements for patients who refuse to consent,  
 539Z (March):6  
 requirements for prior authorization, 539Z  
 (March):6  
 requirements for screening examinations, 539Z  
 (March):4  
 requirements for stabilizing treatment, 539Z  
 (March):4-5  
 requirements for transfer, 539Z (March):5-6  
 update, 539Z (March):1-8  
**Emergency ultrasound**. *See* Ultrasound  
**EMTALA**. *See* Emergency Medical Treatment and  
 Active Labor Act  
**Encephalopathy, drug-induced**, 12:165-166  
**Endocarditis**, 6:80-81  
 classification of, 15:201-202, 201t  
 Duke diagnostic criteria for, 15:202, 202t  
 infectious (IE), 15:201-203, 202t  
**Endotracheal tube introducer**, Trauma 2:7  
**Endotracheal tube lightwand unit (ETT-LW)**,  
 Trauma 2:6-7  
**Endotracheal tubes**, Trauma 1:4t  
**Endovaginal ultrasound**, 1:4, 5-6, 5f, 6f  
**End-tidal carbon dioxide (etCO<sub>2</sub>)**, 26:350  
**Entamoeba histolytica**, 4:40t, 5:55, 56  
**Enterobacter cloacae**  
 incidence of, 7:88, 89t  
 in UTIs, 7:87, 88t  
**Enterobius (pinworm)**, 4:40  
**Enterococci, vancomycin-resistant**, 10:140  
**Enterococcus faecalis**  
 antibiotic therapy for, 7:92t, 10:137-138  
 incidence of, 7:88, 89t  
 in UTIs, 7:87, 88t  
**Envenomations**, Trauma 3:1-11  
 hymenoptera, Trauma 3:8  
 scorpions, Trauma 3:7  
 snakes, Trauma 3:1-5  
 spiders, Trauma 3:5-7  
**Epidermolysis bullosa**, 539Z (June):4  
**Epidural abscess, spinal**, 15:206-207  
**Epinephrine (EpiPen)**  
 for anaphylactic shock, 26:355, 355t  
 for hymenoptera stings, Trauma 3:8  
**Equipment**

personal protective (PPE), 9:131, 132  
 thoracotomy, Trauma 6:4t, 5  
**Erythromycin**, 14:195t, 23:307  
**Escherichia coli**  
 antibiotic therapy for, 10:137-138, 140  
 complicated lower UTIs, 7:91  
 incidence of, 7:88, 89t  
 resistance, 7:88-89  
 UTIs, 7:87-88, 88t  
 UTIs in men, 10:141  
**Esophageal intubation detector (EID)**, Trauma 1:  
 8-9  
**Esophageal motility disorders**  
 with chest pain, 17:223  
 modern classification of, 17:223, 224t  
 non-specific, 17:223, 224t  
 treatment of, 17:224, 224t  
**Esophageal perforation**, 17:222  
**Esophageal spasm, diffuse**, 17:223, 224t  
**Esophageal-tracheal Combitube**, Trauma 2:8  
**Ethics**, S03180:1-8  
**Etomidate (Amidate)**, Trauma 1:6-7, 6t  
**Evidence-based therapy**  
 for bronchiolitis, 24:323t  
 guidelines for sepsis management, 25:329-343  
**Explosive nitro compounds and oxidizers**, 9:131t  
**Extensor tendon injuries**, 20:272  
**External Laryngeal Manipulation (ELM)**, Trauma  
 1:8  
**Extrauterine pregnancy**, 1:6  
**Extremity problems**, 4:33-34, 34t  
**Eyes**  
 CX effects, 8:113  
 problems elicited by physical examination, 4:33-  
 34, 34t

## F

**Fab fragment therapy**  
 Crotalidae Polyvalent Immune Fab antivenin  
 (FabAV), Trauma 3:3-4  
 digoxin-specific Fab (Digibind or DigiTab),  
 14:195-196  
 for sodium-potassium ATPase blocker toxicity,  
 14:195  
**Failed airway**, Trauma 2:2-3  
**FAST**. *See* Focused Assessment with Sonography in  
 Trauma  
**Female circumcision**, 5:62-64  
 pharaonic, 5:63  
 sunna, 5:63  
**Female genital mutilation**, 5:62  
**Female pelvis**  
 sagittal view, 3:26f  
 transverse view, 3:27f  
**Fentanyl**  
 awake intubation suggestions, Trauma 2:6t  
 dosage, 7:97  
**Fetal alcohol syndrome**, Trauma 4:4t  
**Fetal structures**, 1:4-5

**Fetus**, 1:6, 7f  
**Fever**  
Dengue, 5:58-59  
dengue hemorrhagic (DHF), 5:58  
in immigrants, 5:54t  
injection drug use with, 15:200-201  
**Fiberoptic bronchoscope, flexible**, Trauma 2:8  
**Fibular compression test**, 20:259  
**First-trimester pregnancy**  
location and categorization, 1:4t, 5  
pelvic ultrasound, 1:1-9  
ultrasound interpretation, 1:4  
**Flexor tendon injuries**, 20:272-273  
**Floxin®**. *See* Ofloxacin  
**Fludrocortisone**, 25:336  
**Fluid resuscitation**, 25:337-338  
**Flumazenil**  
for coma, 11:155  
empiric dosing, 12:170t  
for sedation or CNS depression, 12:169-170  
**Fluoroquinolones**  
for ABECB, 23:305  
for acute bacterial cystitis, 10:139  
advanced generation (AFQs), 10:137, 22:298, 23:305, 309  
for pyelonephritis, 7:93t, 10:141t  
for UTIs, 7:88, 89, 92t, 10:135-137, 139t  
**Focused Assessment with Sonography in Trauma (FAST)**, 3:21  
indications for, 3:22t, 23  
left upper quadrant (splenorenal view), 3:26-27, 26f  
parasternal view, 3:24f, 25-26  
pelvic (suprapubic view), 3:27, 27f, 28f  
recommended protocol, 3:28  
right upper quadrant, 3:24f, 25f, 26  
sonographic windows, 3:22t, 23-24  
subxiphoid (subcostal) view, 3:23f, 24-25  
**Folstein Mini-Mental State Examination**, 13:178t, 179, 179t  
**Fontan procedure**, 6:79, 80f  
**Food and water contamination**, 9:130  
**Foot**, 21:277-290  
anatomy of, 21:277-279  
arches, 21:277  
arteries of, 21:279  
bones of, 21:277, 279f  
evaluation of, 21:279-280  
imaging of, 21:280-281  
joints of, 21:277-278, 279f  
ligaments, 21:278  
nerves of, 21:279  
tendons, 21:278-280  
**Foot fractures**, 21:281-285  
misdiagnosis, 21:281  
open, 21:281  
**Forefoot fractures**, 21:287-288  
**Fosfomycin**  
for acute bacterial cystitis, 10:139  
for acute uncomplicated UTI, 7:92t

for uncomplicated UTI, 10:139t  
**Fractures**  
ankle, 20:264-268, 264t, 265f  
atlas, Trauma 4:7  
bimalleolar, 20:266  
calcaneal, 21:281-283  
cervical spine, Trauma 4:6, 6f  
chest wall pain secondary to, 18:235t, 236  
in child abuse, Trauma 5:7-8  
in children, 539Z (June):4-5, 6f  
cuboid, 21:286  
cuneiform, 21:286  
early diagnosis of, Trauma 5:6t  
of foot, 21:281-285  
forefoot, 21:287-288  
hammer, 20:267  
hangman's, Trauma 4:7, 8f  
hindfoot, 21:281-283  
lateral malleolar, 20:266  
Le Fort, Trauma 2:3, 5f  
Maisoneuve, 20:267  
medial malleolar, 20:266  
medical conditions with propensity to, 539Z (June):5  
metatarsal, 21:287-288  
navicular, 21:285-286  
nonaccidental, Trauma 5:6t  
open, 21:281  
phalangeal, 21:288  
pilon, 20:267  
rib, 18:235t, 539Z (June):4, 6f, Trauma 5:3-4, 4f  
skull, Trauma 5:6t  
talar, 21:283-285, 284f  
Tillaux, 20:268  
trimalleolar, 20:266-267  
triplane, 20:268f, 269  
**Fusobacterium**, 15:203, 204t

**G**  
**Gardnerella vaginalis**, 7:87  
**Gastroesophageal reflux disease**  
chest pain with, 17:222-223  
treatment of, 17:224, 224t  
**Gastrointestinal chest pain**, 17:222-224, 224t, 18:236t  
**Gatewood v. Washington Healthcare Corporation**, 539Z (March):4  
**Gatifloxacin (Tequin®)**  
for ABECB, 23:309  
for acute exacerbations of COPD, 22:297t, 23:303t  
for UTIs, 10:136, 137  
**GCS**. *See* Glasgow Coma Scale  
**Genital mutilation, female**, 5:62  
**Gentamicin**  
for IDU-related infectious endocarditis, 15:202-203, 203t  
for open fractures, 21:281  
for pyelonephritis, 7:93t, 10:141t  
**Geriatric patients**, 26:351

**Giardia lamblia**, 4:39, 40t  
**Glasgow Coma Scale (GCS)**, 11:148, 149t  
**Glasgow or Imrie criteria**, 19:250, 250t  
**Glasgow Outcome Coma Scale**, 11:158, 158t  
**Glenn shunt**, 6:79, 81f  
**Global diseases**, 4:35-38  
**Glossary**, 6:73t  
**Gloves**, 9:132  
**Glucagon**  
for beta-blocker toxicity, 14:191  
for calcium channel blocker toxicity, 14:190  
for delirium, 13:181  
**Glucocorticoids**, 24:319-320  
**Glucose**, 11:154-155  
**Glucose-6-phosphate dehydrogenase deficiency**, 5:59  
**Goldenhar syndrome**, Trauma 4:4t  
**Grisel's syndrome**, Trauma 4:7-8

## H

**Halogenated oximes**, 8:112-113  
**Haloperidol (Haldol)**, 13:182, 183  
**Hammer fractures**, 20:267  
**Hampton's hump**, 18:232  
**Hangman's fracture**, Trauma 4:7, 8f  
**Hawkins classification of talar neck fractures**, 21:284, 284f  
**HBOCs**. *See* Hemoglobin-based oxygen carriers  
**Head and neck problems**, 4:33-34, 34t  
**Head trauma**  
abusive, 539Z (June):5-7  
in child abuse, Trauma 5:4-6  
closed, 539Z (June):7, Trauma 2:3  
rapid sequence intubation (RSI) in, Trauma 2:3, 3t  
**Heart**  
dilated and hypodynamic, 3:23f  
gross wall motion abnormality, 3:23f, 25  
hypovolemic, 3:23f  
parasternal view, 3:24f, 25-26  
problems elicited by physical examination, 4:33-34, 34t  
subxiphoid (subcostal) view, 3:23f, 24-25  
**Heart borders**, 3:25  
**Heart disease, congenital**, 6:71-83  
**Heart failure (HF)**  
BNP levels in, 16:213-214, 216f  
BNP vs. NYHA classification of, 16:213, 214f  
diagnosis of, 16:211-212, 213, 215t  
prevention of VTE in, 16:216-217  
**Heart transplantation**, 6:80  
**Heart valves**, 15:201-202, 202t  
**Heavy metals**, 9:131t  
**Hematologic evaluation**  
methods for, 25:332t  
in non-accidental injury, Trauma 5:3  
**Hemispheric coma**, 11:148-149, 151t  
**Hemodynamic resuscitation**, 25:337-339  
**Hemoglobin**  
disorders in immigrants, 5:59-60

<p>variation of child's sodium nitrite dose with hemoglobin concentration, 9:128-129, 129t</p> <p><b>Hemoglobin-based oxygen carriers (HBOCs)</b>, 26:351</p> <p><b>Hemoglobinopathy</b>, 5:59</p> <p><b>Hemopericardium</b> parasternal view, 3:24f, 25 subxiphoid (subcostal) view, 3:23f, 24 traumatic, Trauma 6:3, 4f</p> <p><b>Hemoperitoneum</b>, 3:24f, 25f, 26 splenorenal view, 3:26, 26f suprapubic view, 3:27, 27f, 28f</p> <p><b>Hemorrhage</b> intra-abdominal, Trauma 6:5 intrathoracic, Trauma 6:3, 5f subarachnoid, 11:157 subdural, Trauma 5:5, 5f</p> <p><b>Hemorrhagic fever</b>, 5:58</p> <p><b>Hemorrhagic shock</b>, 26:351-352</p> <p><b>Hemothorax</b>, 3:25f, 26</p> <p><b>Heparin</b>, 18:234</p> <p><b>Hepatic dysfunction</b>, 25:332t</p> <p><b>Hepatitis B</b>, 4:41-43 chronic, 4:33t clinical spectrum, 4:42-43 epidemiology, 4:41-42 prevalence of, 15:207-208, 207t</p> <p><b>Hepatitis C</b>, 15:207-208, 207t</p> <p><b>Heroin</b>, 15:200</p> <p><b>Herpes zoster (shingles)</b>, 18:235t, 236-237</p> <p><b>HF</b>. <i>See</i> Heart failure</p> <p><b>HGG-12</b>, 9:125-126</p> <p><b>HGG-42</b>, 9:125-126</p> <p><b>HHS</b>. <i>See</i> U.S. Department of Health and Human Services</p> <p><b>HI-6</b>, 9:125-126, 126f</p> <p><b>High risk populations</b>, 10:140-142</p> <p><b>Hindfoot fractures</b>, 21:281-283</p> <p><b>Hippocratic Oath</b>, S03180:3</p> <p><b>HIV infection</b> <b>HIV drugs strongly associated with acute pancreatitis</b>, 19:245t prevalence of, 15:207-208</p> <p><b>HMG-CoA reductase inhibitors</b>, 19:245t</p> <p><b>Hookworm</b>, 4:39, 40-41, 40t</p> <p><b>Hospital Corporation of America, Baber v.</b>, 539Z (March):2</p> <p><b>Hospital guidelines</b> for bronchiolitis, 24:321-322, 321t Cincinnati experience, 24:321-322 obligations under EMTALA, 539Z (March):2 for pyelonephritis admission, 10:139</p> <p><b>H oximes</b>, 9:125-126</p> <p><b>Human immunodeficiency virus</b> HIV drugs strongly associated with acute pancreatitis, 19:245t prevalence of, 15:207-208, 207t</p> <p><b>Hun Stuff</b>, 8:107</p> <p><b>Hydrocortisone</b>, 25:336</p> <p><b>Hydrogen cyanide HCN (AC)</b>, 9:127</p>	<p><b>Hydroxychloroquine</b>, 14:192t, 195t</p> <p><b>Hydroxychloroquine overdose</b></p> <p><b>QT interval prolongation after</b>, 14:193-194, 194f sine wave pattern after, 14:192-193, 193f</p> <p><b>Hydroxycobalamin (vitamin B12a)</b>, 9:129</p> <p><b>Hymenolepis nana</b>, 4:39</p> <p><b>Hymenoptera</b>, Trauma 3:1, 8</p> <p><b>Hymenoptera stings</b>, Trauma 3:8</p> <p><b>Hyperalgesia, visceral</b>, 17:223-224, 224t</p> <p><b>Hyperbaric oxygenation</b>, 9:129</p> <p><b>Hypertensive LES</b>, 17:223, 224t</p> <p><b>Hyperventilation</b> central neurogenic or primary (CNH), 11:150 for coma, 11:154 intentional, Trauma 1:3 in unresponsive patients, 11:150, 152t</p> <p><b>Hypnotics, sedative</b> toxidromes, 12:164-165, 165t, 166t withdrawal syndromes, 12:164-165, 166t</p> <p><b>Hypodynamic heart</b>, 3:23f</p> <p><b>Hypoplastic left heart syndrome</b>, 6:75 fenestrated Fontan procedure for, 6:79, 80f staged reconstruction or Norwood procedure for, 6:79, 81f</p> <p><b>Hypotension</b>, Trauma 1:9</p> <p><b>Hypothermia</b>, 11:158</p> <p><b>Hypoventilation</b>, 11:150, 152t</p> <p><b>Hypovolemic heart</b>, 3:23f</p> <p><b>Hypoxia</b> cellular, 26:347 in newborn, 6:73</p> <p><b>I</b></p> <p><b>Ibuprofen</b>, 10:139</p> <p><b>ID50 (incapacitating dose)</b>, 8:101</p> <p><b>IDU</b>. <i>See</i> Injection drug use</p> <p><b>IE</b>. <i>See</i> Infectious endocarditis</p> <p><b>Imaging</b> ankle, 20:259-260 foot, 21:280-281 of IDU abscesses, 15:203-204, 205t Ottawa ankle rules, 20:259, 259t, 21:280, 281t pelvic ultrasound techniques, 1:3-4 tendon injuries, 20:270-271 in UTL, 7:92</p> <p><b>Imipramine</b>, 17:224t</p> <p><b>Immigrant medicine</b> commonly encountered diseases, 4:31-49, 5:51-69 common presenting problems, 5:54t global diseases commonly encountered, 4:35-38 historical evaluation, 4:32-33 physical examination, 4:33-34</p> <p><b>Immobilization</b>, Trauma 1:2</p> <p><b>Immunization</b> measles, 4:44-45 rubella, 4:45 underimmunization, 4:44-45</p> <p><b>Immunosuppressive agents</b>, 19:245t</p> <p><b>Inapsine (droperidol)</b>, 13:182, 14:195t</p>	<p><b>Incapacitating agents</b>, 8:102t, 9:131t</p> <p><b>Incapacitating dose (ID50)</b>, 8:101</p> <p><b>Incendiary agents</b>, 9:130</p> <p><b>Incision and drainage</b>, 15:203-204, 205t</p> <p><b>Induction agents</b>, Trauma 1:6-7, 6t</p> <p><b>Industrial acids and bases, corrosive</b>, 9:131t</p> <p><b>Industrial gases, liquids, and solids</b>, 9:131t</p> <p><b>Infantile RSV disease, severe</b>, 24:317, 318t</p> <p><b>Infection</b> bacterial, 22:296, 297t, 23:302, 303t drug-induced, 12:166 IDU-related, 15:199-209 lower respiratory tract, 24:314 necrotizing soft-tissue, 15:204-205 respiratory tract, 22:296, 297t, 23:302, 303t time until symptom onset, 4:33t urinary tract, 7:85-97 viral seroprevalence and transmission, 15:207-208, 207t</p> <p><b>Infectious endocarditis (IE)</b> classification of, 15:201-202, 201t empiric treatment for, 15:202-203, 203t IDU-related, 15:201-203 valve involvement, 15:201-202, 202t</p> <p><b>Infibulation, total</b>, 5:63, 64f</p> <p><b>Inflammatory cascade</b>, 25:331-332</p> <p><b>Inflammatory mediators</b>, 26:347</p> <p><b>Injection drug use (IDU)</b> with fever, 15:200-201 infectious complications, 15:199-209</p> <p><b>Injury</b> atlantoaxial, Trauma 4:7 cervical spine, Trauma 2:5, Trauma 4:1-11 extensor tendon, 20:272 flexor tendon, 20:272-273 head, Trauma 2:3 intracranial, Trauma 5:5, 5f Lisfranc, 21:286-287 midfoot, 21:285-287 navicular, 21:285-286 non-accidental, Trauma 5:1-11 pediatric cervical spine, Trauma 4:1-11 peroneal tendon, 20:271-272 tendon, 20:269-273</p> <p><b>Insulin</b> for beta-blocker toxicity, 14:191-192 for calcium channel blocker toxicity, 14:190</p> <p><b>Intensification of treatment trigger (IOTT) criteria</b>, 23:304, 305t</p> <p><b>Intestinal parasites</b> clinical spectrum, 4:39-40 complications of, 4:39-40, 40t epidemiology of, 4:39 in immigrants, 4:39-41</p> <p><b>Intra-abdominal hemorrhage</b>, Trauma 6:5</p> <p><b>Intracranial injury</b>, Trauma 5:5, 5f</p> <p><b>Intrathoracic hemorrhage</b>, Trauma 6:3, 5f</p> <p><b>Intrauterine pregnancy</b>, 1:5 abnormal, 1:5-6, 6f early, 1:5, 6f</p>
---	--	---

<p>live, 1:5</p> <p><b>Intravenous access</b>, 25:336-337</p> <p><b>Intravenous drug abuse</b>. <i>See</i> Injection drug use</p> <p><b>Intravenous drug use</b>. <i>See</i> Injection drug use</p> <p><b>Intravenous sedation</b>, Trauma 2:6t</p> <p><b>Intraventricular conduction delay</b>, 14:194-195, 196f</p> <p><b>Intubating laryngeal mask airway</b>, Trauma 2:7-8</p> <p><b>Intubation</b></p> <ul style="list-style-type: none"> <li>alternative techniques, Trauma 2:6-8</li> <li>awake, Trauma 2:6, 6t</li> <li>indications for, Trauma 1:3t</li> <li>nasotracheal, Trauma 2:6</li> <li>predictors of difficulty with, Trauma 2:2</li> <li>rapid sequence, Trauma 1:3-4, 4-9, Trauma 2:3, 3t</li> <li>retrograde, Trauma 2:6, 7f</li> </ul> <p><b>Invasive airway intervention</b>, Trauma 1:2-3</p> <p><b>Invasive monitoring</b>, 25:336-337</p> <p><b>Isigwebedhla</b>, 5:55</p> <p><b>Isosorbide dinitrate</b>, 17:224t</p> <p><b>"I Watch Death" mnemonic</b>, 13:180-181</p>	<p>uncompressed, 2:14f</p> <p><b>Left coronary artery, anomalous</b>, 6:76</p> <p><b>Left popliteal vein</b>, 2:15, 16f</p> <p><b>Left upper quadrant imaging</b>, 3:26-27, 26f</p> <p><b>Left ventricular dysfunction</b>, 16:213-214, 216f</p> <p><b>LEMON law</b>, Trauma 2:2, 3t</p> <p><b>Lethal agents</b>, 8:101, 102t</p> <p><b>Lethargy</b>, 11:148</p> <p><b>Levofloxacin (Levaquin<sup>®</sup>)</b></p> <ul style="list-style-type: none"> <li>for ABECB, 23:309</li> <li>for acute exacerbations of COPD, 22:297t, 23:303t, 305</li> <li>for acute uncomplicated UTI, 7:92t</li> <li>for pyelonephritis, 7:93t, 10:141t</li> <li>for UTIs, 7:92t, 10:136, 137, 139t</li> </ul> <p><b>Liability</b>, 539Z (March):7</p> <p><b>Lidocaine</b>, Trauma 2:6t</p> <p><b>Ligamentous cervical spine injury</b>, Trauma 4:6</p> <p><b>Ligaments</b></p> <ul style="list-style-type: none"> <li>cervical spine, Trauma 4:1, 3t</li> <li>of foot, 21:278</li> </ul> <p><b>Lighted stylet</b>, Trauma 2:6-7</p> <p><b>Lilly cyanide kit</b>, 9:128</p> <p><b>Lisfranc injury</b>, 21:286-287</p> <p><b>Lisfranc's ligament</b>, 21:278, 280f</p> <p><b>Live intrauterine pregnancy</b>, 1:5</p> <p><b>Liver flukes</b>, 5:60-61</p> <p><b>Liver function tests</b>, Trauma 5:3</p> <p><b>LMA</b>. <i>See</i> Laryngeal mask airway</p> <p><b>LOAD mnemonic</b>, Trauma 1:5-6, 5t</p> <p><b>Local anesthesia</b>, 15:203-204, 205t</p> <p><b>Loeffler's syndrome</b>, 4:40</p> <p><b>Lorazepam (Ativan)</b></p> <ul style="list-style-type: none"> <li>for acute panic, 18:236</li> <li>for delirium, 13:183</li> </ul> <p><b>LOST</b>, 8:107</p> <p><b>Lower esophageal sphincter (LES), hypertensive</b>, 17:223, 224t</p> <p><b>Lower extremity vascular anatomy</b>, 2:12, 13f</p> <p><b>Lower respiratory tract infection</b>, 24:314</p> <ul style="list-style-type: none"> <li>bacterial, 22:296, 297t, 23:302, 303t</li> </ul> <p><b>Lower urinary tract infection</b></p> <ul style="list-style-type: none"> <li>complicated, 7:90t, 91</li> <li>uncomplicated, 7:90-91</li> </ul> <p><b>Loxapine</b>, 14:192t</p> <p><b>Loxosceles (brown recluse spiders)</b>, Trauma 3:5-6</p>	<p><b>Malaria</b>, 4:36-39</p> <p><b>Mallampati classification</b>, Trauma 2:2, 4f</p> <p><b>Mannitol</b></p> <ul style="list-style-type: none"> <li>for coma, 11:154</li> <li>for subarachnoid hemorrhage, 11:157</li> </ul> <p><b>MARK I kits</b>, 9:126, 127</p> <p><b>Mask ventilation</b>, Trauma 2:2</p> <p><b>Massage, cardiac</b>, Trauma 6:4-5, 7f</p> <p><b>Maxillofacial trauma</b>, Trauma 2:3-4</p> <p><b>Measles</b>, 4:44-45</p> <p><b>Mebendazole</b></p> <ul style="list-style-type: none"> <li>for hookworm, 4:41</li> <li>for pinworm, 4:40</li> <li>for roundworm, 4:40</li> <li>for whipworm, 4:40</li> </ul> <p><b>Mechanical distortion of the airway</b>, Trauma 1:2</p> <p><b>Mechanical obstruction, airway</b>, Trauma 1:3</p> <p><b>Medial malleolar fractures</b>, 20:266</p> <p><b>Medical Center of Southwest Florida, Miller v.</b>, 539Z (March):2</p> <p><b>Medical screening examinations</b>, 539Z (March):4</p> <p><b>Medications</b>. <i>See</i> Drugs</p> <p><b>Memorial Delirium Assessment Scale</b>, 13:179t</p> <p><b>Men, UTIs in</b>, 10:141</p> <p><b>Mental illness</b>, 4:43-44</p> <p><b>Mental status</b></p> <ul style="list-style-type: none"> <li>altered, 12:164, 167, 168f</li> <li>decreased, 12:165</li> </ul> <p><b>Mental Status Questionnaire</b>, 13:179t</p> <p><b>Meperidine</b>, 12:169</p> <p><b>Metals, heavy</b>, 9:131t</p> <p><b>Metapneumovirus</b>, 24:314</p> <p><b>Metatarsal fractures</b>, 21:287-288</p> <p><b>Methamphetamine</b>, 15:199-200</p> <p><b>Methylprednisolone (Solumedrol)</b></p> <ul style="list-style-type: none"> <li>for anaphylactic shock, 26:355t</li> <li>for hymenoptera stings, Trauma 3:8</li> <li>for sepsis, 25:335-336</li> </ul> <p><b>Metronidazole</b>, 5:56</p> <p><b>Midazolam</b>, Trauma 2:6t</p> <p><b>Midfoot injuries</b>, 21:285-287</p> <p><b>Miller v. Medical Center of Southwest Florida</b>, 539Z (March):2</p> <p><b>Mini-Mental State Examination (MMSE)</b>, 13:178t, 179, 179t</p> <p><b>Mission oriented protective posture (MOPP)</b>, 9:132</p> <p><b>Morison's pouch</b>, 3:24f, 26</p> <p><b>Movement disorders, drug-induced</b>, 12:166</p> <p><b>Moxifloxacin</b></p> <ul style="list-style-type: none"> <li>for ABECB, 23:305, 307</li> <li>for acute exacerbations of COPD, 22:295, 297t, 23:303t</li> </ul> <p><b>Mucopolysaccharidosis</b>, Trauma 4:4t</p> <p><b>Multiple organ dysfunction syndrome</b>, 25:331t, 26:347</p> <p><b>Musculoskeletal chest pain</b>, 18:235t, 236-237</p> <p><b>Mustard agents</b>, 8:107-112</p> <ul style="list-style-type: none"> <li>body parts most affected by, 8:108, 109t</li> <li>effects on humans, 8:108, 108t</li> <li>threat analysis, 8:113</li> </ul>
<p><b>J</b></p> <p><b>Johnson v. University of Chicago Hospitals</b>, 539Z (March):2-3</p> <p><b>K</b></p> <p><b>Kager's triangle, loss of</b>, 20:270-271, 271f</p> <p><b>Katayama fever</b>, 5:61-62, 62</p> <p><b>Kelocyanor (dicobalt-EDTA)</b>, 9:129</p> <p><b>Ketamine (Ketalar)</b>, Trauma 1:6t, 7, Trauma 2:6t</p> <p><b>Killer honeybees</b>, Trauma 3:8</p> <p><b>Klebsiella pneumoniae</b></p> <ul style="list-style-type: none"> <li>antibiotic therapy for, 10:137-138</li> <li>incidence of, 7:88, 89t</li> <li>in UTIs, 7:87, 88t</li> </ul> <p><b>Klippel-Feil syndrome</b>, Trauma 4:4t</p>	<p><b>Lighted stylet</b>, Trauma 2:6-7</p> <p><b>Lilly cyanide kit</b>, 9:128</p> <p><b>Lisfranc injury</b>, 21:286-287</p> <p><b>Lisfranc's ligament</b>, 21:278, 280f</p> <p><b>Live intrauterine pregnancy</b>, 1:5</p> <p><b>Liver flukes</b>, 5:60-61</p> <p><b>Liver function tests</b>, Trauma 5:3</p> <p><b>LMA</b>. <i>See</i> Laryngeal mask airway</p> <p><b>LOAD mnemonic</b>, Trauma 1:5-6, 5t</p> <p><b>Local anesthesia</b>, 15:203-204, 205t</p> <p><b>Loeffler's syndrome</b>, 4:40</p> <p><b>Lorazepam (Ativan)</b></p> <ul style="list-style-type: none"> <li>for acute panic, 18:236</li> <li>for delirium, 13:183</li> </ul> <p><b>LOST</b>, 8:107</p> <p><b>Lower esophageal sphincter (LES), hypertensive</b>, 17:223, 224t</p> <p><b>Lower extremity vascular anatomy</b>, 2:12, 13f</p> <p><b>Lower respiratory tract infection</b>, 24:314</p> <ul style="list-style-type: none"> <li>bacterial, 22:296, 297t, 23:302, 303t</li> </ul> <p><b>Lower urinary tract infection</b></p> <ul style="list-style-type: none"> <li>complicated, 7:90t, 91</li> <li>uncomplicated, 7:90-91</li> </ul> <p><b>Loxapine</b>, 14:192t</p> <p><b>Loxosceles (brown recluse spiders)</b>, Trauma 3:5-6</p>	<p><b>M</b></p> <p><b>M256A1 detector</b>, 8:113</p> <p><b>Macrolides</b>, 23:305, 308-309</p> <p><b>Magnesium</b></p> <ul style="list-style-type: none"> <li>for potassium efflux blocker toxicity, 14:194</li> <li>for sodium-potassium ATPase blocker toxicity, 14:195</li> </ul> <p><b>Magnetic resonance imaging (MRI)</b></p> <ul style="list-style-type: none"> <li>in children with non-accidental injury, Trauma 5:4</li> <li>in children with subdural hemorrhage, Trauma 5:5, 5f</li> </ul> <p><b>Maisonneuve fracture</b>, 20:267</p>
<p><b>L</b></p> <p><b>Labor</b>, 539Z (March):4-5</p> <p><b>Lactate</b>, 26:350</p> <p><b>Larsen's syndrome</b>, Trauma 4:4t</p> <p><b>Laryngeal mask airway (LMA)</b>, Trauma 2:7-8</p> <p><b>Laryngoscopy</b>, Trauma 1:4t</p> <p><b>Lateral malleolar fractures</b>, 20:266</p> <p><b>Latin America</b></p> <ul style="list-style-type: none"> <li>commonly encountered diseases, 5:52-59</li> <li>common refugee conditions, 5:53t</li> </ul> <p><b>Latrodectus (black widow spiders)</b>, Trauma 3:6-7</p> <p><b>Lauge-Hansen classification of ankle fractures</b>, 20:265</p> <p><b>Lee Jones test</b>, 9:128</p> <p><b>Le Fort fractures</b>, Trauma 2:3, 5f</p> <p><b>Left common femoral vein</b></p> <ul style="list-style-type: none"> <li>compressed, 2:13, 13f, 14f</li> <li>hyperchoic clot in, 2:13, 15f</li> <li>thrombosis, 2:15, 16f</li> </ul>	<p><b>M</b></p> <p><b>M256A1 detector</b>, 8:113</p> <p><b>Macrolides</b>, 23:305, 308-309</p> <p><b>Magnesium</b></p> <ul style="list-style-type: none"> <li>for potassium efflux blocker toxicity, 14:194</li> <li>for sodium-potassium ATPase blocker toxicity, 14:195</li> </ul> <p><b>Magnetic resonance imaging (MRI)</b></p> <ul style="list-style-type: none"> <li>in children with non-accidental injury, Trauma 5:4</li> <li>in children with subdural hemorrhage, Trauma 5:5, 5f</li> </ul> <p><b>Maisonneuve fracture</b>, 20:267</p>	<p><b>M</b></p> <p><b>M256A1 detector</b>, 8:113</p> <p><b>Macrolides</b>, 23:305, 308-309</p> <p><b>Magnesium</b></p> <ul style="list-style-type: none"> <li>for potassium efflux blocker toxicity, 14:194</li> <li>for sodium-potassium ATPase blocker toxicity, 14:195</li> </ul> <p><b>Magnetic resonance imaging (MRI)</b></p> <ul style="list-style-type: none"> <li>in children with non-accidental injury, Trauma 5:4</li> <li>in children with subdural hemorrhage, Trauma 5:5, 5f</li> </ul> <p><b>Maisonneuve fracture</b>, 20:267</p>

**Mycobacterium tuberculosis**  
in immigrants, 4:35  
time between infection and symptom onset, 4:33t  
**Myxedema coma**, 11:156-157

## N

**Nacogdoches County Hospital, Owens v.**, 539Z  
(March):6  
**Nafcillin**, 15:202-203, 203t  
**Nalmefine**, 11:155  
**Naloxone**  
for coma, 11:155  
empiric dosing, 12:170t  
for sedation or CNS depression, 12:169  
**Narcotic antagonists**, 11:155  
**Nasotracheal intubation**, Trauma 2:6  
**Navicular injuries**, 21:285-286  
**NDIUP**. *See* No definitive intrauterine pregnancy  
**Nebulizer treatments**, 8:102-103  
**Necator americanus**, 4:40-41  
**Neck zones**, Trauma 2:4, 5f  
**Necrotizing soft-tissue infections, IDU-related**,  
15:204-205  
**Neisseria gonorrhoeae**, 7:88  
**Nerve agents**, 8:102t, 9:119-126  
acute physiologic effects of, 9:120, 121t  
CDC threat list, 9:131t  
chemical structure of, 9:122f  
improvisational, 9:130t  
and pregnancy, 9:127  
toxidromes, 12:164-165, 165t  
treatment of, 9:124-126  
**Nerves, of foot**, 21:279  
**Neurocysticercosis**, 5:52-55  
**Neurogenic shock**, 26:353-355  
**Neurologic chest pain**, 18:236t  
**Neurologic examination**  
of comatose patient, 11:150-153  
methods for, 25:332t  
**Neuropsychiatric agents**, 19:245t  
**Newborns**  
congenital heart disease in, 6:73  
hypoxia in, 6:73  
shock in, 6:73  
**New York Heart Association (NYHA) classifica-  
tion**, 16:213, 214f  
**Nifedipine**, 17:224t  
**Nifurtimox**, 5:57  
**Nitrates**, 17:224t  
**Nitrofurantoin**  
for acute bacterial cystitis, 10:138, 139  
for acute uncomplicated UTI, 7:92t  
for uncomplicated UTI, 10:139t  
**Nitrogen mustard**, 8:112  
**Nitroglycerine**, 17:224t  
**Nizatidine (Axid)**, 26:355t  
**No definitive intrauterine pregnancy (NDIUP)**, 1:6,  
8f  
**Non-accidental injury**, Trauma 5:1-11

early diagnosis of, Trauma 5:6, 6t  
**Noncardiac chest pain**, 17:221-228, 18:229-240  
causes of, 18:236t, 237  
epidemiology of, 17:222, 223t  
gastrointestinal causes, 17:222-224, 224t, 18:236t  
musculoskeletal causes, 18:235t, 236-237  
neurologic causes of, 18:236t  
pitfalls in management of, 18:237  
psychiatric causes, 18:235-236, 236t  
pulmonary causes, 18:229-235, 236t  
vascular causes of, 18:236t  
**Norepinephrine**, 25:338-339  
**Norfloxacin**  
for acute uncomplicated UTI, 7:92t  
for pyelonephritis, 7:93t, 10:141t  
for uncomplicated UTI, 10:139t  
**Norwood procedure**, 6:79, 80f, 81f  
**Notification requirements**, 539Z (March):6  
**Nutcracker esophagus**, 17:223, 224t

## O

**Obidoxime (Toxogonin)**, 9:126  
**Obtundation**, 11:148  
**Occipitoatlantal dislocation**, Trauma 4:7  
**Ocular therapy**, 8:111  
**Oculocephalic reflex testing**, 11:152  
**Odontoid, asymmetric**, Trauma 4:8  
**Odontoid epiphysis, apical**, Trauma 4:8  
**Ofloxacin (Floxin®)**  
for pyelonephritis, 7:93t, 10:141t  
for UTIs, 7:92t, 10:136, 139t  
**Ohio State University airway cart**, Trauma 1:4t  
**Omeprazole**, 17:224t  
**Omeprazole Challenge Test**, 17:223  
**On-call requirements**, 539Z (March):6  
**Open cardiac massage**, Trauma 6:4-5, 7f  
**Opioids**  
toxidromes, 12:164-165, 165t, 166t  
withdrawal syndromes, 12:164-165, 166t  
**Opisthorchis sinensis**  
complications of, 4:40t  
time between infection and symptom onset, 4:33t  
**Opisthorchis viverrini**, 5:60  
**Organic Brain Syndrome Scale**, 13:179t  
**Organophosphate insecticides**, 12:164-165, 165t  
**Organophosphate intoxication**, 9:126  
**Organ system dysfunction**, 25:332t  
**Orphenadrine**, 14:192t  
**Orthopedic consultation**, 20:264-265, 264t  
**Os odontoideum**, Trauma 4:7  
**Osteomyelitis, IDU-related**, 15:205-206  
**OTIS CAMPBELL mnemonic**, 12:165, 167t, 168f  
**Ottawa ankle rules**, 20:259, 259t, 21:280, 281t  
**Overdrive pacing**, 14:194  
**Overseas screening exam**, 4:33  
**Owens v. Nacogdoches County Hospital**, 539Z  
(March):6  
**Oxidizers**, 9:130, 131t  
**Oxygenation**

central venous oxygen saturation (ScvO<sub>2</sub>), 26:350  
hyperbaric, 9:129

**Oxygen carriers, hemoglobin-based (HBOCs)**,  
26:351  
**Oxygen therapy**  
for PFIB inhalation, 8:106  
for phosgene inhalation, 8:105  
for thoracotomy, Trauma 6:7

## P

**PA catheters**. *See* Pulmonary artery catheters  
**Pain**  
abdominal, in immigrants, 5:54t  
chest, 17:221-228, 18:229-235, 236t  
chest wall, 18:235t, 236  
visceral hyperalgesia, 17:223-224  
**Palivizumab (Synagis)**, 24:324  
recommendations for prophylaxis candidates,  
24:322t, 324  
summary recommendations, 24:323t, 324  
**2PAM**. *See* Pralidoxime  
**Pancreatic enzymes**, Trauma 5:3  
**Pancreatitis**, 19:241-254  
acute, 19:242, 243, 244-245, 244t, 245t, 248-249  
chronic, 19:242-243, 243-244, 245, 249  
clinical presentation of, 19:243-244  
complications, 19:249  
CT severity index, 19:247, 247t  
diagnostic workup, 19:245-247  
differential diagnosis of, 19:245, 245t  
drugs strongly associated with, 19:244, 245t  
epidemiology of, 19:241-242  
etiologies, 19:244-245, 244t  
management, 19:248-249  
pathophysiology, 19:242-243  
prognosis, 19:249-251  
Ranson's vs. Glasgow criteria for, 19:250, 250t  
**Panic disorder**, 18:235-236  
**Paralytic agents**, Trauma 1:7-8, 7t  
**Parasites, intestinal**, 4:39-41  
**Paraspinal disease, chest wall pain secondary to**,  
18:235t, 237  
**Pasadena kit**, 9:128  
**Patent ductus arteriosus**, 6:74  
**Patient monitoring**, 26:350-351  
**PE**. *See* Pulmonary embolism  
**Pediatric patients**  
2PAM chloride doses, 9:127t  
airway management, Trauma 1:9  
ankle fractures, 20:268-269  
antidote doses for chemical warfare agents, 9:  
126-127  
cervical spine injuries, Trauma 4:1-11  
child abuse, 539Z (June):1-8, Trauma 5:1-11  
doses of antidotes for chemical warfare agents,  
9:124t  
non-accidental injury in, Trauma 5:1-11  
physical abuse of, 539Z (June):1-8  
steroids in, Trauma 4:9

<p>variation of child's sodium nitrite dose with hemoglobin concentration, 9:128-129, 129t</p> <p><b>Pelvic ultrasound</b>, 1:1-9</p> <p>endovaginal, 1:4, 5-6, 5f, 6f</p> <p>first-trimester pregnancy, 1:4</p> <p>imaging techniques, 1:3-4</p> <p>suprapubic view, 3:27, 27f, 28f</p> <p>transabdominal, 1:3-4, 3f</p> <p><b>Pelvis</b></p> <p>female, 3:26f, 27f</p> <p>problems elicited by physical examination, 4:33-34, 34t</p> <p>ultrasound imaging techniques, 1:3-4</p> <p><b>Penetrating chest wound</b>, Trauma 6:4, 5f</p> <p><b>Penicillin G</b>, 21:281</p> <p><b>Pentamidine</b>, 14:195t</p> <p><b>Pentothal (thiopental)</b>, Trauma 1:6t, 7</p> <p><b>Peptostreptococcus</b>, 15:203, 204t</p> <p><b>Perfluoroisobutylene (PFIB)</b>, 8:101, 104f, 106-107</p> <p><b>Pericardial tamponade</b>, Trauma 6:3-4, 3f</p> <p><b>Peroneal tendon injury</b>, 20:271-272</p> <p><b>Persistent vegetative state</b>, 11:158-159</p> <p><b>Personal protective equipment (PPE)</b>, 9:131, 132</p> <p><b>Personal protective gear</b>, 9:131, 132</p> <p><b>Pesticides</b>, 9:131t</p> <p><b>PFIB</b>. <i>See</i> Perfluoroisobutylene</p> <p><b>Phalangeal fractures and dislocations</b>, 21:288</p> <p><b>Pharaonic circumcision</b>, 5:63</p> <p><b>Pharmaceutical industry</b>, S03180:6</p> <p><b>Phenazopyridine</b>, 10:139</p> <p><b>Phenothiazines</b>, 14:192t</p> <p><b>Phenylalkylamines</b>, 14:189, 189t</p> <p><b>Phosgene (CG) gas</b>, 8:101, 103-106</p> <p>chemical structure of, 8:104f</p> <p>clinical effects of, 8:104-105, 104t</p> <p><b>Phosgene oxime (CX)</b>, 8:104f, 112-113</p> <p><b>Physical abuse</b></p> <p>of children, 539Z (June):1-8, Trauma 5:1-11</p> <p>cutaneous manifestations, 539Z (June):2-4, 3f, 5f</p> <p>epidemiology, 539Z (June):1-2</p> <p>fractures, 539Z (June):4-5, 6f</p> <p>head trauma, 539Z (June):5-7</p> <p>manifestations of, Trauma 5:4-10</p> <p><b>Physical examination</b></p> <p>in CNS drug toxicity, 12:166-167</p> <p>in comatose patient, 11:149-153, 153t</p> <p>immigrant, 4:33-34</p> <p>problems elicited by, 4:33-34, 34t</p> <p><b>Physician arrogance</b>, S03180:5</p> <p><b>Physicians, abusive</b>, S03180:5-6</p> <p><b>Physiotherapy, chest</b>, 24:321</p> <p><b>Physostigmine</b>, 12:170t</p> <p><b>Pilon fractures</b>, 20:267</p> <p><b>Pinworm</b>, 4:40</p> <p><b>PIOPED (prospective investigation of pulmonary embolism diagnosis)</b>, 18:233, 233t</p> <p><b>Piperacillin/tazobactam</b>, 7:93t, 10:141t</p> <p><b>Pit viper envenomations</b>, Trauma 3:2, 4f</p> <p><b>Pit vipers (Viperidae)</b>, Trauma 3:1, 3f</p> <p><b>Plasmodium</b></p>	<p>in immigrants, 4:36, 37, 38</p> <p>time between infection and symptom onset, 4:33t</p> <p><b>Pneumonia, community-acquired (CAP)</b>, 10:137</p> <p><b>Pneumothorax (PTX)</b></p> <p>clinical presentation of, 18:230</p> <p>secondary spontaneous, 18:230, 231, 231t</p> <p>spontaneous, 18:229-231</p> <p>tension, 18:230</p> <p>treatment of, 18:230-231</p> <p><b>Poison industrial gases, liquids, and solids</b>, 9:131t</p> <p><b>Polymer fume fever</b>, 8:106</p> <p><b>Popliteal artery</b></p> <p>aneurysms, 2:17f, 18, 18f</p> <p>ultrasound evaluation, 2:14-15, 16f, 17f, 18</p> <p><b>Popliteal or Baker's cysts</b>, 2:17f, 18</p> <p><b>Popliteal vessels</b>, 2:13, 15f</p> <p><b>Post-traumatic stress disorder</b>, 4:43</p> <p><b>Potassium</b></p> <p>for sodium channel blocker toxicity, 14:193</p> <p>sodium-potassium ATPase blocker toxicity, 14:194-197</p> <p>for sodium-potassium ATPase blocker toxicity, 14:195</p> <p><b>Potassium efflux blockers</b>, 14:193-194, 195t</p> <p><b>Potassium efflux blocker toxicity</b>, 14:193-194</p> <p><b>Potts shunt</b>, 6:77, 77f</p> <p><b>Powers ratio</b>, Trauma 4:7, 7f</p> <p><b>PPE</b>. <i>See</i> Personal protective equipment</p> <p><b>Pralidoxime (2PAM)</b>, 9:125-126</p> <p>pediatric doses, 9:127t</p> <p>in pregnancy, 9:127</p> <p>regeneration of cholinesterase by, 9:125, 125f</p> <p>structure of, 9:124f</p> <p><b>Praziquantel</b></p> <p>for liver flukes, 5:61</p> <p>for schistosomiasis, 5:62</p> <p><b>Predental space, increased</b>, Trauma 4:8</p> <p><b>Prednisolone</b>, 24:320</p> <p><b>Pregnancy</b></p> <p>abnormal intrauterine, 1:5-6, 6f</p> <p>chemical warfare agents and, 9:127</p> <p>definitive signs of, 1:5, 5t</p> <p>early intrauterine, 1:5, 6f</p> <p>ectopic, 1:6, 7f, 8f</p> <p>extrauterine, 1:6</p> <p>first-trimester, 1:4t, 5</p> <p>first-trimester pelvic ultrasound, 1:1-9</p> <p>identification and localization of, 1:4t, 5-6</p> <p>intrauterine, 1:5</p> <p>live intrauterine, 1:2-3, 3f, 5</p> <p>no definitive intrauterine pregnancy (NDIUP), 1:6, 8f</p> <p>UTIs in, 10:141-142, 142t</p> <p><b>Prevotella</b>, 15:203, 204t</p> <p><b>Primaquine</b>, 4:38, 39t</p> <p><b>Prior authorization requirements</b>, 539Z (March):6</p> <p><b>Professionalism</b>, S03180:1-8</p> <p>behaviors of, S03180:4, 4t</p> <p>case discussions, S03180:6-7</p> <p>characteristics of, S03180:4, 4t</p>	<p>components of, S03180:3-5</p> <p>definition of, S03180:1-2</p> <p>history of, S03180:2-3</p> <p>in organized medicine, S03180:5</p> <p>responsibilities of, S03180:4, 5t</p> <p><b>Professional organizations</b>, S03180:5, 5t</p> <p><b>Propofol (Diprivan)</b>, Trauma 1:6t, 7</p> <p><b>Propoxyphene overdose</b>, 14:192-193, 192f</p> <p><b>Propranolol</b>, 14:192t</p> <p><b>Prospective investigation of pulmonary embolism diagnosis (PIOPED)</b>, 18:233, 233t</p> <p><b>Protection, respiratory</b>, 9:132</p> <p><b>Protective attire</b>, 9:131-132</p> <p><b>Protective gear, personal</b>, 9:131, 132</p> <p><b>Proteus mirabilis</b></p> <p>antibiotic therapy for, 10:137-138</p> <p>incidence of, 7:88, 89t</p> <p>in UTIs, 7:87, 88t</p> <p><b>Pseudomonas aeruginosa</b></p> <p>antibiotic therapy for, 10:137, 140</p> <p>incidence of, 7:88, 89t</p> <p>in UTIs, 7:87, 88t</p> <p><b>Pseudosubluxation, cervical spine</b>, Trauma 4:8</p> <p><b>Psychiatric chest pain</b>, 18:235-236, 236t</p> <p><b>PTX</b>. <i>See</i> Pneumothorax</p> <p><b>Pulmonary (choking) agents</b>, 8:101-107, 102t</p> <p>CDC threat list, 9:131t</p> <p>improvisational, 9:130t</p> <p><b>Pulmonary artery banding</b>, 6:77-78</p> <p><b>Pulmonary artery (PA) catheters</b></p> <p>in sepsis, 25:336-337</p> <p>in shock, 26:350</p> <p><b>Pulmonary atresia</b>, 6:76</p> <p><b>Pulmonary chest pain</b>, 18:229-235, 236t</p> <p><b>Pulmonary embolism (PE)</b>, 18:231-235</p> <p>prospective investigation of pulmonary embolism diagnosis (PIOPED), 18:233, 233t</p> <p>rating likelihood for, 18:233, 233t</p> <p><b>Pyelonephritis</b></p> <p>acute, 10:140</p> <p>antibiotic treatment of, 7:93t, 10:141t</p> <p>guidelines for admission, 10:139</p> <p><b>Pyridoxine</b>, 12:170</p> <p><b>Q</b></p> <p><b>QT interval, prolonged</b>, 14:193-194, 194f</p> <p><b>Quantitative serum BHCG</b>, 1:2</p> <p><b>Quelicin (succinylcholine)</b>, Trauma 1:7t, 8</p> <p><b>Quick Confusion Scale (QCS)</b>, 13:179, 179t, 180t</p> <p><b>Quinidine</b>, 4:39, 39t</p> <p><b>Quinine</b>, 4:38-39, 39t, 14:192t, 195t</p> <p><b>R</b></p> <p><b>Radiographic evaluation</b></p> <p>in bronchiolitis, 24:318, 318t</p> <p>in cavitory tuberculosis, 4:36f</p> <p>in cervical spine injury, Trauma 4:5-7, 5t, 6f</p> <p>normal variants simulating cervical spine injury,</p>
--	---	--

<p>Trauma 4:8-9 for pancreatitis, 19:247-248 for pulmonary embolus, 18:233 in shock, 26:348-349 standard skeletal survey, Trauma 5:3-4, 4t</p> <p><b>Radionuclide bone scans</b>, Trauma 5:4</p> <p><b>Ranitidine</b>, 26:355t</p> <p><b>Ranson's criteria</b>, 19:250, 250t</p> <p><b>Rapacuronium (Rapalon)</b>, Trauma 1:8</p> <p><b>Rapid sequence intubation (RSI)</b>, Trauma 1:3-4 airway cart contents, Trauma 1:4t in head-injured patient, Trauma 2:3, 3t induction agents for, Trauma 1:6-7, 6t LOAD mnemonic for pretreatment phase, Trauma 1:5-6, 5t paralytic agents for, Trauma 1:7-8, 7t technique, Trauma 1:4-9</p> <p><b>Rastelli procedure</b>, 6:79, 80f</p> <p><b>Red blood cell disorders</b>, 5:59</p> <p><b>Redbud Community Hospital, Bryant v.</b>, 539Z (March):5</p> <p><b>Reflux, gastroesophageal</b>, 17:222-223, 224, 224t</p> <p><b>Refugee conditions</b>, 5:53t</p> <p><b>Refusal to consent</b>, 539Z (March):6</p> <p><b>Renal dysfunction</b>, 25:332t</p> <p><b>Renal stones</b>, 10:141</p> <p><b>Respirators</b> cartridge, 9:132 supplied air, 9:132</p> <p><b>Respiratory failure</b> evaluation of, 25:332t impending, clues to, Trauma 1:3t invasive airway intervention for, Trauma 1:2 with mustard gas exposure, 8:109-110</p> <p><b>Respiratory muscle fatigue</b>, Trauma 1:3</p> <p><b>Respiratory protection</b>, 9:132</p> <p><b>Respiratory syncytial virus (RSV) infection</b>, 24:314-315 clinical presentation of, 24:316 predictors of, 24:317, 318t prevention of, 24:323-324 risk factors for severe disease, 24:316, 317t</p> <p><b>Respiratory therapy</b>, 8:111</p> <p><b>Respiratory tract infection</b> treatment guidelines, 22:296, 297t, 23:302, 303t Tucson Children's Respiratory Study, 24:315, 316t</p> <p><b>Retrograde intubation</b>, Trauma 2:6, 7f</p> <p><b>Reverse dumping</b>, 539Z (March):6</p> <p><b>Rib fracture</b> acute, 539Z (June):4, 6f chest wall pain secondary to, 18:235t, 236 radiography of, Trauma 5:3-4, 4f</p> <p><b>Right superficial femoral vein</b>, 2:13, 15f</p> <p><b>Right upper quadrant imaging</b>, 3:24f, 25f, 26</p> <p><b>Right ventricle, double outlet</b>, 6:76</p> <p><b>Rocuronium (Zemuron)</b>, Trauma 1:7t, 8</p> <p><b>Roentgenographic skeletal survey</b>, Trauma 5:3-4</p> <p><b>Roundworm</b>, 4:39, 40, 41f complications of, 4:40t</p>	<p>time between infection and symptom onset, 4:33t</p> <p><b>RSI</b>. <i>See</i> Rapid sequence intubation</p> <p><b>RSV Immune Globulin (RSVIG, Respigam)</b>, 24:324</p> <p><b>RSV infection</b>. <i>See</i> Respiratory syncytial virus (RSV) infection</p> <p><b>Rubella</b>, 4:45</p> <p><b>S</b></p> <p><b>Sarin (GB, Russian Substance 35)</b>, 9:119, 122, 122f</p> <p><b>Saskatoon Delirium Checklist</b>, 13:179t</p> <p><b>Schistosomiasis</b>, 4:33t, 5:61-62</p> <p><b>SCMARTI (Selection of Cephalosporins, Macrolides, and AFQs for Respiratory Tract Infections) Clinical Consensus Panel Report OMBIRT treatment guidelines</b>, 22:296, 297t, 23:302, 303t year 2003 update, 22:293-300, 23:301-311</p> <p><b>Scorpions</b>, Trauma 3:7</p> <p><b>Screening examinations</b> EMTALA requirements, 539Z (March):4 overseas, 4:33</p> <p><b>SEA</b>. <i>See</i> Spinal epidural abscess</p> <p><b>Sedation</b> drug-induced, 12:169-170 intravenous, Trauma 2:6t for treatment of IDU abscesses, 15:203-204, 205t</p> <p><b>Sedative hypnotics</b> toxidromes, 12:164-165, 165t, 166t withdrawal syndromes, 12:164-165</p> <p><b>Seizures</b> drug-induced, 12:165, 170 drugs that cause, 12:165, 167t</p> <p><b>Self-contained breathing apparatus (SCBA)</b>, 9:132</p> <p><b>Sepsis</b> antibiotic therapy for, 25:339 definition of, 25:330-331, 331t diagnostic approach to, 26:354f early goal-directed therapy for, 25:332-334 evidence-based guidelines for management, 25:329-343 intravenous access and invasive monitoring, 25:336-337 severe, 25:331t therapeutic advances, 25:332 timeline, 25:333t treatment of, 25:336, 337f</p> <p><b>Septic arthritis</b>, 15:205-206</p> <p><b>Septic shock</b> antibiotic regimens for, 25:339t antibiotic selection for, 26:352, 352t definition of, 25:330-331, 331t management of, 26:352-353</p> <p><b>SERF (Severity of Exacerbation and Risk Factor) pathway</b> for antibiotic selection in ABE/COPD, 23:301-304, 304t intensification of treatment trigger (IOTT) criteria for risk-stratification in ABE/COPD, 23:304, 305t</p>	<p><b>Serum amylase, increased</b>, 19:246, 246t</p> <p><b>Serum BHCG, quantitative</b>, 1:2</p> <p><b>Serum digoxin levels</b>, 14:195</p> <p><b>Shaken-baby syndrome</b>, Trauma 5:4-5</p> <p><b>Shaken-impact syndrome</b>, Trauma 5:4-5</p> <p><b>Shiley tracheal tube</b>, Trauma 2:9</p> <p><b>Shingles (herpes zoster)</b>, 18:235t, 236-237</p> <p><b>Shock</b>, 26:345-356 anaphylactic, 26:355, 355t ancillary studies, 26:348 autonomic response to, 26:347 basic principle of, 26:346 cardiogenic, 26:353 cause-specific management, 26:351-355 clinical features, 26:347-348 congenital heart disease in newborn in, 6:73 current controversies, 26:351-355 dengue shock syndrome (DSS), 5:58, 59t epidemiology, 26:346 etiology, 26:346 in geriatric patients, 26:351 hemorrhagic, 26:351-352 inflammatory mediators, 26:347 initial approach to, 26:349 neurogenic, 26:353-355 pathophysiology, 26:346-347 pulmonary artery (PA) catheter in, 26:350 septic, 25:330-331, 331t, 339t, 26:352-353 treatment of, 26:349-351</p> <p><b>SHOCK mnemonic</b>, 26:346, 347t</p> <p><b>Short Portable Mental Status Questionnaire</b>, 13:179t</p> <p><b>Short Test of Mental Status (STMS)</b>, 13:179, 179t</p> <p><b>Shunt procedures</b> Blalock-Taussig shunt, 6:77, 78f central shunt, 6:77, 77f for congenital heart disease, 6:77 Glenn shunt, 6:79, 81f Potts shunt, 6:77, 77f Waterston shunt, 6:77, 77f</p> <p><b>Sinus bradycardia</b>, 14:194-195, 196f</p> <p><b>Skeletal survey</b> roentgenographic, Trauma 5:3-4 standard, Trauma 5:3-4, 4t</p> <p><b>Skeletal trauma</b>, 539Z (June):5</p> <p><b>Skin lesions</b> with CX, 8:112-113 with mustard gas, 8:109, 111-112 problems elicited by physical examination, 4:33-34, 34t</p> <p><b>Skin tenting</b>, 20:265</p> <p><b>Skin therapy</b>, 8:111-112</p> <p><b>Skull fractures</b>, Trauma 5:6t</p> <p><b>S-LOST</b>, 8:107</p> <p><b>Snakebite</b>, Trauma 3:1-5 antivenin therapy, Trauma 3:3-4 clinical manifestations, Trauma 3:2 ED management, Trauma 3:3 epidemiology of, Trauma 3:1-2 management, Trauma 3:2-5</p>
---	---	---

<p>pre-hospital care, Trauma 3:2-3 surgical management, Trauma 3:4-5</p> <p><b>Snakebite Severity Score</b>, Trauma 3:2, 5t</p> <p><b>Snapping peroneal tendon syndrome</b>, 20:272</p> <p><b>Sodium bicarbonate</b> for calcium channel blocker toxicity, 14:190 for sodium channel blocker toxicity, 14:193, 194f</p> <p><b>Sodium channel blockers</b>, 14:192, 192t</p> <p><b>Sodium channel blocker toxicity</b>, 14:192-193, 194f</p> <p><b>Sodium nitrite</b>, 9:128-129, 129t</p> <p><b>Sodium-potassium ATPase blockers</b>, 14:194, 196t</p> <p><b>Sodium-potassium ATPase blocker toxicity</b>, 14:194-197</p> <p><b>Soft-tissue infections, necrotizing</b>, 15:204-205</p> <p><b>Solumedrol</b>. <i>See</i> Methylprednisolone</p> <p><b>Soman (GD, Russian Substance 55)</b>, 9:119, 122-123 “aging” of cholinesterase associated with, 9:122, 123f treatment of, 9:126</p> <p><b>Somatization</b>, 4:43-44</p> <p><b>South Asia</b>, 5:59-61</p> <p><b>Southwest Detroit Hospital, Thornton v.</b>, 539Z (March):5</p> <p><b>Spectral Doppler</b>, 2:15, 16f</p> <p><b>SPERM test</b>, 11:153</p> <p><b>Spiderbite</b>, Trauma 3:6</p> <p><b>Spiders</b>, Trauma 3:5-7</p> <p><b>Spinal epidural abscess (SEA), IDU-related</b>, 15:206-207</p> <p><b>Spinal or paraspinal disease, chest wall pain secondary to</b>, 18:235t, 237</p> <p><b>Spine injury</b> cervical, Trauma 2:5, Trauma 4:1-11 pediatric cervical, Trauma 4:1-11</p> <p><b>Spontaneous pneumothorax</b>, 18:229-231 secondary, 18:230, 231, 231t</p> <p><b>Sprains, ankle</b>, 20:260-264</p> <p><b>Squeeze or fibular compression test</b>, 20:259</p> <p><b>Stabilizing treatment</b>, 539Z (March):4-5</p> <p><b>Stab wounds, chest</b>, Trauma 6:4, 6f</p> <p><b>Stanford classification</b>, 17:224, 225</p> <p><b>St. Anthony Hospital v. United States Department of Health and Human Services</b>, 539Z (March):6</p> <p><b>Staphylococcus aureus</b>, 539Z (June):4 in endocarditis, 15:201-202, 201t, 202-203 in IDU abscesses, 15:203, 204t</p> <p><b>Staphylococcus saprophyticus</b> antibiotic therapy for, 10:137-138 in UTIs, 7:87, 88, 88t, 89t</p> <p><b>Steroids</b> for cervical spine injury, Trauma 4:9 in children, Trauma 4:9 for chlorine exposure, 8:103 for PFIB inhalation, 8:106 for phosgene inhalation, 8:105 for sepsis, 25:335-336</p> <p><b>Stocking-glove burns</b>, 539Z (June):4, 5f</p> <p><b>Strain, chest wall pain secondary to</b>, 18:235t, 236</p> <p><b>Streptococcus</b>, 15:203, 204t</p> <p><b>Streptococcus pneumoniae</b>, 10:137</p>	<p><b>Streptococcus pyogenes</b>, 539Z (June):4</p> <p><b>Streptococcus viridans infectious endocarditis</b>, 15:201-202, 201t</p> <p><b>Stress, post-traumatic</b>, 4:43</p> <p><b>Stress tests, ankle</b>, 20:259</p> <p><b>Stroke, drug-induced</b>, 12:166</p> <p><b>Strongyloides stercoralis</b>, 4:39, 41 complications of, 4:40t time between infection and symptom onset, 4:33t</p> <p><b>Stupor</b>, 11:148</p> <p><b>Subarachnoid hemorrhage</b>, 11:157</p> <p><b>Subdural hemorrhage</b>, Trauma 5:5, 5f</p> <p><b>Subluxation</b> atlantoaxial rotary, Trauma 4:7-8 cervical spine fracture with, Trauma 4:6, 6f cervical spine pseudosubluxation, Trauma 4:8</p> <p><b>Succinylcholine (Anectine/Quelicin)</b>, Trauma 1:7t, 8</p> <p><b>Sulfur mustard (H)</b>, 8:107 chemical structure of, 8:104f threat analysis, 8:113</p> <p><b>Sunna circumcision</b>, 5:63</p> <p><b>Superoxide dismutase</b>, 8:112</p> <p><b>Supplied air respirators</b>, 9:132</p> <p><b>Surgical airway</b>, Trauma 2:8-9</p> <p><b>Surgical airway tools</b>, Trauma 1:4t</p> <p><b>Surgical treatment</b> for congenital heart disease, 6:76-80 for snakebite, Trauma 3:4-5</p> <p><b>Swedish Reaction Level Scale (RLS 85)</b>, 11:148, 150t</p> <p><b>Sympathomimetics</b>, 12:164-165, 166t</p> <p><b>Synagis</b>. <i>See</i> Palivizumab</p> <p><b>Synchondrosis of the dens, persistent</b>, Trauma 4:8</p> <p><b>Syndrome X</b>, 17:223</p> <p><b>Systemic inflammatory response syndrome (SIRS)</b>, 25:330-331, 331t, 26:347</p> <p><b>T</b></p> <p><b>Tabun (GA)</b>, 9:119, 121-122, 122f</p> <p><b>Taenia solium</b>, 4:33t, 5:52, 53, 54</p> <p><b>Talar dislocations</b>, 21:285</p> <p><b>Talar fractures</b>, 21:283-285 major, 21:284-285 minor, 21:283-284</p> <p><b>Talar neck fractures</b>, 21:284-285, 284f</p> <p><b>Talar tilt test</b>, 20:259</p> <p><b>Tazobactam</b>, 7:93t, 10:141t</p> <p><b>Teflon™</b>, 8:101</p> <p><b>Tendons</b> ankle injuries, 20:269-273 of foot, 21:278-280</p> <p><b>Tension pneumothorax</b>, 18:230</p> <p><b>Tequin®</b>. <i>See</i> Gatifloxacin</p> <p><b>Terminology</b> chemical warfare agents, 8:100-101 congenital heart disease, 6:73t</p> <p><b>Tetanus, IDU-related</b>, 15:207</p> <p><b>Tetracycline</b>, 4:39t for ABECB, 23:309</p>	<p>for ABE/COPD, 23:307 resistance to, 7:88</p> <p><b>Tetralogy of Fallot</b>, 6:74-75 corrected, 6:78, 78f surgical repair of, 6:78</p> <p><b>Thalassemia</b>, 5:59-60 alpha-Thalassemia, 5:60 beta-Thalassemia, 5:60</p> <p><b>Thiamine</b> for coma, 11:155 for delirium, 13:181 empiric dosing, 12:170t</p> <p><b>Thiopental (Pentothal)</b>, Trauma 1:6t, 7</p> <p><b>Thompson’s test</b>, 20:259</p> <p><b>Thompson test</b>, 20:270, 270f</p> <p><b>Thoracic trauma</b>, Trauma 2:5</p> <p><b>Thoracotomy</b>, Trauma 6:1-10 aftermath, Trauma 6:7 complications, Trauma 6:7 current guidelines, Trauma 6:8-9 equipment for, Trauma 6:4t, 5 historical perspective, Trauma 6:2 indications for, Trauma 6:8 motives for performing, Trauma 6:3 preparation, Trauma 6:5 procedure, Trauma 6:5-7, 7f rationale for use, Trauma 6:2-5 recommendations for, Trauma 6:8, 9t survival rate, Trauma 6:8 technical aspects, Trauma 6:5-7</p> <p><b>Thornton v. Southwest Detroit Hospital</b>, 539Z (March):5</p> <p><b>Thromboembolic disease</b>, 18:231-232, 232t</p> <p><b>Thromboembolism, venous (VTE)</b>, 16:216-217</p> <p><b>Thrombosis, left common femoral vein</b>, 2:15, 16f</p> <p><b>Tillaux fractures</b>, 20:268</p> <p><b>Tissue factor-pathway inhibitor (TFPI)</b>, 25:332, 335f</p> <p><b>Tissue plasminogen activator</b>, 18:234</p> <p><b>TMP-SMX</b>. <i>See</i> Trimethoprim/sulfamethoxazole</p> <p><b>Topical anesthesia</b>, Trauma 2:6t</p> <p><b>Torture</b>, 4:34, 35t</p> <p><b>Toxicity</b> beta-blocker, 14:191-192 calcium channel blocker, 14:189-191 potassium efflux blocker, 14:193-194 sodium channel blocker, 14:192-193, 194f sodium-potassium ATPase blocker toxicity, 14:194-197</p> <p><b>Toxidromes</b>, 12:164-165, 166t classification and examples, 12:164-165, 165t withdrawal syndromes, 12:164-165, 166t</p> <p><b>Toxins</b> cardiotoxins, 14:187-198 CDC threat list, 9:131t volatile, 9:131t</p> <p><b>Toxogonin (obidoxime)</b>, 9:126</p> <p><b>Traditional health practices, immigrant</b>, 4:34</p> <p><b>Transabdominal ultrasound</b>, 1:3-4, 3f</p> <p><b>Transducers</b>, 3:23</p>
---	---	---

**Transfer requirements**, 539Z (March):5-6

**Transplantation**, heart, 6:80

**Transposition of the great vessels**, 6:75

surgical repair of, 6:78-79, 80f

## Trauma

abdominal, Trauma 5:6-7, 8f

acute, 3:21-29

airway management, Trauma 2:3-6

chest wall pain secondary to, 18:235t, 236

FAST exam, 3:21, 22t, 23-24, 28

head, 539Z (June):5-7, Trauma 2:3, Trauma 5:

4-6

maxillofacial, Trauma 2:3-4

nonaccidental, Trauma 5:6, 6t

pediatric patients, Trauma 5:1-11

penetrating chest wound, Trauma 6:4, 5f

pericardial tamponade, Trauma 6:3, 3f

skeletal, 539Z (June):5

stab wound to chest, Trauma 6:4, 6f

thoracic, Trauma 2:5

ultrasound imaging technique, 3:23

**Trauma airway**, Trauma 1:1-2

complicating factors, Trauma 1:2t

pediatric issues, Trauma 1:9

**Trauma immobilization**, Trauma 1:2

**Traumatic brain injury**, 11:156, 156t

**Traumatic hemopericardium**, Trauma 6:3, 4f

FAST exam, 3:24

**Trazodone**, 17:224, 224t

**Trichuris trichiura (whipworm)**, 4:39, 40, 40t

**Tricuspid atresia**, 6:76

**Tricyclic antidepressants**

potassium efflux blockers, 14:195t

sodium channel blockers, 14:192t

toxidromes, 12:164-165, 165t

**Trimalleolar fractures**, 20:266-267

**Trimethoprim/sulfamethoxazole (TMP-SMX)**

for ABECB, 23:309

for acute bacterial cystitis, 10:138-139

for acute exacerbations of COPD, 22:297t,

23:303t

for acute pyelonephritis, 10:140

for acute uncomplicated UTI, 7:92t

for asymptomatic bacteriuria, 10:138

for pyelonephritis, 7:93t, 10:141t

resistance to, 7:88, 89

for uncomplicated UTI, 10:139t, 142

**Triplane fractures**, 20:268f, 269

**Trypanosoma cruzi**, 5:56, 57

**Tuberculosis**

cavitary, 4:36, 36f

in immigrants, 4:35-36

**Tucson Children's Respiratory Study**, 24:315, 316t

**Turner syndrome**, Trauma 4:4t

**Tyalar Pharmaceuticals**, 9:128

## U

**Ultrasound**

benefits of, 1:2t

common femoral vein, 2:15, 17f

diagnostic, 3:27-28

dilated and hypodynamic heart, 3:23f

DVT diagnosis, 2:11-19, 13f

endovaginal, 1:4, 5-6, 5f, 6f

FAST exam, 3:21, 22t, 23-24, 28

hemopericardium, 3:23f, 24f

hemoperitoneum, 3:24f, 25f, 26, 26f, 27, 27f, 28f

hemothorax, 3:25f, 26

hypovolemic heart, 3:23f

left common femoral vein, 2:13, 13f, 14f, 15, 15f,

16f

left popliteal vein, 2:15, 16f

left upper quadrant, 3:26-27, 26f

pelvic, 1:1-9, 3:27, 27f, 28f

popliteal artery, 2:14-15, 16f, 17f, 18, 18f

popliteal vessels, 2:13, 15f

rib artifact, 3:25f

right superficial femoral vein, 2:13, 15f

right upper quadrant, 3:24f, 25f, 26

splenorenal view, 3:26-27, 26f

suprapubic view, 3:27, 27f, 28f

transabdominal, 1:3-4, 3f

transducers, 3:23

trauma imaging technique, 3:23

traumatic hemopericardium, 3:23f, 24

windows, 3:23-24

## Underimmunization

epidemiology, 4:44

in immigrants, 4:44-45

measles, 4:44-45

rubella, 4:45

**Uniform Determination of Death Act**, 11:159

**United States Department of Health and Human Services, Burditt v.**, 539Z (March):5-6

**United States Department of Health and Human Services, St. Anthony Hospital v.**, 539Z (March):6

**University of Chicago Hospitals, Johnson v.**, 539Z (March):2-3

**Upper cervical spine injury, severe**, Trauma 4:3, 5f

**Upper urinary tract infection**, 7:91

**Upstate Medical Center (Syracuse, NY)**, 24:322-323

**Ureaplasma urealyticum**, 7:87

**Urinalysis**, 1:2

in non-accidental injury, Trauma 5:3

in UTI, 7:91-92

**Urinary tract infection**, 7:85-97

antibiotic therapy for, 7:89, 92t, 10:135-145, 139-140

antimicrobial management of, 10:138-139

common pathogens, 7:87, 88t

complicated, 7:90t, 91, 10:139-140

in diabetes, 10:142

diagnostic approach, 7:91

diagnostic strategies, 7:91-93

disease-specific syndromes, 10:138-139

epidemiology, 7:87

in high risk populations, 10:140-142

imaging techniques, 7:92-93

incidence of, 7:88, 89t

lower, 7:90-91, 90t

in men, 10:141

microbiology, 7:87-89

in pregnancy, 10:141-142, 142t

renal stones and, 10:141

resistance patterns, 7:87-89

uncomplicated, 7:90-91, 10:137-138

upper, 7:91

in women, 7:89-91

**Urine collection**, 7:92

**Urine culture**, 7:92

**Uropathogens**

incidence of, 7:88, 89t

most common, 7:87, 88t

**US.** See Ultrasound

**U.S. Department of Health and Human Services (HHS)**, 539Z (March):1-8

## V

**Valsalva maneuver**, 2:15, 17f

**Vancomycin**, 15:202-203, 203t

**Vancomycin-resistant enterococci**, 10:140

**Vascular anatomy, lower extremity**, 2:12, 13f

**Vascular chest pain**, 18:236t

**Vascular compromise**, 20:265

**Vasopressor support**, 25:338-339

**VATER syndrome**, Trauma 4:4t

**Vegetative state, persistent**, 11:158-159

**Venlafaxine**, 14:195t

**Venous thromboembolism (VTE)**, 16:216-217

**Ventilation**

abnormal, in unresponsive patients, 11:150, 152t

mask, Trauma 2:2

**Ventilation failure**, Trauma 1:2

**Ventilation-perfusion (V/Q) scanning**, 18:233

**Ventricular septal defects**, 6:73-74

surgical repair of, 6:76, 80f

**Verapamil**, 14:192t

**Verapamil overdose**, 14:189, 190f

**Vertebra, cervical**, Trauma 4:1, 2f

**Vertebral wedging, apparent anterior**, Trauma 4:8, 8f

**Vesicant (blister) agents**, 8:102t, 107-112

CDC threat list, 9:131t

improvisational, 9:130t

threat analysis, 8:113-114

**Vespidis**, Trauma 3:8

**Vestibulo-ocular reflex testing**, 11:152

**V-gas (Russian Substance 33)**, 9:122f, 123-124

**Victor Meyer-Clarke process**, 8:113

**Viperidae (pit vipers)**, Trauma 3:1, 3f

**Viral infections**

IDU-related, 15:207-208

parenterally transmitted, 15:207-208, 207t

seroprevalence and transmission, 15:207-208

**Visceral hyperalgesia**, 17:223-224, 224t

**Vital signs**, 11:150

**Vitamin A**, 4:45  
**Vitamin B12a (hydroxycobalamin)**, 9:129  
**Volatile toxins**, 9:131t  
**Vomit agents**, 8:102t  
**VTE**. *See* Venous thromboembolism  
**VX**, 9:119, 123  
    chemical structure of, 9:122f  
    treatment for exposure, 9:126

## W

**Wackenheilm clivis line**, Trauma 4:7, 7f  
**Warfarin**, 18:234  
**Washington Healthcare Corporation, Gatewood v.**,  
    539Z (March):4  
**Water contamination**, 9:130  
**Waterston shunt**, 6:77, 77f  
**Whiplash Shaken Infant Syndrome**, 539Z (June):6  
**Whipworm**, 4:39, 40, 40t  
**Women**  
    female circumcision, 5:62-64  
    UTIs in, 7:89-91  
**Wong, Arrington v.**, 539Z (March):3

## X

**Xanthines**, 12:164-165, 165t  
**X-rays**. *See* Radiographic evaluation

## Y

**Yellow jackets**, Trauma 3:8

## Z

**Zemuron (rocuronium)**, Trauma 1:7t, 8

### **FINANCIAL DISCLOSURE STATEMENT**

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we present the following annual statement of disclosure for the editorial board members of *Emergency Medicine Reports*.

**Paul S. Auerbach, MD; William Brady, MD; Kenneth H. Butler, DO; Michael L. Coates, MD; Alasdair K.T. Conn, MD; David A. Kramer, MD; Larry B. Mellick, MD; Paul E. Pepe, MD; Robert Powers, MD; Barry H. Rumack, MD; Richard Saluzzo, MD; David Sklar, MD; J. Stephan Stapczynski, MD; Charles E. Stewart, MD; Steven M. Winograd, MD; and Allan B. Wolfson, MD**, report no relationships with companies related to the field of study covered by this CME program.

**Brooks F. Bock, MD**  
Speaker's Bureau: American College of Emergency Physicians  
President, American Board of Emergency Medicine

**Charles L. Emerman, MD**  
Consultant: Scios, Aventis  
Speaker's bureau: Scios, Pfizer, Roche, Bayer  
Research: Scios, Aventis

**Kurt Kleinschmidt, MD**  
Speaker's bureau: Aventis

**Charles V. Pollack Jr., MD**  
Consultant: Aventis, MLN, Key  
Speaker's bureau: Aventis, MLN, Key, Sanofi, BMS  
Research: Aventis

**David J. Robinson, MD**  
Honoraria: Centocor

**Steven G. Rothrock, MD**  
Stockholder: Pfizer, Johnson/Johanson, Merck, Amgen, Gilead Sciences, IVAX, Medtronic

**Sandra M. Schneider, MD**  
Stockholder: Roche

**David A. Talan, MD**  
Consultant: Bayer  
Speaker's bureau: Pfizer, Bayer, and Ortho-McNeil  
Research: Bayer, OrthoMcNeil, Pfizer, Lilly, BMS, Astra-Zeneca  
Research: Bristol-Myers, Bayer, and Eli Lilly

**Gregory A. Volturo, MD**  
Consultant: Aventis  
Speaker's Bureau: Pfizer, Scios  
Research: Roche

**Albert C. Weihl, MD**  
Consultant and Speaker's Bureau: Fujisawa Pharmaceutical

**Gideon Bosker, MD**, editor-in-chief, is on the speaker's bureau for Pfizer, Rhone-Poulenc Rorer, and Parke-Davis. Dr. Bosker also acknowledges that he receives royalties, commissions, and other compensation relating to the sale of textbooks, reprints of articles, and other written materials to the following pharmaceutical companies: Pfizer, Genentech, Aventis, Pharmacia, and Bayer.

**John A. Schriver, MD, and Corey M. Slovis, MD**, did not return disclosure forms.

## Emergency Medicine Reports 2003 Titles

### **JANUARY 1, 2003**

Emergency Ultrasound. Part I: Pelvic Ultrasound and the First Trimester Patient

### **JANUARY 13, 2003**

Emergency Ultrasound. Part II: Diagnosis of Deep Vein Thrombosis

### **JANUARY 27, 2003**

Emergency Ultrasound. Part III: Acute Trauma

### **FEBRUARY 10, 2003**

Immigrant Medicine: The Emergency Department Perspective  
Part I: Evaluation, Diagnosis, and Treatment of Commonly Encountered Diseases

### **FEBRUARY 24, 2003**

Immigrant Medicine: The Emergency Department Perspective  
Part II: Commonly Encountered Diseases of Latin America, Asia, and Africa

### **MARCH 10, 2003**

Congenital Heart Disease in the Emergency Department

### **MARCH 24, 2003**

Urinary Tract Infection: Risk Stratification, Clinical Evaluation, and Evidence-Based Antibiotic Therapy  
Part I: Epidemiology, Emerging Resistance Patterns, and Patient-Specific Treatment Strategies

### **APRIL 7, 2003**

Chemical Warfare Agents. Part I: Choking Agents, Vesicants, and Halogenated Oximes

### **APRIL 21, 2003**

Chemical Warfare Agents. Part II: Nerve Agents, Blood Agents, and Protective Gear

### **MAY 5, 2003**

Urinary Tract Infection: Risk Stratification, Clinical Evaluation, and Evidence-Based Antibiotic Therapy  
Part II: Antibiotic Selection, New Treatment Options, and Special Considerations

### **MAY 19, 2003**

Coma: A Systematic Approach to Patient Evaluation and Management

### **JUNE 2, 2003**

Central Nervous System Manifestations of Drug Toxicity

### **JUNE 16, 2003**

Delirium: A Systematic Approach to Diagnosis and Initial Management

### **JUNE 30, 2003**

Cardiotoxins: A Systematic Approach to the Evaluation and Management of Patients with Life-Threatening Manifestations of Drug-Induced Cardiotoxicity

### **JULY 14, 2003**

Infectious Complications of Injection Drug Use

### **JULY 28, 2003**

B-Type Natriuretic Peptide: Clinical Utility in the Emergency Department Setting

### **AUGUST 11, 2003**

Noncardiac Causes of Chest Pain in the Emergency Department: Part I

### **AUGUST 25, 2003**

Noncardiac Causes of Chest Pain in the Emergency Department: Part II

### **SEPTEMBER 8, 2003**

Emergency Department Management of Pancreatitis

### **SEPTEMBER 22, 2003**

Management of Acute Foot and Ankle Disorders in the Emergency Department. Part I: The Ankle

### **OCTOBER 6, 2003**

Management of Acute Foot and Ankle Disorders in the Emergency Department. Part II: Fractures of the Foot

### **OCTOBER 20, 2003**

Appropriate and Outcome-Effective Antibiotic Use in Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB). Year 2003 Update: Part I

### **NOVEMBER 3, 2003**

Appropriate and Outcome-Effective Antibiotic Use in Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB). Year 2003 Update: Part II

### **NOVEMBER 17, 2003**

Bronchiolitis: A Systematic Approach to Evaluation, Treatment, and Prevention

### **DECEMBER 1 2003**

Evidence-Based Guidelines for Sepsis Management in the Emergency Department: A Systematic Approach to Patient Risk-Stratification, Stabilization, and Multi-Modal Therapy—Focus on Early, Goal-Directed Therapy, Activated Protein C, Antibiotics, and Corticosteroids

### **DECEMBER 15, 2003**

Shock: Beyond the "Golden Hour"